Drug Coated Balloon (DCB) angioplasty; DCB Norwich Registry (2009-2015) and a Propensity Score Matched Comparison between DCB and Second Generation Drug Eluting Stents. by Wickramarachchi, Upul
 
 
Drug Coated Balloon (DCB) angioplasty; DCB Norwich 
Registry (2009-2015) and a Propensity Score Matched 
Comparison between DCB and Second Generation Drug 
Eluting Stents. 
Dr Upul Wickramarachchi MBBS, MRCP (UK) 
Department of Cardiology 
Norfolk and Norwich University Hospital 
Colney Lane, Norwich NR4 7UY 
Submitted for the Degree of MD (Res) 
To the University of East Anglia 
2020 
Supervisors 
Dr Simon Eccleshall 
Professor Marcus Flather 
 
1 
 
 
Abstract 
Background 
Drug coated balloons are semi compliant balloons coated with a chemotherapeutic drug 
to reduce neo intimal hyperplasia thus reducing the risk of re-stenosis. The lack of any 
permanent metal/polymer in the coronary artery may reduce future risk of adverse 
clinical events.  
Objectives 
The main objective of the DCB NORWICH observational registry was to assess the 
efficacy and safety of drug coated balloon angioplasty in a real world setting. The 
propensity matched analysis compared clinical outcomes between DCB-only 
angioplasty and second generation drug eluting stents (DES).  
Methods 
All patients who received DCB angioplasty in the Norfolk and Norwich University 
Hospitals NHS Foundation Trust from 01/01/2009 to 31/12/2015 were included 
retrospectively in the DCB NORWICH registry study. In the propensity score matched 
study, DCB-only PCI in de novo vessels were compared to second generation DES. 
Clinical outcomes were obtained from the National Institute for Cardiovascular 
Outcomes Research and NHS Digital. 
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Results 
A total of 1394 lesions in 1122 patients were treated with DCBs. There were 1026 
lesions in 812 patients in the de novo group.  The mean age was 65.8. 60.1% presented 
with MI or acute coronary syndrome. 12 month all cause death was 3.6%, MI 3.1% and 
target lesion revascularisation (TLR) 2.1%. MACE (death, MI, TLR) was 8.1%. No 
definite treated segment thrombosis was noted up to 12 months.  
The propensity score matched study had 904 DCB and 1424 DES treated de novo 
lesions. Results showed no difference in clinical outcomes between PCI with DCB-only 
strategy vs. 2nd generation DES. The MACE rate for the DCB arm met the pre specified 
non-inferiority margin of 4.5%.  
Conclusions 
DCB-only PCI is safe and feasible in a wide range of patients and showed no difference 
in clinical outcomes compared to second generation DES up to 12 months.  
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Chapter 1- Introduction 
1.1 Background 
According to WHO in 2012, 7.4 million people died (13.1% of all deaths) due to 
coronary artery disease and this is the leading cause of mortality worldwide.1 This 
number is continuing to increase despite effective treatment strategies. The two 
methods of coronary revascularisation available for patients presenting with acute 
coronary syndromes (ACS) and stable coronary artery disease are percutaneous 
coronary intervention (PCI) and coronary artery bypass graft surgery (CABG). In the 
United Kingdom, in 2014, there were 17,513 isolated CABG surgeries and 96,143 PCI 
procedures. About two thirds of all PCIs were done for ACS and a third for stable 
coronary artery disease (BCIS audit 2015).2  
In 1993, stents were used in only about 5% of all PCI procedures in the UK and by 2003 
this number has risen to over 90%. Drug eluting stents (DES) are used in about 85% of 
PCI procedures in the UK both in the setting of stable and unstable coronary artery 
disease. This number has risen significantly over the years from a mere 17% in 2003. In 
2014, 2.5% of all PCI’s were done for Stent Thrombosis and 4.8% for In-stent 
restenosis (BCIS audit 2015). 2  
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1.2 Percutaneous Coronary Interventional Treatment Options and Role of Dual 
Antiplatelets 
1.2.1 Balloon only Angioplasty (also known as POBA) 
Percutaneous coronary intervention techniques and devices have evolved enormously 
since Dotter and Judkins performed the first angioplasty in 1964 and Grϋntzig the first 
coronary angioplasty in 1977.3 Now referred to as Plain Old Balloon Angioplasty 
(POBA), this technique revolutionised the approach to treating coronary artery disease, 
but was associated with complications such as acute vessel closure due to vessel 
dissections, elastic recoil and thrombosis as well as high restenosis rates requiring a 
second procedure. National Heart, Lung and Blood Institute angioplasty registry from 
1977-1981 showed a vessel closure rate of 4% and a dissection rate of 9% out of 1500 
enrolled patients.4 Sixty-nine percent of the patients with angiographic evidence of 
coronary dissection did not have any associated adverse effects or require emergency 
bypass surgery. 
1.2.2 Bare Metal Stents (BMS) 
Bare metal stents were originally developed to overcome the acute and short term 
complications of balloon only angioplasty/POBA. The Benestent trial investigated the 
difference of primary clinical end points of death, myocardial infarction, cerebro vascular 
accident, need for coronary artery bypass graft surgery or a second angioplasty 
procedure and angiographic end point of minimal luminal diameter at 7 months between 
balloon angioplasty and bare metal stent insertion in 520 patients with stable angina. 
This showed evidence for a reduction in the need for a second angioplasty procedure 
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(relative risk 0.58; 95 percent confidence interval 0.40 to 0.85; P = 0.005) with reduced 
restenosis rates (22% in stent group vs. 32% in angioplasty group (P = 0.02)).5 The 
Stress trial compared angiographic restenosis at 6 months and clinical outcomes 
between angioplasty and bare metal stents in 410 patients with symptomatic coronary 
artery disease. Results showed improved restenosis rates (31.6% vs. 42.1%, P = 0.046) 
with BMS compared to balloon angioplasty but no difference in death, MI, vessel 
closure or need for a bypass surgery or a second procedure.6 This improvement of 
restenosis led to a substantial increase in use of BMS in the 1990’s. However, it is 
important to note that only 5.1% (Benestent) and 6.9% (Stress trial) of patients from the 
angioplasty-only arm had to cross over to the stent group due to acute complications (ie 
acute vessel closure, flow-limiting dissection, and a suboptimal angiographic result). 
1.2.3 Role of Dual Antiplatelets 
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel (initially ticlopidine) has 
contributed to the reduction of stent thrombosis and myocardial infarction after 
percutaneous coronary intervention. The reduction of these events from late 1990’s 
onwards was partly due to the widespread use of DAPT. Publications by Schömig A., 
Neumann F.J. et al and other studies such as STARS, MATTIS and FANTASTIC 
showed significantly less stent thrombosis with use of aspirin and ticlopidine over aspirin 
mono-therapy and aspirin with warfarin/heparin.7-10 Neumann et al in a study of 140 
patients who received bare metal stents showed that platelet fibrinogen receptor 
expression was an independent predictor of sub-acute stent occlusion.11 Gawaz et al 
showed reduced activated platelet fibrinogen receptor with asprin and ticlopidine against 
aspirin and heparin/phenprocoumon after stenting in 46 vs. 151 patients respectively.12 
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Schomig A et al compared 257 patients treated with antiplatelet therapy (ticlopidine) to 
260 patients who received anticoagulant therapy (phenprocoumon) after bare metal 
stent implantation. The group who received antiplatelets had 0 stent thrombosis as 
opposed to 5% (p <0.001) with anticoagulation, MI rates of 0.8% and 4.2% (p=0.02) and 
a haemorrhagic event rate of 0% vs. 6.5% (p <0.001) respectively at 30 days.7 STARS 
trial which compared aspirin alone, aspirin plus warfarin and aspirin plus ticlopidine after 
BMS implantation in a total of 1653 patients revealed significantly less stent thrombosis 
(2.9, 2.7,0.5%, p 0.005) and MI (2.7, 2.0, 0.5%, p 0.01) rates at 30 days in the aspirin 
and ticlopidine group. Haemorrhagic complications in the aspirin and ticlopidine group 
were not different to aspirin and warfarin group but was higher than the aspirin alone 
group.8  In the MATTIS trial 350 high risk patients who underwent bare metal stenting 
were randomised to receive either aspirin and ticlopidine or aspirin and an oral anti-
coagulant for 30 days after the procedure. There was no statistical difference of the 
primary end point (composite of cardiac death, MI or repeat revascularisation) between 
the groups but was numerically lower in the aspirin and ticlopidine group at 30 days. 
The major vascular bleeding rate was less in the aspirin and ticlopidine group (RR, 4.1; 
95% CI, 1.2 to 14.3; P=0.02)9 236 patients were randomised to standard anticoagulation 
(heparin/oral anticoagulant) and 249 to dual antiplatlelets (aspirin plus ticlopidine) in the 
FANTASTIC study. At 6 months sub-acute stent occlusion and any bleeding 
complication was less in the dual antiplatelet group.10 All these studies paved the way 
for dual antiplatelets to be the conventional treatment after angioplasty as opposed to 
oral anticoagulation. 
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1.2.4 Drug Eluting Stents (DES) 
Whilst restenosis rates were better with BMS compared to balloon only 
angioplasty/POBA, they were still in the order of 20-30% over six months as shown in 
the above two studies. In Benestent, 15% of stented patients required some form of 
revascularisation at 7 months. Development of a stent covered with a chemotherapeutic 
drug (drug eluting stent - DES) to reduce neo-intimal proliferation and thus reduce the 
incidence of clinical in-stent restenosis was the next step.1st generation DES were 
coated with paclitaxel or sirolimus and the second generation DES utilise everolimus, 
zotarolimus or biolimus. The TAXUS I, prospective, double blind, randomised, controlled 
study comparing BMS to paclitaxel coated DES showed a significant reduction of late 
lumen loss and diameter stenosis in the DES group at 6 months.13 TAXUS II, III and IV 
studies showed similar beneficial results of DES over BMS.14-16 Taxus VI was a 
prospective, randomised trial comparing paclitaxel eluting DES to BMS comprising 446 
patients and the final five year results showed better target lesion revascularisation 
(TLR) rate of 14.6% in the DES group compared to 21.4% in BMS group (P = 0.0325).17 
SIRIUS (prospective, double blind, randomised, controlled trial comparing sirolimus 
eluting stent to BMS, 1058 patients) trial showed a TLR of 4.1% versus 16.6% 
(P<0.001) respectively at 270 days.18 The prospective, randomised, double blind, 
controlled RAVEL study comparing sirolimus eluting DES to BMS in 238 patients 
showed similar improvements with MACE rates (death, MI, CABG, and TVR) of 5.8% vs 
28.8% respectively at 12 months.19 
Second generation stents were introduced with the aim of further reducing restenosis 
and need for repeat revascularisations. The most commonly used anti proliferative 
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agents are zotarolimus and everolimus and the drug is mounted to a polymer which is 
covering a cobalt chromium or platinum chromium metal stent. Significant achievements 
have been made in reducing the strut thickness and improving deliverability, visibility 
and pushability. For example the Xience V stent had a strut thickness of 81 μms 
compared with 130 to 140μms strut thickness of first generation stainless steel stents. 
The improvements of the polymer to be more haemo-compatible and biocompatible 
were also notable. The hydrophilicity/hydrophobicity, purity, in-vivo stability and 
interactions with blood-borne proteins are factors which determine haemo- and bio 
compatibility of the polymer. The first generation DES used durable polymers such as 
polyethylene-covinyl (PEVA) and poly n-butyl methacrylate (PBMA) releasing 80% of 
the drug sirolimus (140 μg/cm2) in the first month. The paclitaxel concentration of the 
Taxus® stent was 1 μg/mm2.  The second generation DES use polymers such as poly-
vinylidene fluoride and hexafluoropropylene (PVDF–HFP) which are considered more 
bio compatible. The concentration of everolimus in Evrolimus eluting second generation 
DES was of 1 μg/mm2. 80% of everolimus is released within 1 month and 100% 
released within 4 months after implantation. Resolute Integrity® stent has Cobalt 
chromium struts with a thickness of 91 μm, biocompatible polymer of 4.1 μm with 
zotarilimus 160 μg/cm2. Drug is released completely in six months. Biodegradable 
polymer was incorporated in to stents next. Synergy® stent has 71 μm thick Platinum 
chromium struts with a 4.0 μm bio degradable polylactic-co-glycolic acid (PLGA) 
polymer. The everolimus concentration is 1μg/mm2 and drug release is complete in four 
months. 20,21, 22 The polymer free BioFreedom™ drug coated stent (DCS) has a 112 μm 
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thick stent struts with a modified abluminal surface to release biolimus for up to 100 
days.23 
These improvements of drug eluting stents resulted in better clinical outcomes 
compared to first generation DES. Five year follow up results of the randomised, 
controlled Endeavor clinical trial programme (zotarolimus eluting stent vs paclitaxel 
eluting stent vs BMS), showed TLRs of 10.4 vs. 21.5% for ZES and BMS respectively.24 
In the same study  the ZES vs PES  comparison showed cardiac death/myocardial 
infarction rate of 5.8% vs. 8.8% (p = 0.003) respectively. These advantages of second 
generation DES over 1st generation DES were further shown in Spirit II and III studies.25, 
26  
In the United Kingdom alone, there have been 100,294 PCI’s undertaken during the 
year of 2018. In 88.6% of the above procedures, some form of a coronary stent has 
been used (BCIS audit 2020). This reflects the current standard practice of insertion of 
stents in both stable and acute coronary artery disease.  
Real world studies/Late complications of DES 
Even though technology has improved with the stent systems, long-term complications 
such as late and very late stent thrombosis and in-stent restenosis continue to be a 
problem. These are associated with both mortality and morbidity and otherwise may 
lead to difficult repeat revascularisations (Dangas G.D. et al).27 Factors such as delayed 
endothelialisation, chronic inflammation due to permanent presence of polymer/metal 
implant, mal- apposition and under expansion of stent and non-homogenous drug 
delivery all contribute to these long term complications. 
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In real world studies using DES for off-label indications, similar to current day-to-day 
practice, event rates are inevitably higher than those quoted in the original controlled 
studies. The 4 year follow up of the randomised Resolute all comer (included patients 
presenting with stable coronary artery disease and myocardial infarctions, no limitations 
on number of lesions/vessels or stent length) study comparing ZES vs EES showed a 
composite end point (all cause death, MI, any revascularisation) of 30.4% and 28.6% 
respectively.28 Target vessel failure (cardiac death, target vessel MI or clinically-
indicated target vessel revascularization) was 17.6% and 17.1% for the two groups 
respectively. A real world randomised study comparing Xience vs Promus DES 
(Hernandez et al), reported event rates (composite of all cause death, MI, 
revascularisation) of 8.8% and 9.3% after 12 months follow up. 29 
Similarly,  a surveillance angiography follow up study carried out in patients receiving 
DES by Cassese S. et al showed a restenosis rate of 12% in patients who received a 
2nd generation DES after 6-8 months (4669 patients with a 2nd generation DES).30 
The COMPARE study examined real life patients receiving second generation 
everolimus eluting stent (Xience V) and paclitaxel eluting Taxus Liberte stent, and found 
a composite of all cause death, MI and TVR of 6% in the Xience group after 12 months 
(897 Xience patients).31 
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Table 1 Real world studies investigating second generation drug eluting stents 
Study Randomised 
or not 
Devices and 
numbers 
Follow 
up 
period 
  Results  p 
value 
Cassese et 
al
30
 
No, 
retrospective 
analysis of 
angiograms 
to assess 
restenosis 
BMS vs. 1st gen 
DES vs. 2nd gen 
DES 
6-
8months 
angiographic restenosis 30.1, 
14.6 and 12.2% 
1st  generation DES vs. BMS (OR 
0.35, 95% CI 0.31 to 0.39) and 
2nd generation DES vs.1st 
generation DES (OR 0.67, 95% 
CI 0.58 to 0.77) were 
independent predictors of lower 
rates of restenosis 
 
COMPARE
31 
Randomised 897 EES (Xience) 
vs. 903 PES 
(Taxus liberte) 
1 year composite of all cause death, MI, 
TVR) 6% vs 9% 
0.02 
Hernandez 
et al
29 
Randomised 150 Xience vs. 
150 Promus 
12 
months 
 
Composite of all cause death, MI, 
revascularisation  8.8% and 9.3% 
0.41 
Resolute 
all comer 
study
28 
Randomised 1152 Resolute  
vs. 1140 Xience 
1 year 
 
 
 
4 years 
death, MI, revascularisation  8.7% 
vs.9.7% 
cardac death, target vessel MI, 
TLR 8.2%vs. 8.3% 
death, MI, revascularisation  
30.4% and 28.6% 
cardiac death, target vessel MI, 
TLR 17.6% and 17.1% 
0.42 
0.94 
DES – drug eluting stent, EES – everolimus eluting stent, PES - paclitaxel eluting stent, BMS – bare metal stent, MI- myocardial 
infarction, TLR – target lesion revascularisation, TVR – target vessel revascularisation 
The event rate with modern DES is therefore deemed lower compared to previously 
used bare metal stents and 1st generation stents. As expected the adverse outcomes 
seem to be higher in the real world all comer studies as described in table 1. Whilst the 
12 month outcomes are relatively low compared to early days of angioplasty the major 
adverse cardiac events seem to accumulate over the years to generate higher 
percentages, in some studies up to 30% at 4 years as described in the table 1.  
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1.2.5 Bio-resorbable Vascular Scaffolds (BVS) 
The argument that perhaps the long term outcomes should be more favourable when 
there is no permanent coronary implant has driven the development and implantation of 
bioresorbable vascular scaffolds, with the scaffold being completely reabsorbed in 
approximately 4 years.32  
The term bio-resorption refers to total elimination of polymer by dissolution, assimilation 
and excretion.32 The most commonly researched polymer at present is poly-L-lactic acid 
(PLLA) whilst there is evidence emerging for the use of magnesium alloy as a bio-
resorbable material. In the Absorb III study, scaffold (PLLA scaffold) thrombosis (1.5%), 
target vessel MI, target vessel revascularizations were all higher than the 2nd 
generation DES (but not statistically significant).33 A meta-analysis by Lipinski et al 
showed a definite/probable scaffold thrombosis of 1.2%, MI 2.1% and TLR of 2.0% at 
6.4 +/- 5.1 months follow up.34 The ISAR-ABSORB registry showed definite scaffold 
thrombosis of 2.6% at 12 months follow up.35  The early problems of scaffold 
implantation are still widely discussed and debated, but again, we find these event rates 
higher than the other available treatment modalities. Operators not fully appreciating the 
importance of mandatory pre dilatation, correct vessel sizing and post dilatation 
combined with the high strut thickness may have played a role in the reported high 
incidence of scaffold thrombosis. 
A bio resorbable magnesium scaffold (Magmaris®) has shown definite/probable scaffold 
thrombosis of 0.5% at 12 months in the first 400 patients included in BIOSOLVE IV 
registry. Although there is no direct comparison available, this figure appears to be low 
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compared with previously discussed scaffolds. In the initial Biosolve II and III studies, a 
late loss of 0.25 ± 0.31 mm in-segment and 0.39 ± 0.34 mm in-scaffold was reported 
after 12 months in 184 patients. No definite or probable scaffold thrombosis reported.36, 
37  
1.2.6 Drug Coated Balloons (DCB) 
History 
Professor Bruno Scheller and Professor Ulrich Speck are the founding fathers of this 
technology.38 Both were interested in contrast media and under Professor Speck’s 
guidance contrast media such as iopromide and gadolinium had been developed. 39-41 
Professor Scheller’s interests with contrast media were in its effects on micro circulation 
and thrombotic events after PCI.42, 43  
Contrast Media and Local Drug Delivery 
The duo’s first research collaboration was to find out whether contrast media alone had 
any impact on neo intimal proliferation and restenosis after implantation of a stent in a 
porcine coronary artery.44 This showed that there was no difference between saline, 
iopromide, ioxaglate, and iosimenol. The paper was published in 2003 and their work 
was based in Homburg/Saar in Germany.  
Both were interested in finding a non-stent based treatment method to address in-stent 
restenosis. The next step was to add an anti-proliferative drug to a contrast agent and 
test its cardiac tolerability.  16 pigs were subjected to coronary angiography with 4 of 
them receiving 70-micromol taxane protaxel dissolved in iopromide, and others iosmin, 
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ioxalgate and iopromide alone. No adverse effects such as thrombotic events, ECG, 
blood pressure or contractility changes were reported. 45 In a subsequent study an intra 
coronary bolus of taxane protaxel-iopromide solution showed a reduction of neo intimal 
formation in a porcine coronary stent. This was achieved despite a short exposure of 
the solution to the stent. 46 Paclitaxel was used with iopromide in another study testing 
its effects on bovine vascular smooth muscle cell proliferation in vitro and on neo intimal 
proliferation in vivo in 34 stents implanted in 17 pigs. The results showed a significant 
reduction of both vascular smooth muscle cell proliferation in cell cultures and also a 
dose dependent reduction of neo intimal hyperplasia in the in-vivo arm.47 In addition 
their in-vitro studies showed that short time exposure (3s) of paclitaxel induced more 
apoptosis of coronary artery smooth muscle cells than the beneficial endothelial 
progenitor cells (EPC).  Also migratory potency of EPC is not affected when exposed to 
paclitaxel for a short time (3s) compared to a longer exposure (24hrs) as seen with a 
drug eluting stent. Paclitaxel as compared to other anti-proliferative drugs such as 
sirolimus, upon short-time exposure to a low dose of the drug showed greater effect on 
cell density through immediate inhibition of the cell cycle at mitosis phase and pro-
apoptotic p53 up-regulation. 38 Animal studies and their findings are summarised in 
table 2. 
 
 
 
 
34 
 
Table 2 Animal studies investigating effectiveness of paclitaxel with contrast media on neo intimal 
hyperplasia 
Study Objective Comparators Finding P value 
Clauss et 
al  
To investigate the impact 
of intra coronary contrast 
media on in-stent 
restenosis/neo intimal 
proliferation after coronary 
stenting 
saline, iopromide, 
ioxaglate, and iosimenol 
(in vitro- cell density plus 
in-vivo angiographic 
study on 12 pigs) 
In vitro - no difference of 
change of cell density. 
In vivo – late lumen loss 
after 4 weeks 1.9 +/-0.8 
mm, 1.3 +/- 1.0 mm, 1.2 
+/- 0.8 mm  
 
 
 
 
0.256 
 
 
Scheller 
et al 
To test cardiac tolerability 
of a chemotherapeutic 
agent added to a contrast 
medium that is injected to 
a porcine coronary artery 
Coronary angiography 
performed on 16 pigs. 4 
of them received 70-
micromol taxane 
protaxel dissolved in 
iopromide, and others 
iosmin, ioxalgate and 
iopromide alone 
No thrombotic 
occlusions, no adverse 
effects causing 
electrocardiographic, 
blood pressure or 
contractility changes. No 
ventricular arrhythmias. 
 
Scheller 
et al 
Impact of an intra coronary 
bolus of taxane protaxel-
iopromide solution on neo 
intimal formation in a 
porcine coronary stent and 
in vitro cell culture 
experiment. 
Cell culture experiment  
with bovine aortic 
smooth muscle cells; 
Incubation at 3, 10 and 
60 minutes in saline vs. 
iopromide-protaxel 
medium 
 
In vivo: 16 stents in 8 
pigs. Iopromide injection 
of coronaries after 
stents vs. iopromide-
protaxel injection 
Cell density significantly 
reduced in all three 
incubation times, dose 
dependent at 12 days. 
 
 
 
 
Angiography after 28 
days (iopromide vs. 
iopromide-protaxel 
solution) 
Minimal luminal 
diameter 1.5±0.8 mm 
vs. 2.6±0.6 mm  
Late lumen loss 1.9±0.8 
mm 0.9±0.6 mm 0.01 
Histology: no mono 
nuclear cells or fibrin but 
complete 
endothelialisation of the 
segments treated with 
iopromide-protaxel 
coronary injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.006 
 
 
0.01 
Scheller 
et al 
To test the efficacy of 
paclitaxel added to 
contrast agent iopromide in 
preventing in-stent 
restenosis. 
17 pigs, after bare metal 
stent insertion 
randomised to receive 
control iopromide, 
iopromide and paclitaxel 
Late loss (mm) 1.94 +/-  
0.34 (iopromide), 2.25  
+/-0.35 (iopromide 
paclitaxel IV), 1.19  +/-
0.55 ( IC iopromide 
0.001 
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solution intra coronary 
(IC) and intravenous (IV) 
paclitaxel and 
iopromide. Follow up 
angiography at 28 days.  
 
paclitaxel 100 
micrograms/ml) 0.82 +/- 
0.54 ( IC iopromide 
paclitaxel 
200micrograms/ml) 
 
 
 
Local drug delivery using a balloon catheter 
Mounting the antiproliferative drug together with an excipient on a conventional 
angioplasty balloon catheter was undertaken next. Ethyl acetate and acetone were used 
as solvents in the first studies. 6% loss of the active ingredient was noted from only 
inserting and retracting the balloon to a porcine coronary artery (floated for 5 minutes) 
without inflating it. Approximately 80% of the drug was released to the vessel wall upon 
balloon inflation. The coronary segments were analysed 40-60 minutes from the balloon 
inflation under high-performance liquid chromatography (HPLC) which revealed 
retention of an effective dose by the vessel wall. 8.7% +/- 4.9% of the drug dose was 
retained when delivered with balloon-only PCI and 17.3% +/- 8.5% was delivered when 
the balloon was pre-mounted on a stent. Using a matrix with acetone as the solvent and 
a hydrophilic x-ray contrast medium (as used in PACCOCATH catheters) was proven to 
be more efficacious compared to a coating without a hydrophilic x-ray contrast.  
The next generation, Sequent please catheters used an automated coating technique 
with volumetric dosing resulting in a re-producible, homogenously distributed drug 
coating compared to a previous manual dip coating technique. The matrix was kept the 
same with acetone as the solvent and hydrophilic x-ray contrast being iopromide.  
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Another in vivo pre-clinical study compared the effects of lower inflation time versus 
higher inflation time and two sequential balloon inflations (overlap) on late lumen loss in 
porcine coronary arteries. The control was 10 bare metal stent (BMS) treated porcine 
coronaries. Test groups were 10, 5mcg/mm2 paclitaxel coated balloons (PCB) mounted 
on to bare metal stents inflated for 10 seconds, 10 PCB mounted bare metal stents 
inflated for 60 seconds, 10 PCB mounted bare metal stents inflated for 60 seconds and 
post dilated with the same balloon again for 60 seconds and 10 PCB mounted bare 
metal stents inflated for 60 seconds and post dilated with a second PCB catheter for 
another 60 seconds. After 4 weeks, histological evaluation of the coronary segments 
showed that late lumen loss was significantly less in all test groups compared to the 
control group. It also showed that exposure of paclitaxel to vessel wall for a short period 
such as 10 seconds was enough to achieve significant reduction of late lumen loss. 
Whilst 10 mcg/mm3 (two overlapping balloons) of paclitaxel which is equivalent to 3 
times the usual dose of paclitaxel on a paclitaxel coated balloon was tolerated well 
(which was important to understand in terms of overlapping segments in treating human 
coronaries), there was no difference of late lumen loss compared to other paclitaxel 
coated catheter test groups. 
In summary drug coated balloons are standard (semi-compliant) angioplasty balloons 
coated with a cytotoxic chemotherapeutic agent. Currently, the majority of commercially 
available DCBs use paclitaxel.  In our center we predominantly use the balloon we feel 
has the best evidence (SeQuent Please NEO, B. Braun Melsungen AG, Germany). It is 
the DCB that has been used in most studies and also has the largest pool of treated 
patients as described in table 4 below.This balloon utilises iopramide (a contrast 
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medium) to act as the excipient to retain the drug on the balloon and, on balloon 
inflation, to facilitate rapid delivery to the vessel wall due to its lipophilicity. The dose of 
paclitaxel is approximately 3 micrograms/mm2. The drug is delivered homogenously to 
the vessel wall during balloon expansion (unlike the very uneven distribution seen with 
drug eluting stents). The terminal half-life is almost two months.48  There are different 
types of paclitaxel coated balloons available in the market using different coating 
techniques and excipients (summarized in table 3). Figure 1 shows an example of a 
drug coated balloon mounted on a wire. 
Figure 1 Example of an over the wire drug coated balloon 
 
DCB = semi compliant balloon + excipient + drug 
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Table 3 Types of paclitaxel eluting balloons and coating techniques used. 
DCB type Excipient/coating technique Drug dose 
SeQuent Please Iopromide matrix coating 3 μg/mm2 
Pantera Lux Butyryl-tri-hexyl Citrate (BTHC) 
matrix coating 
3 μg/mm2 
IN PACT Falcon FreepacTM  matrix coating 3 μg/mm2 
Dior second 
generation 
Shellac matrix coating 3 μg/mm2 
Elutax SV No excipient 2 μg/mm2 
Lutonix Polysorbate and Sorbitol carriers 3 μg/mm2 
Danubio BTHC excipient 2.5 μg/mm2 
 
A sirolimus coated (1.27μg/mm2) balloon (SCB) has been introduced more recently with 
satisfactory bench testing and clinical outcomes. Data of a registry of 424 patients with 
247 de novo lesions treated with Magic touch sirolimus coated balloon were presented 
at Trans Catheter Therapeutics (TCT) conference, 2018.  Composite of cardiac death, 
target vessel MI and target lesion revascularisation at one year was 4.36%.49 
To perform DCB-only PCI, care is taken to prepare the lesion adequately before 
delivering the drug. Standard semi- and or non-compliant balloons, and, if necessary, 
more specialised cutting or scoring balloons are used in order to achieve an adequate 
angiographic result. If <30% stenosis is achieved with no dissections of more than type 
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B, the final treatment is then carried out using the Drug Coated Balloon, which is kept 
expanded for 30-60 seconds (as per German consensus guidelines).50  
A good understanding of types of coronary dissections is a must to perform DCB only 
PCI in de novo lesions. Figure 2 shows the National Heart, Lung and Blood Institute 
(NHLBI) classification of coronary dissections.  
Figure 2 Coronary Dissections; classification by the National Heart Lung Blood Institute (NHLBI) 
 
It is not always easy to classify the dissections you see in real life to these categories 
hence the importance of one to one proctoring and dedicated learning. Type A coronary 
dissection is seen mostly as a haziness without any persistence of contrast or flow 
limitation. It is comprised of only a minor radio lucent area. Type B coronary dissection 
appears mostly as a parallel line to the contrast in the lumen with no or very little 
contrast hang up. Sometimes this can give rise to double lumen appearance. Type C 
dissection could look like a type b initially but there is obvious persistence of contrast. It 
can also appear as a bulb of contrast that does not clear which may represent an 
intramural haematoma. Type D is a spiral dissection which can sometimes be difficult to 
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judge but images taken on at least two different planes will help alleviate any doubt. 
Type E is a filling defect in the middle of the lumen. Type F represents vessel closure. 
The angiographic images below illustrate some of the types further. 
Once the optimal lesion preparation has been performed with satisfactory lumen gain 
(less 30% recoil) and no dissections above type B, the DCB is advanced to deliver the 
drug. It is recommended that the balloon is delivered and fully expanded at the lesion in 
less than 2 minutes from the time of insertion to the circulation to minimise the drug 
loss. The DCB should not be of a bigger diameter than the largest pre dilatation balloon 
and should be about 5mms longer than the pre dilated segment to avoid geographic 
miss. Once the it’s deployed (kept expanded for 30-60s depending on the brand) and 
removed, a check angiogram should be performed with a longer acquisition period to 
allow the full contrast clearance to make sure there is no higher than type B dissection 
left.  
Dual antiplatelet therapy is required for only 1 month after DCB-only elective procedures 
or one year for treatment of acute coronary syndrome. 
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Figure 3 Example of a type B coronary dissection in the mid Circumflex artery 
Arrow indicates the contrast staining that clears with the rest of the coronary. 
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Figure 4 Type C coronary dissection 
(a) Arrow points to the contrast staining of the mid left anterior descending (LAD) 
artery which has persisted after the clearance of contrast from the rest of the 
coronary.  
 
 
 
 
 
 
 
 
 
43 
 
(b) Arrow points to the contrast hanging up in the proximal right coronary artery when 
the rest of the coronary is clear of contrast. 
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Figure 5 Type D/Spiral dissection 
Arrows point at the visible sections of the spiral dissection 
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Figure 6 Type D/Spiral coronary dissection 
Arrow pointing at the spiral shaped radio lucent area. 
 
1.3 Evidence for angioplasty with DCB  
DCBs were first used to treat in-stent restenosis i.e. a luminal narrowing within a 
previously placed stent.  This was driven by the appeal of not having to implant another 
layer of metal on top of the existing one when DCB is used. The pathophysiology, 
treatment and use of DCBs in in-stent restenosis is discussed below. Also most early 
DCB studies (PEPCAD IV, PEPCAD V, DEBAMI, and PEPCAD CTO) were carried out 
in conjunction with implantation of a BMS which, in our view, takes away the long term 
advantages of no permanent implant.51-54  We will therefore not discuss these further. 
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1.3.1 In-Stent Restenosis (ISR) 
Sigwart reported the first human coronary stent implantation in 1986 in 24 lesions (17 
restenoses, 4 abrupt closures after angioplasty and 3 deteriorated bypass grafts).55  
Since then the use of stents has increased exponentially and is now considered to be 
the standard treatment for significant flow limiting coronary artery disease. This paved 
the way for a new disease entity called in-stent restenosis which is the development of a 
stenosis within or in association to the previously stented segment. In a retrospective 
study involving 10,004 patients Cassese et al reported ISR incidence of 30.1%, 14.6% 
and 12.2% for bare metal stents (BMS), first generation DES and second generation 
DES respectively at 6-8 months angiography. 30 Even though the percentage of ISR has 
reduced with drug eluting stents (DES), their absolute number is ever increasing due to 
wide spread use of stents.  
1.3.1.1 Angiography patterns of ISR 
Mehran et al identified four patterns of ISR which is described as Type 1 (Focal) - 
<10mm in length, Type 2 (Diffuse) - >10mm in length, Type 3 (Proliferative) - >10mm in 
length and extending beyond the stent and Type 4 (Occlusive) – complete occlusion 
within the stent. 56 Better clinical outcomes have been reported after treatment of focal 
ISR compared to diffuse ISR. 57, 58 All types of ISR have been reported with both BMS 
and DES but BMS-ISR tends to be more of diffuse whilst DES-ISR is more focal 
nature.57  
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1.3.1.2 Pathophysiology 
Pathophysiology of ISR consists of two important mechanisms namely neointimal 
hyperplasia due to smooth muscle cell proliferation and neoatherosclerosis.   
1.3.1.3 Neointimal hyperplasia (NIH) 
Angioplasty results in a vessel wall injury and the vessel wall responds triggering a 
healing process. Re stenosis after balloon-only angioplasty is considered to be due to a 
combination of elastic recoil, vessel remodelling and neo intimal hyperplasia (NIH). 
Histopathological and IVUS studies showed that vessel remodelling (reduction of area 
under internal elastic lamina/external elastic lamina) played a greater role compared 
with NIH in restenosis after balloon-only PCI.59,60, 61  
In-stent restenosis is mainly due to NIH and neoatheresclerosis. Platelet rich thrombi 
(up to 30 days) as well as fibrin rich thrombi (commonly up to 12 days) are formed 
around stent struts.62 In addition medial injury and penetration of the lipid core by stent 
struts seem to instigate an inflammatory process.62 The presence of acute inflammatory 
cells (neutrophils) around stent struts has been demonstrated up to 30 days after 
angioplasty and chronic inflammatory cells (macrophages and lymphocytes) from less 
than 3 days to more than 30 days.62 A linear correlation between presence of 
monocytes and degree of smooth muscle cell proliferation has been shown after stent 
implantation in a rabbit iliac artery. 63 NIH is comprised of smooth muscle cells and 
proteoglycan rich matrix and the formation of NIH is believed to be detectable at 
approximately two weeks from stent insertion. 62  Clinical events due to restenosis in 
BMS (which is mainly due to NIH) has been reported increasingly up to 12 months but 
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then plateaus thereafter  suggesting NIH is an active process in the first year.64 
Pathophysiology of ISR appears to differ from BMS to DES and NIH due to smooth 
muscle cell proliferation has been shown to be more prevalent in BMS ISR compared to 
DES ISR. Presence of proteoglycan rich extra cellular matrix was more common in DES 
ISR than BMS ISR.65 
1.3.1.4 Neoatherosclerosis (NA) 
The formation of atherosclerotic disease inside a stented segment is termed as 
neoatherosclerosis. It is reported in different forms such as foamy macrophage clusters 
with or without calcification, fibro atheroma, thin cap fibro atheroma and ruptured plaque 
.66 An absent/incomplete endothelial coverage, dysfunctional endothelium and poorly 
formed inter cellular junctions which may lead to increased permeability to lipid and 
inflammatory cells could play a key role in neo atherosclerosis. 66-68 Whilst neo 
atherosclerosis is commonly seen as a late process compared to neointimal 
hyperplasia, the former has been reported as early as 70 and 120 days in DES ISR .66 
ISR due to neo atherosclerosis seems to be more prevalent in DES compared to BMS 
.66, 69 When it occurs in BMS-ISR, it is of late onset compared to DES-ISR (median of 
2160 days as oppose to 420 days).66 Otsuka et al has demonstrated that there is no 
difference of neo atherosclerosis formation between first and second generation DES. 70 
Necrotic core and thin cap fibro atheroma appear more commonly in DES ISR than 
BMS ISR. 71 
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1.3.1.5 Risk factors and clinical presentation 
Patient factors such as diabetes mellitus, multi vessel disease, small vessel diameter, 
drug resistance and hypersensitivity are associated with increased risk of developing 
ISR. 64, 72-75 Similarly as mentioned above BMS implantation has higher risk of ISR than 
DES. Length of stented segment, stent fracture, stent under expansion, multiple stents, 
bifurcation stenting, stent overlap and non-uniform stent struts are also associated with 
higher incidence of ISR. 65, 73, 76-79 
Patients with ISR can present with stable angina or acute coronary syndromes 
(unstable angina, non ST elevation MI or STEMI) and studies have reported acute 
coronary syndrome rates of 18% and 35.9%. 57, 80 
1.3.1.6 Treatment options 
Balloon only angioplasty (POBA), vascular brachytherapy (VBT), excimer laser coronary 
angioplasty (ELCA), DES and drug coated balloons (DCB) are recognized treatment 
modalities for ISR. Out of these DCB and DES are the most widely used methods at 
present.   
Balloon only Angioplasty (POBA) 
Aggressive dilatation with semi and or non-compliant balloons was the first method of 
treatment for ISR lesions. But its high restenosis rates such as 22% after 6 months in 
focal ISR and up to 75% after 3 months in diffuse ISR has made its use obsolete in 
current practice.81, 82 
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Vascular Brachytherapy (VBT) 
VBT involves delivery of a radio-active isotope directly inside the diseased stent with the 
help of a radio-active ribbon. Use of VBT has been described by Teirstein et al (reduced 
angiographic re stenosis at angiography after 6 months compared to placebo), Alli OO 
et al (no significant difference of MACE compared to sirolimus eluting stents after five 
years) and Leon MB et al (reduced re stenosis rates compared to placebo but increased 
thrombosis rate at 9 months). 83-85 Benjo et al showed an increased risk of TLR (OR 
2.37; CI 1.55-3.63; P < 0.001) and TVR (OR 2.23; CI 1.01-4.94; P = 0.05) at 2-5 year 
follow up in a meta-analysis of 1375 patients comparing VBT to DES. 86 These high 
rates of late stent thrombosis and revascularisations prompted a search for an 
alternative safer treatment modality. 
Excimer Laser Coronary Angioplasty (ELCA) 
ELCA is carried out using a laser fibre catheter to deliver energy for tissue ablation 
inside a stenosed stent and has shown mixed results. Mehran et al showed better 
luminal gain with adjunct ELCA in comparison to POBA alone, but no significant 
difference in target vessel revascularization (TVR) after 6 months in a study of 107 ISR 
lesions.87 Köster R et al showed high restenosis rate (54%) and re intervention rate 
(31%) after adjunct ELCA in a study of 141 stents at 6 months clinical and angiography 
follow up.88  Bejarano et al showed high repeat restenosis rates of 24.2% at 6 months 
and 27.3% at 12 months in a study of 33 lesions treated with ECLA.89 Similar to VBT, 
due to high restenosis and clinical event rates ECLA is not used routinely for ISR 
treatment in the present day practice. 
51 
 
BMS/DES/BRS/DCB 
Bare Metal Stents (BMS) 
Early studies comparing BMS to POBA in treatment of ISR showed no difference in 
mortality or event rates but better luminal gain after BMS. A study involving 63 patients 
undergoing repeat BMS stenting for ISR revealed a restenosis rate of 30% at 6 months 
angiographic follow up.90 RIBS I showed similar restenosis rates for BMS (38%) and 
POBA (39%) at six months but no significant difference of event rates. For vessels 
larger than 3mm event free survival and restenosis were better with BMS. 91 
Drug Eluting Stents (DES) 
Introduction of DES as a treatment option for ISR led to reduction of restenosis and 
event rates. RIBS II study compared outcomes of ISR treatment with angioplasty to 
sirolimus eluting stents (SES) and showed lower TVR rate in the SES arm at one year 
follow up (29.7% vs. 10.5% respectively, p 0.003) as well as lower recurrent restenosis 
rate at 9 months angiography(39% vs. 11%; p < 0.001).92 ISAR DESIRE showed 
restenosis rates of 44.6% (41/92) in the balloon angioplasty group, 14.3% (13/91) in the 
sirolimus stent group (P<.001 vs balloon angioplasty), and 21.7% (20/92) in the 
paclitaxel stent group (P = .001 vs balloon angioplasty) at 6 months follow up 
angiography. 93 Better outcomes are expected for second generation DES over first 
generation in treating ISR due to the thinner struts of former. However two studies have 
shown comparable results of the two methods. In 66 cases of diffuse DES ISR, in-
segment restenosis rate (5.0% vs. 14.3%, p = 0.32), and the composite incidence of 
death, myocardial infarction, or target lesion revascularization (9.6% vs. 8.8%, p > 0.99) 
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did not differ between SES group (n = 32) and everolimus eluting stent (EES) group (n = 
34) in a randomized trial by Song et al.94 In another prospective registry of 198 patients, 
no significant difference of MACE, TVR and restenosis was noted between the EES and 
PES arms. 95 
Whether a drug eluting stent with the same drug (homo-DES) or a different drug 
(hetero-DES) is better in treating ISR is still debated and has mixed evidence. Garg et al 
showed no significant difference in TVR-MACE at one year follow up of 116 patients 
with DES-ISR treated with same or different DES.96 A meta-analysis by Vyas et al which 
included 1680 patients revealed treatment with hetero-DES reduces TLR and TVR but 
not MI or death.97 ISAR-DESIRE 2 trial showed no difference in restenosis, TLR, MI or 
death in hetero-DES vs. homo-DES groups.98 The subgroup analysis of homo-DES and 
hetero DES groups in RIBS III trial showed better minimal luminal diameter at 
angiographic follow up (median of 278 days, IQR: 226 to 409 days) of the hetero-DES 
group but similar TLR, TVR, MI and death rates for both groups.99 
Biovascular Resorbable Scaffolds (BRS) 
Biovascular resorbable scaffolds (BRS) have been tried in the treatment of ISR aiming 
for better long term outcomes as the scaffold is re-absorbed fully in 3 to 4 years. But 
their high strut thickness, low radial strength and low burst pressures make them 
unattractive for this cohort of patients. An Italian multicenter prospective registry of 116 
patients has shown a composite cardiac death, target vessel myocardial infarction, and 
ischemia-driven target lesion revascularization rate of 9.1% at 15 months follow up .100 
Moscarella et al in a study of 315 patients showed a MACCE rate of 12%, TLR 7.7% 
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and 1.1% definite BRS-in-stent thrombosis at median of 7 (IQR 3-18) months follow-
up.101 Jamshidi et al in a cohort of 84 ISR lesions treated with BRS showed TLR rate of 
3.1% at six months and 12.2% at 12 months.102 Whilst BRS is not routinely used for ISR 
at present further improvements such as reduced strut thickness may increase its role in 
ISR treatment. 
1.3.2 Drug Coated Balloons for ISR 
1.3.2.1 Advantages of DCB in ISR 
The most advantageous factor over other stenting options is that no permanent or semi-
permanent metal/polymer is left in the already diseased stented segment. Thereby it 
arguably avoids stent induced accumulation of inflammatory cells and other 
disadvantageous factors of stents such as stent fractures, mal-apposition, under-
expansion, stent overlap, stent gap and non-uniform struts.  
Stent strut thickness has been shown to influence percentage of endothelial coverage 
after stent insertion.67, 103 Therefore two or more layers of stent struts could lead to 
delayed and less endothelial coverage. 
In addition a higher percentage of covered stent has been reported after DCB in 
comparison to everolimus eluting stent (EES) after 9 months of BMS-ISR treatment.104 
The Ability to undergo repeat angioplasty if needed without additional stent layers would 
also be an advantage. 
Requirement for a shorter duration of dual antiplatelet therapy (4 weeks after DCB vs. 
12 months with DES) will be another advantage. 
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1.3.2.2 Evidence for DCB in ISR 
DCB vs. POBA 
Randomised PEPCAD-DES study showed less late luminal loss (0.43 ± 0.61 mm 
versus 1.03 ± 0.77 mm (p < 0.001)) and reduced restenosis rates (17.2% vs. 58.1% (p < 
0.001)) with DCB compared to POBA in 110 DES-ISR patients at 6 months follow up. 
Composite of cardiac death, target vessel related MI and TLR was 16.7% vs 50.0% (p < 
0.001) respectively.105 DCB continued to show better outcomes both in terms of TLR 
(19.4% vs. 36.8%; p = 0.046) and MACE (20.8% vs. 52.6%, log-rank p = 0.001) over 
POBA in the 3 year follow up study of this cohort.106 
Five year follow up results of Paccocath ISR I and II (randomised study of 108 patients 
with mainly BMS-ISR (96%)) showed better outcomes of DCB over POBA (MACE of 
27.8% vs. 59.3%, p = 0.009). This was largely driven by low rates of TLR (9.3% vs. 38.9 
(p = 0.004)).107 
DCB vs. PES 
In the randomised PEPCAD II study (131 patients with BMS-ISR) which compared PES 
(65 patients) vs. DCB (66 patients), at 12 months, the rate of major adverse cardiac 
events were 22% and 9% (P=0.08), respectively.108 This difference was primarily due to 
the need for target lesion revascularization of 6% in the coated-balloon group, 
compared with 15% in the stent group (P=0.15). At 6 months angiographic follow-up, in-
segment late lumen loss was 0.38±0.61 mm in the drug-eluting stent group versus 
0.17±0.42 mm (P=0.03) in the drug-coated balloon group. Three year follow up data 
showed persistently better results for DCB over PES.109 
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Randomised controlled PEPCAD CHINA study (DCB vs. PES in DES-ISR) showed non 
inferior in segment late lumen loss (LLL) in the DCB group compared to DES group 
(0.46 ± 0.51 mm vs. 0.55 ± 0.61 mm; difference: -0.06 mm with 95% confidence 
interval: -0.23 to 0.10; p for non-inferiority = 0.0005) and no significant difference of 
binary restenosis rates at 9 months angiographic follow up. No significant difference of 
target lesion failure rate both at 12 months and 24 months was noted.110, 111 
DCB vs. DES 
In a propensity matched retrospective study involving 685 real life patients (777 ISR 
lesions) who received DCB vs DES (471 lesions in the repeat DES group; 177 (37.6%) 
were treated by SES, 164 (34.8%) by PES, and 130 (27.6%) by EES), there was no 
difference in binary restenosis, TLR, and major adverse cardiac events. A sub group 
analysis showed a significant trend favouring DCB with respect to binary restenosis and 
TLR in non-focal type lesions and bifurcation lesions. 112 
DCB vs. POBA vs. PES 
ISAR DESIRE III (POBA vs DCB vs PES for DES-ISR, 402 patients) showed no 
significant difference between DCB and PES in treatment of ISR (clinical follow up at 1 
year showed a death rate 2.2% in DCB vs. 4.6% in DES and restenosis on 6-8 months  
angiography was 26.5% vs. 24% respectively). Both PES and DCB were superior to 
POBA. 113 
3 year follow up results of this cohort showed no significant difference of TLR (29 
(24.2%) vs. 44 (33.3%), p 0.11) between the PES and DCB groups but both cardiac (10 
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(8.1%) vs. 3 (2.4%), p 0.03) and all cause death (19 (15.3%) vs 8 (6.0%), p 0.02) rates 
were better in the DCB arm.114 
DCB vs. EES 
Almalla M et al in an observational study involving 86 patients compared DCB to EES in 
treatment of DES-ISR. This showed TLR rates of 4.3% and 22.5% respectively 
(P = 0.029) at 1 year follow up. There was no difference in MI rates (2% vs. 5%, 
P = 0.595).115 
In the SEDUCE study (OCT and clinical follow up of 50 patients with BMS-ISR 
randomized to angioplasty with DCB and EES), better strut coverage (1.4% vs. 3.1%, 
p=0.025) and well healed dissections were noted in the DCB arm at 9 months follow up. 
Minimal lumen diameter was better in the EES arm (2.13 vs. 2.54 mm, p=0.006) and no 
significant difference was noted in neo-intimal hyperplasia area (2.4±1.08 mm in DCB 
vs. 1.92±0.67 mm in EES (p=0.1806)). No significant difference in clinical outcomes was 
noted at 12 months.104 
RIBS IV trial (EES vs. DCB in 309 DES-ISR patients) has shown better outcomes of 
EES over DCB. At 1-year clinical follow-up (100% of patients), the main clinical outcome 
measure (composite of cardiac death, myocardial infarction and target vessel 
revascularization) was significantly reduced in the EES arm (10% vs. 18%; p = 0.04).116 
However, immediate post procedure stenosis of <50% was considered as an 
acceptable result in the DCB arm whereas in most centers <30% stenosis is considered 
as acceptable. Also in the EES group, only 47% of the repeated ISR lesions underwent 
TLR but 74% in the DCB group.  
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RIBS V showed no significant difference of outcomes between EES and DCB in 
treatment of BMS-ISR in 189 patients after 12 months. Notably, as in RIBS IV final 
angiographic minimal luminal diameter of <50% in the DCB arm was accepted in this 
study too. Occurrences of the combined clinical outcome measure (cardiac death, 
myocardial infarction, and target vessel revascularization) were 6% vs. 8%; hazard ratio 
[HR]: 0.76; 95% CI: 0.26 to 2.18, p = 0.6).117 Three year follow up results have shown 
no significant difference in cardiac death, MI and target vessel revascularization rates. 
However TLR rate with EES was better compared DCB (2% vs. 8%; p = 0.04). 118 
Pleva et al showed significantly lower LLL with DCB compared to EES (0.02 versus 
0.19 mm; P=0.0004) in BMS-ISR at 12 months follow up in another prospective 
randomized study involving 136 patients. The difference in the incidence of repeated 
binary restenosis (8.7% versus 19.12%; P=0.078) and 12-month MACE (10.29% versus 
19.12%; P=0.213) was not significant. 119 
Normal PTCA+DCB vs. Scoring balloon + DCB  
Byrne et al presenting results of ISAR DESIRE IV study (252 DES-ISR patients 
randomized to scoring balloon plus DCB and normal PTCA balloon plus DCB) at TCT 
October, 2015 reported better outcomes in the scoring balloon plus DCB arm 
(Angiographic stenosis at 6-8 months 35% vs. 40.4%, p = 0.047 and restenosis rate of 
18.5% vs. 32%, p = 0.03). Though numerically better there was no statistically 
significant difference in TLR rates (16.8% vs. 22.6%, p = 0.25). 120 
Drug coated scoring balloon vs. standard scoring balloon 
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Scheller et al recently published the first in man study of a drug coated scoring balloon 
(DCSB) for ISR treatment (61 patients with BMS-ISR randomized to DCSB vs. standard 
scoring balloon angioplasty) and showed better in-segment late luminal loss (0.17 ± 0.40 
mm vs. 0.48 ± 0.51 mm, P = 0.01; ITT analysis) and binary restenosis rate (7% vs 41%, 
P = 0.004) in the DCSB arm at 6 months follow up angiography. Clinical follow up at 1 
year showed  MACE rate of 6% vs 32% (P = 0.016), mainly driven by low TLR rate of 
3% vs. 32% (P = 0.004) in favour of the DCSB group. 121 
In conclusion both second generation drug eluting stent and drug coated balloon 
angioplasty seem to be safe and effective treatment options for this cohort of patients. 
DCB is an attractive option especially as it does not add an additional stent layer. Large 
randomized trials comparing DCB over second generations DES are necessary to 
assess superiority of one over the other. DCB has shown better outcomes over first 
generation drug eluting stents and plain old balloon angioplasty. Initial results of novel 
drug coated scoring balloon is encouraging and may indeed offer even better results. 
We have used drug coated balloons for treatment of ISR in all settings in our 
department. The registry of ISR lesions treated with DCBs will give valuable information 
regarding their outcomes in a real world setting. 
We have used Drug Coated Balloon therapy in both de-novo and in stent 
restenosis/stent thrombosis groups in all settings of coronary artery disease in our 
centre.  
 
 
59 
 
1.3.3 De novo disease/Small vessel disease: 
There are a number of registries showing low event rates with DCB-only angioplasty in 
de novo small vessel disease. Studies are summarised in table 4. PEPCAD I study (82 
patients with 2.25 to 2.80mm vessel diameter) showed MACE rate (composite of death, 
MI, TLR, treated lesion/stent thrombosis) of 6.1% and a TLR rate of only 4.9% at 3 year 
follow up.122 Zeymer U et al. in a real world prospective registry of 479 patients with 
small vessel coronary artery disease ((≥2.0 mm, ≤2.75 mm) treated with DCB 
angioplasty showed TLR rate of only 3.6% at 9 months follow up.123 There were no 
cardiac deaths. In the Sequent please worldwide all-comer registry, the DCB-only group 
(390 patients) showed event rates for MI 0.7%, cardiac death 1%, TVR 1% and TLR 1% 
at 9 months follow up.124 Elutax small vessel registry with 251 real world patients, 59% 
of whom had native vessels treated with DCB angioplasty showed TLR rate of 2.0%, 
cardiac death of 0.8% and no target vessel MI or thrombosis at an average 225 days 
follow up.125Ho et al reported TLR of 4% at 9 months in a real world registry of 320 
South East Asian patients (76% of whom were for de novo disease, 54% small vessels 
and 76% presented with ACS).126 The single arm, prospective, multicentre Valentines-II 
trial (103 patients, treated with the DIOR DCB) showed a TLR rate of 2.9%, a TVR of 
6.9% (including TLR), 1% MI and 0% cardiac death at 7.5months.127 The Leipzig 
Prospective Drug-Eluting Balloon-Registry reported 76 patients treated with DCB-only 
for native coronary artery disease with no TLR at over 2 years.128 The incidence of MI 
was 3.9% with 9 deaths (all causes) during follow up. It is important to note that most of 
these registries were real life studies which included patients from high risk categories 
such as post STEMI, NSTEMI and bifurcation lesions. 
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The randomised controlled multicentre BELLO study (total of 180 patients) showed 
better outcomes of DCB-only treatment as compared to paclitaxel eluting stent for 
vessels with a diameter of less than 2.8mm.129 The primary endpoint of in-stent (or “in-
balloon”) late loss was significantly less with DEB compared with PES (0.08 ± 0.38 mm 
vs. 0.29 ± 0.44 mm; difference -0.21; 95% CI: -0.34 to -0.09; p (non-inferiority) < 0.001; 
p (superiority) = 0.001). Of note, bailout stenting was required in 20% of lesions in the 
DEB group. The three year results of the BELLO study showed a significant reduction of 
MACE in the DCB arm compared to PES (DCB group: 13 [14.4%], and PES group:  28 
[30.4%], p 0.015) but the study was underpowered to assess this outcome.130 
Table 4 Drug coated balloon angioplasty in de novo disease; summary of studies 
Name of 
Study 
Study Design DCB type Number 
of 
patients 
Follow 
up 
period 
Outcomes Target lesion 
revascularisation 
(TLR) 
PEPCAD 1122 Single arm DCB 
De novo small 
vessels 
82 patients 
 
SeQuent® 
Please 
82 3 years MACE 6.1% 
 
TLR 4.9% 
Zeymer, U 
et al123 
Real world 
prospective 
registry 
Small vessels 
479 patients 
SeQuent® 
Please 
479 9 
months 
Deaths 0% TLR 3.6% 
Sequent 
Please124 
Worldwide all 
comer registry 
DCB only group 
390 patients 
SeQuent® 
Please 
390 9 
months 
MI 0.7% 
Cardiac death 
1% 
TVR 1%,  
 
TLR 1% 
Elutax Small 
Vessel 
Registry125 
Real world 
patients- 
Native vessels 
251 patients 
Elutax SV 251 225 
days 
Cardiac death 
0.8% 
TLR 2% 
Ho et al131 Real world 
registry 
South east Asians 
320 patients 
SeQuent® 
Please 
320 9 
months 
 TLR 4% 
Valentines Single-arm, Dior (2nd 103 7.5 TVR 6.9% TLR 2.9% 
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II127 prospective,multi 
center 
 
generation) patients months MI 1% 
Cardiac death 
0% 
Leipzig 
Prospective 
Drug Eluting 
Balloon 
Registry128 
Native coronaries 
76 patients 
SeQuent® 
Please 
76 2 years MI 3.9% TLR 0% 
BELLO130 Randomised 
Control DCB Vs 
Paclitaxel Eluting 
Stent 
180 patients 
Vessel 
diameter<2.8mm  
IN.PACT 
Falcon 
180 3 years In-
balloon/stent 
late loss 0.08 
± 0.38 mm vs. 
0.29 ± 0.44 
mm; 
difference -
0.21; 95% CI: 
-0.34 to -0.09;  
p < 0.001 
MACE:13 
[14.4%] vs 28 
[30.4%], p 
0.015) 
TLR 6.7 vs. 13% 
(p 0.14) 
PEPCAD-
BIF132 
Randomised  
Bifurcation 
lesions  
DCB vs POBA 
64 patients 
SeQuent® 
Please 
64 9 
months 
Binary 
restenosis: 
6% vs 26% 
(p=0.045) 
Late luminal 
loss:  
0.13mm vs 
0.51mm 
(p=0.013) 
 
TLR: 3.125 vs 
9.38% 
Rosenberg 
M et al133 
Multicentre 
prospective 
registry 
731 De novo 
lesions 
Vessel size 2-4 
mm 
 
 
SeQuent® 
Please 
731 9 
months 
 
MACE 5.6% 
TLR 2.3% 
DEBUT 134 Randomised trial 
De novo lesions 
in patients with 
high bleeding risk 
102 DCB vs 106 
BMS 
SeQuent® 
Please 
208 9 
months 
MACE: 1% vs 
14% 
TLR 0% vs. 6% 
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Li M et al135 Systematic 
review and 
metanalysis 
small vessel 
lesions 
DCB vs DES 
1800 patients 
581- 
SeQuent® 
Please 
186- 
IN.PACT 
Falcon 
28-Dior 
1800 Follow 
up 
period 
6-12 
months 
Non- fatal MI 
0.53% OR 
CI 0.31-0.90, 
p=0.02 
Other 
outcomes; no 
difference 
TLR OR 1.24 
(95% CI 0.73-2.1, 
p=0.43) 
FALCON136 Registry with de 
novo lesions and 
ISR 
757 patients 
IN.PACT 
Falcon 
757 12 
months 
MACE 9.7% 
 
TLR 4.9% 
Venatsanos 
D et al137 
Small vessel DCB 
vs DES 
1197 lesions in 
each arm, 
propensity score 
matched 
816-
SeQuent® 
Please 
150-
IN.PACT 
Falcon 
231- 
Pantera® 
Lux 
TM
 
 
2394 965 
days 
Target lesion 
thrombosis: 
0.2% vs 1.1% 
 
TLR 7% vs 6.2% 
BASKET 
SMALL 2138 
Randomised 
controlled trial, 
DCB vs DES in 
small vessel 
coronaries 
756 lesions 
SeQuent® 
Please 
756 12 
months 
MACE: 7.5% 
vs 7.3% 
HR 0.97 (95% 
CI 0.58-1.64), 
4% non-
inferiority 
margin met. 
TLR 3.4 vs. 4.5% 
The PEPCAD-BIF trial randomised 64 patients with bifurcation lesions to DCB-only or 
balloon only angioplasty/POBA treatment and showed binary restenosis rate of 6% vs 
26% (p = 0.045) respectively at 9 month follow up.132 Late luminal loss was significantly 
less with DCB-only treatment (0.13 mm in the DCB and 0.51 mm in the control POBA 
group, p = 0.013; 95 % CI (-0.66 to -0.08)), whilst the TLR rates were 3.12% for DCB 
and 9.38% for POBA (not statistically significant).  
Rosenberg M et al. showed a TLR rate of only 2.3% in 731 de novo lesions (vessel size 
of 2-4mm and lesion length of less than 25mm) after 9 months clinical follow up.133 This 
was a prospective, international, multi center registry with a total of 1025 patients with 
both de novo and ISR lesions. 
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Cortese et al. have reported angiographic follow up data at a mean 201 days post 
procedure of 48 DCB treated patients, who had a type A-C dissection (18, 25 and 5 
patients respectively) left uncovered with a stent.139 Of these, 45 (93.8%) had healed 
completely, 3 had persisting dissections and 1 received a DES at the time of follow up. 
No cardiac death or other TLRs occurred in this group of patients with un-stented 
dissections. This latter study highlights the issue of safe outcomes after balloon 
angioplasty only despite the angiographic appearances of vessel dissection.  
Rissanen T. et al in randomised, non- inferiority DEBUT trial (Drug-coated balloon for 
treatment of de-novo coronary artery lesions in patients with high bleeding risk) showed 
that coronary angioplasty with DCB is superior to bare metal stents in patients with high 
bleeding risks. There were 102 DCB treated patients and 106 BMS treated patients. 
MACE at 9 months were 1% in the DCB group and 14% in the BMS group (absolute risk 
difference −13·2 percentage points [95% CI −6·2 to −21·1], risk ratio 0·07 [95% CI 0·01 
to 0·52]; p<0·00001 for non-inferiority and p=0·00034 for superiority). There were two 
definitive stent thrombosis in the BMS group and no acute vessel closures in the DCB 
group.134 
Li M. et al in their systematic review and meta analysis encompassing 6 studies with 
1800 patients showed non inferiority of DCB angioplasty to drug eluting stents in small 
vessel (<3mm) coronary lesions. 135 The DCB group showed a significant reduction of 
non-fatal MI (OR 0.53, 95% CI 0.31-0.90, P = .02). 
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Widder JD in the FALCON registry showed a 12 months MACE rate of 9.7% for 757 
patients (43.1% - de novo, 56.9% - ISR) treated with  IN.PACT Falcon paclitaxel coated 
balloon. In the de novo group 12 months TLR rate was 4.9%.136 
Venetsanos D. et al compared DCB vs. DES in 1197 lesions in each arm after 
propensity score matching. At a median follow up of 965 days TLR and target lesion 
thrombosis were 7.0 vs. 6.2% and 0.2 vs. 1.1%.(adjusted HR 1.05; 95% CI 0.72–1.53).  
DCB was associated with significantly lower rate of target lesion thrombosis compared 
to new generation DES (adjusted HR 0.18; 95% CI 0.04–0.82).137 There was no 
difference in TLR between Sequent Please, Pantera Lux and In.Pact Falcon DCBs. 
Jeger RV et al in the randomised BASKET SMALL -2 trial compared DCB Vs. DES 
angioplasty in small vessel (<3mm) coronary lesions. 756 patients were randomised 1:1 
to DCB and second generation drug eluting stents. 12 months MACE rates were 7.5 
and 7.3% ([HR] 0·97 [95% CI 0·58-1·64], p=0·9180). Non inferiority of MACE for DCB 
arm to DES was confirmed as the absolute difference of the MACE was below the pre- 
defined 4% non-inferiority margin ([HR] 0·97 [95% CI 0·58-1·64], p=0·9180).138 
1.3.4 DCB angioplasty as Primary Percutaneous Coronary Intervention (PPCI) 
The management of ST-elevation myocardial infarction (STEMI) has evolved 
significantly with the introduction of new pharmacological therapies as well as 
interventional procedures and devices. The GISSI and ISIS-2 studies showed a 
mortality benefit of streptokinase over standard therapy (heparin +/- oral 
anticoagulation)/placebo which lead to the widespread use of streptokinase in the late 
1980’s. 140, 141 The use of recombinant tissue plasminogen activator (rt-PA) was shown 
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to be more beneficial than streptokinase in the TIMI and GUSTO trials.142, 143 Results of 
other studies such as CLARITY and COMMIT paved the way for addition of clopidogrel 
to the drug regime which further reduced mortality. 144, 145  
Primary percutaneous coronary intervention (PPCI) became the preferred choice of 
treatment for acute STEMI, with balloon angioplasty (BA) showing an improvement in 
mortality and the combined endpoint of mortality and MI over thrombolysis in a meta-
analysis comparing the two.146, 147 Subsequently, bare metal stent (BMS) implantation in 
STEMI showed a reduction in target vessel revascularisations (TVR) in comparison to 
BA but without a reduction in death or MI in the Stent PAMI and CADILLAC trials. 148, 149 
The percentage of vessels with TIMI III flow was numerically higher in the BA group as 
compared to the BMS group, whilst mortality and MI rates were numerically but not 
statistically lower.148 When stenting (BMS) was compared with thrombolysis as in the 
STAT study, the results were similar with stenting showing a reduction in TVR but no 
reduction in death or MI. 150 When both first and second generation drug eluting stents 
(DES) were compared to BMS in the setting of an acute STEMI, target vessel/lesion 
revascularization rates were shown to be lower with DES but yet again no reduction in 
death or MI was shown.151-154 Brodie et al in a single center study of 2195 patients over 
a follow up period of 16 years showed  long term target vessel MI and stent or lesion 
thrombosis were significantly higher with both BMS and DES as compared to BA (after 
landmark analysis at 1 year).155  
Theoretically stenting may work as a method of mechanical plaque sealing however this 
has not been proved in studies. It could be argued that this potential advantage will be 
lost when carrying out DCB-only PCI in acute myocardial infarction. The CADILLAC trial 
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which compared BA vs. BMS with or without Abciximab did not show any difference in 
post procedure TIMI flow grades between the two groups149. Also the below mentioned 
DCB studies which show high post procedure TIMI III flow rates would provide some 
evidence against this argument. The theory that less instrumentation in a thrombotic 
lesion might improve TIMI III flow should also be considered. 
Despite the advances in the care of this high risk group, the case mix standardised 30 
day mortality after AMI remains at 8.4% and 9.7% for Sweden and the United Kingdom 
respectively.156 The annual UK wide audit conducted by the British Cardiovascular 
Intervention Society (BCIS) in 2014 revealed a 30 day mortality of 6.9% for all patients 
who received PPCI.2 This was 7.9% for the 2017/18 financial year.157 
Evidence for DCB angioplasty in PPCI. 
Several studies have reported their experience of using DCB without stenting in the 
PPCI setting. Vos et al carried out a pilot study involving 100 patients presenting with 
acute STEMI using the paclitaxel coated Pantera LuxTM.  Cardiogenic shock and 
intubated out of hospital arrests were excluded. 59% had DCB-only PCI, with the rest 
requiring BMS implantation due to dissections of type C or greater (National Heart, Lung 
and Blood Institute - NHLBI classification). 12 month follow up revealed cardiac death in 
2%, MI 0% and target lesion revascularization rate of 3% in this selected group. TIMI III 
flow was achieved in 96% of patients. 158 
Ho et al reported their preliminary experience with paclitaxel coated balloon (SeQuent 
Please) in the PPCI setting for 89 patients. 70% had TIMI 0 flow pre procedure and TIMI 
III flow was achieved in 98% patients. Glycoprotein IIb/IIIa inhibitors were used in 80% 
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and thrombus aspiration was carried out in 56%. DCB-only PCI was carried out in 96% 
whilst the other 4% had bail out stenting for significant acute recoil or dissections. They 
reported a death rate of 4.5%, MI 0% and TLR/TVR of 0% at 30 days. 159 Whilst results 
are impressive it should be noted that these are observational studies therefore will 
have their inherent limitations such as selection and treatment bias. 
Nijhoff et al in a subgroup analysis from the DEBAMI trial showed that there was no 
difference in major adverse cardiac events in 40 patients treated with DCB-only PPCI in 
comparison to BMS only, BMS+DCB and paclitaxel eluting stent implantation at 6  
months follow up. 160 
The REVELATION trial randomised 120 patients presenting with STEMI to DCB and 
DES. Randomisation was carried out if more than 50% luminal diameter was achieved 
after initial pre dilatation. Primary end point was fractional flow reserve after 9 months. 
The mean fractional flow reserve value was 0.92 ± 0.05 in the DCB group (n = 35) and 
0.91 ± 0.06 in the DES group (n = 38) (p = 0.27) indicating non inferiority of DCB to DES 
in FFR follow up at 9 months.161 
These publications suggest that DCB-only PPCI may be a safe alternative to standard 
stent implantation in this high risk group.  
Technical Tips and Tricks with DCB-only Angioplasty in Primary PCI 
It is recommended to follow the German consensus guidelines but with additional steps 
to successfully perform DCB-only PPCI.50 
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1. Lesion preparation:  
Aspiration thrombectomy is recommended when faced with a high thrombus burden i.e.: 
TIMI thrombus grade 3 or more, aiming to reduce the thrombus burden to TIMI 
thrombus grade of 2 or less. A thrombus- laden lesion is more likely to hamper effective 
drug delivery to the vessel wall.  
This should be followed by mandatory pre dilatation of the lesion using semi or non- 
compliant balloons with a balloon to vessel ratio of 0.8 to 1.0. This should be done 
carefully and slowly with enough pressure only to fully inflate the balloon (usually 6-8 
atm). Liberal use of intra coronary nitrates is recommended as this helps accurate 
vessel sizing. We have a low threshold for the use of glycoprotein IIb/IIIa inhibitors in 
treating lesions with high thrombus burden. Whilst bleeding risks could be higher with 
glycoprotein IIb/IIIa inhibitor use, risk of intracerebral bleeding or stroke was not higher 
compared with placebo and most early studies were carried out when arterial access 
was transfemoral.
162 A more recently published study analysing 110,327 patients in the 
BCIS registry has shown that routine (>75%) use of Glycoprotein IIb/IIIa inhibitors 
reduced mortality over a 5 year period.
163  
The fluoroscopic acquisitions after pre dilatation should be of a slightly longer duration 
to carefully look for evidence of vessel threatening dissections, in particular any contrast 
hang up or accumulation within a dissection plane indicating a NHLBI type C dissection 
and possible early vessel closure due to intramural haematoma formation.  
Coronary dissections are an inevitable result of BA, but most are micro dissections that 
cannot be seen on angiography and are of no clinical significance. However, abrupt 
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vessel closure remains one of the most fearful complications of BA usually associated 
with NHLBI dissection grades of type C and above. With a good knowledge of the 
different NHLBI grades of coronary dissection, careful selection of those patients 
suitable for DCB-only angioplasty is possible.164 Ho et al in their study reported no 
abrupt closure of the culprit artery. Only 4% of patients required bailout stenting for 
significant recoil/dissections of type C and above.  
2. Drug delivery: 
If there are no dissections of more than NHLBI type C, TIMI III flow and not more than 
30% residual stenosis, drug delivery should be considered with the deployment of the 
DCB. DCB diameter should be the diameter of the largest balloon used to pre dilate the 
lesion.  The DCB should be used only for drug delivery and not for further angioplasty. It 
is good practice to check the guide catheter and wire position and ensure the O-ring is 
fully open before start delivering the DCB. Care should be taken not to touch the DCB 
prior to introduction. We recommend following manufacturer’s instructions for use to 
ensure adequate drug delivery.  This will include maximum transit time to the lesion and 
balloon inflation times.  
The use of DCB as primary therapy in primary PCI represents a novel approach in 
treating STEMI patients. This approach is possible with appropriate patient selection 
and by performing 2 key preconditioning steps namely aspiration thrombectomy for 
lesions with high thrombus burden and careful lesion preparation. However, it is 
recommended to perform DCB-only angioplasty in stable patients first, preferably with 
proctoring before treating such high risk patient groups. 
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1.3.5 Bifurcation PCI 
It is estimated that PCI for bifurcation lesions account for about 20% of the total 
coronary interventions undertaken165. It is perceived to be a challenging area due to 
reasons discussed below. 
There are numerous criteria for classification of bifurcation lesions but the most 
commonly used one is the Medina Classification which is shown below in figure 7. 
Figure 7 Medina classification for bifurcation lesions 
 
True Bifurcation lesions are considered to be the ones affecting both main and side 
branches. (1,1,1, 1,0,1 and 0,1,1). 
Intervention to such lesions is challenging due to location, angle of the side 
branch/distal main branch, technical difficulties such as lesion visualisation and 
accurate stent placement as well as higher adverse outcome rates as compared to 
intervention in non-bifurcation lesions. Side branch occlusion due to plaque/carina shift, 
flow limiting dissections of the side branch and compromise of flow in main branch 
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stents due to strut deformation as well as increased re-stenosis and thrombosis rates 
are a few specific adverse outcomes in addition to the known complications of PCI.  
Major adverse cardiac events in this group were reported to be very high prior to use of 
DES. Al Suwaidi et al reported MACE rates of 32% at 1 year follow up.166 Even after the 
introduction of DES, adverse events such as side branch restenosis rates remain high 
compared to non-bifurcation lesions. The British Bifurcation Coronary (BBC) study 
which compared simple vs. complex two stent strategy for bifurcation lesions in 500 
patients showed a composite of death, MI and TVR of 8.0% vs. 15.2% (hazard ratio 
2.02, 95% confidence interval 1.17 to 3.47, P=0.009) at 9 months follow up.167 Side 
branch restenosis rates of 14.6% and 12.5% at six months were reported in the two 
arms of the CACTUS study which tested crush vs provisional techniques using sirolimus 
eluting Cypher stents.168 In the Nordic Baltic III bifurcation study, at 8 months 
angiography follow-up, the percentage of binary restenosis (diameter stenosis ≥50%) in 
the entire bifurcation lesion (MV and SB) was 11.0% in the final kissing balloon 
dilatation (FKBD) and 17.3% in the no-FKBD group.169 Recently published DKCRUSH 
VI study (comparison between angiography guided vs FFR guided provisional stenting) 
reported MACE (Cardiac death, MI, ischaemia driven TVR) rates of 18.1% for both arms 
at one year follow up.170 Dedicated bifurcation stents have been developed and tested 
in studies involving small number of patients but they are not yet in use as part of day to 
day practice.  
There are various approaches/techniques of angioplasty/stent insertion described in 
literature and being used in practice. Provisional approach (Stenting the main branch 
with a jailed wire in the side branch, and stenting of side branch only if required) is the 
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current preferred approach. When a two stent strategy is required, stent insertion 
techniques such as culotte, crush, T stenting and TAP, with or without final double 
kissing balloon inflation are used, with the choice of technique dictated by angiographic 
characteristics as well as operator preference. 
DCB-only treatment in Bifurcation Lesions. 
As there is no permanent metal implant/polymer left behind, DCBs are an attractive 
option in treating bifurcation lesions. In most dual stent techniques there is overlap of 
stent struts which potentially increases the risk of stent thrombosis, side branch 
occlusion and dissections. Furthermore the amount of plaque/carina shift will be less 
intense with a balloon-only approach because no permanent implant is deployed (the 
latter always requires optimisation of the lumen as assessed by angiography +/- 
intravascular imaging). There is evidence of late luminal gain after DCB alone treatment 
due to restoration of normal vasomotion and positive remodelling.171 This will be hugely 
beneficial in this cohort of patients as it will help restore flow dynamics. 
There have been studies conducted using DCB’s in bifurcation lesions but most 
adopted a strategy of implanting a BMS in the main branch/vessel (DEBUIT and 
PEPCAD V).52, 172 This is at odds with the biggest potential benefit of DCB use, which is 
in the setting of no permanent implant (stent).  The literature available suggests that 
DCB plus BMS is a flawed concept with no advantage over BMS alone. 
Schulz A et al has published an observational study of 39 patients who were treated 
with DCB only strategy and follow up angiography at 4 months. MACE was reported as 
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7.7% and restenosis rates were low at 3.3 % of the side branch and 6.7 % of the main 
branch. No deaths, MI or strokes were reported.173 
DCB-only group of the PEPCAD-BIF (comparison of DCB-only vs POBA) study had 
restenosis rates of only 6% at 9 months and LLL of only 0.15mm.132 
1.3.6 Chronic Total Occlusions 
A chronic total occlusion is defined as 100% occlusion in the coronary artery with TIMI 0 
flow of at least 3 months duration. 174 
CTOs are complex lesions encountered in 15-30% of patients referred for coronary 
angiography and are considered a significant challenge in percutaneous coronary 
intervention (PCI).175 Due to the lower rates of success compared to sub-total stenosis, 
CTOs remain the strongest independent predictive factor for referral for coronary artery 
bypass grafting.175 Successful recanalization is known to reduce angina, reduce the 
ischaemic burden and improve left ventricular function. It is also thought to have a 
reduction in mortality rates (on the basis of observational studies).176 Certainly, patients 
who have an acute coronary syndrome (ACS) with a CTO are known to have 
significantly worse outcomes compared to those without a CTO, even accounting for 
patients with multi-vessel coronary disease. 177-180 
CTO PCI procedural success has always been associated with poorer outcomes than 
sub-total stenosis PCI, with rates currently at about 77% angiographic success (Pooled 
Estimate Rate).181  
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Instent restenosis (ISR) rates in CTO PCI are relatively high, although the introduction 
of drug eluting stents (DES) has seen a reduction in ISR from 41% to 11% compared to 
bare metal stents (BMS). 182Therefore, the majority of CTO PCI practice involves the 
use of DES (82.2%).176 The fact still remains however that ISR rates in CTO are still 
significantly high at 10-15% at one year. 182-187 TLR rate of 6.3% and MACE rate of 10% 
at 12 months have been reported after everolimus eluting stent implantation.188  TVR of 
7.5% and 13.8% at 12 months were reported with sirolimus and zotarolimus eluting 
stents respectively in another study by Park HJ et al.186 
The pathophysiological changes in CTOs after intervention are complex. Galassi et al. 
looked at the transient vasomotor impairment following successful recanalization of the 
CTO. He reported that after recovery of antegrade flow and a period of hibernation of 
the vessel wall, distal vessel diameter increased as a result of recovery of vasomotor 
tone.189 One IVUS study has shown 69% of the re-canalized vessel had a mean 
increase in diameter of 0.4mm at 6 month follow-up.190 This may well account for the 
higher rate of instent restenosis seen in CTOs due to distal stent segment 
malapposition, as stent sizing may be underestimated.191  
A multicenter registry of 34 patients who received DCB treatment for CTOs showed 
restenosis rate of 11.8% (n=4) and re-occlusion rate of 5.9%.192 Benefits of DCB only 
angioplasty in CTOs may be attributable to anti restenotic drug delivery reducing 
restenosis whilst avoiding other stent related issues such as chronic inflammation, neo 
atheroma, stent fracture, stent gap, stent overlap, non- uniform stent struts, non-
homogenous drug delivery, uncovered stent struts and under expansion. It is further 
advantageous as late lumen gain caused by recovery of vasomotor tone which would 
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have led to malaposition of a stent is no longer an issue as there is no permanent or 
temporary implant in DCB angioplasty. It may be further beneficial over stents as longer 
coronary segments are treated during angioplasty of CTOs.  
1.4 Potential Advantages and Disadvantages of DCB angioplasty 
1.4.1 Potential advantages of not having a permanent metal implant in de novo 
disease. 
Brodie et al have published a long term longitudinal follow up registry of 2,195 
consecutive patients treated for STEMI, comparing POBA to BMS and DES and 
showed better long term outcomes in the balloon angioplasty arm (POBA (n = 601), 
stenting (n = 1,594) from 1994 to 2010).155 Target vessel re-infarction and stent/lesion 
thrombosis were better with POBA compared to stents between 1 and 9 years (3.1 vs 
7.9%, p<0.001 and 2.9 vs 6.1 %, p 0.002 respectively).  Landmark analysis at 12 
months showed a trend in favour of stenting with a non-significantly lower re-infarction 
rate only (figure 8).  However it should be noted that there was no bail out stent option 
in case of a vessel threatening complication (stents were only used from 1999 onwards 
outside of research procedures) and only single anti-platelet therapy was often used. In 
this cohort of BA cases only 23% were discharged on thienopyridines. However, all 
patients received standard treatment of the time. The authors concluded that there is a 
long-term risk associated with a permanent coronary metallic implant.   
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Figure 8 Kaplan-Meier estimates of event rates and cardiac mortality in patients treated with drug eluting 
stents, bare metal stents and balloon angioplasty for ST segment elevation myocardial infarctions at a single 
center over 16 years. Figures (a) Stent or lesion thrombosis, (b) Target vessel infarction, (c) cardiac mortality. 
Brodie et al. 
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A DCB-only strategy has the potential to overcome the long-term complications of stent 
systems by avoiding a permanent implant, thus allowing the blood vessel to regain its 
original vasomotion and undergo positive remodelling. Togni et al illustrated how 
stented segments do not undergo any vasodilatation during exercise, whilst those 
segments adjacent to Sirolimus stents showed paradoxical vasoconstriction on 
exercise.193 Adverse effects of Sirolimus stents on local endothelium dependent 
vasomotion have also been shown by Hofma et al.194 In contrast, whilst there is no 
published data on restoration of normal endothelial vasomotor function after DCB-only 
PCI, there is evidence of positive remodelling resulting in late luminal gain as shown by 
Kleber et al.171 This remodelling process is beneficial post DCB-PCI, but in the presence 
of a permanent metallic cage could result in late mal-apposition with subsequent late 
complications. The role of DCB angioplasty in late lumen enlargement is discussed in 
the following section in detail. The disadvantages of delayed endothelialisation, chronic 
inflammation, mal-apposition and under-expansion are all irrelevant when there is no 
permanent implant.  
The major difference between DCB and other treatment options is that the DCB option 
does not require even a temporary implant. Hence we suggest that a strategy which 
tackles the problem of restenosis whilst not involving a permanent metal stent or semi-
permanent polymeric scaffold could be attractive in the vast majority of patients who 
undergo angioplasty when acute complications such as a flow limiting dissection, vessel 
closure or recoil do not occur (that is, more than 90% of patients undergoing angioplasty 
as shown in Benestent and Stress trials, but we do accept current PCI practice 
incorporates much more complex anatomy and techniques). We propose this is where 
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Drug Coated Balloon angioplasty has a role to play. It does not leave a permanent 
implant but targets restenosis with the delivery of a cytotoxic/cytostatic drug to vessel 
wall. Obviously, DES and BVS will be very necessary tools to have in the armoury in 
case of acute complications mentioned above.   
1.4.2 The Role of Drug-Coated Balloons on Late Lumen Enlargement 
Late lumen enlargement (LLE) is defined as an increase of the minimal luminal diameter 
or area of a coronary artery at follow up angiography as compared to the minimal 
luminal diameter or area immediately after a percutaneous coronary intervention. This 
has been described in the treated segment of the coronary artery as well as segments 
distal to the treated lesion. The latter downstream late lumen enlargement is considered 
to be due to re-establishment of vasomotor tone in the hibernating vessel wall and may 
be observed, for example, after recanalization of a chronically occluded or severely 
stenosed artery. 189, 190 In this section focus is on in-segment late lumen gain in the 
setting of drug coated balloon (DCB)-only angioplasty.  
Importance of LLE 
Any late lumen enlargement should be considered beneficial by way of mitigation 
against the development of flow limiting coronary restenosis. However, in the presence 
of a permanent or semi- permanent implant it may theoretically result in late mal-
apposition and subsequent implant-related complications (particularly stent or scaffold 
thrombosis).  
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Possible contributory factors for LLE 
In a very early study of 47 patients who received balloon only angioplasty, Johnson et al 
described the three possible luminal outcomes at angiographic follow up (in this case 
7.2+/-3 months).  A decreased lumen diameter was seen in 34.8%, the dimensions 
were unchanged in 30.4% whilst an increased lumen diameter was seen in 34.8%. 195 
Two theories were postulated for the late lumen gain; coronary spasm during the 
procedure which subsequently resolved or intimal plaque fracture resulting in late 
plaque retraction with healing and re-endothelialisation.  
Coronary Dissections 
Adding to the Johnson et al data, there are other studies suggesting late lumen 
enlargement may be enhanced by the presence of a coronary dissection. Cappelletti et 
al studied 129 consecutive patients treated with POBA only, of whom 49 had a non- 
occlusive dissection (NHLBI type A-E, figure 2, page 48) left uncovered.196 Restenosis 
rates at 6 months angiographic follow up were lower in the dissection group as 
compared to the group without a dissection (12 vs. 44% (p<0.001)) A matched cohort of 
60 patients who had bail out stenting after a coronary dissection had a restenosis rate of 
25%.  
In a study of 986 patients treated with POBA, of whom 248 had intimal dissections, 
restenosis rates were numerically lower in the group left with a dissection (24 vs 30%, p 
0.08). 197 In the group with a post procedure trans-stenotic pressure gradient of less 
than 15 mmHg, the restenosis rate was significantly better in the group left with a 
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coronary dissection (19 vs. 28%, p <0.05). As Figure  9 shows the long term gain was 
significantly better in the group left with a coronary dissection (35 vs 40%, p 0.01). 
Figure 9 Mean percent stenosis (+/- SD) in patients without intimal dissection and in patients with intimal 
dissection before angioplasty (pre-PTCA), immediately after angioplasty (post-PTCA), and at the time of 
follow-up angiography (F/U-angio). (Leimgruber  et al) 
  
Cortese et al published a prospective registry of 48 patients with uncovered type A to C 
dissections after treatment with a paclitaxel eluting balloon. 139 The late lumen loss at 6 
months angiographic follow up was only 0.14 (−0.14 to 0.42) mm. Figure 10 shows how 
the curve representing minimal lumen diameter (MLD) has shifted to the right at follow 
up angiography. Whilst this may have been influenced by the presence of paclitaxel 
which we will discuss later, the association with uncovered dissections should not be 
ignored. 
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Figure 10 Minimal luminal diameter before DCB PCI, after DCB PCI, and at angiographic follow-up in patients 
left with a dissection (Cortese et al) 
 
Whilst the exact mechanism of LLE is unknown after POBA dissections, it has been 
suggested that healing and fibrosis occur with retraction and endothelialisation of the 
separated intimal flaps, resulting in a larger lumen area and smoothening the inner 
contour. 198 
Resolved acute recoil and coronary spasm 
Resolved acute recoil and coronary spasm are two other possible contributory factors to 
late lumen gain when there is no permanent or semi–permanent stent, but we are not 
aware of any specific data on this subject.    
Absence of an implant 
A coronary artery that has been caged with an implant does not have the ability to 
change its dimensions or respond to vasomotor reflexes as compared to a non-caged 
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artery. There are no studies to our knowledge that show late lumen enlargement after 
stenting (unlike POBA as described above). However late stent mal-apposition is 
reported in about 10-25% of drug eluting stent implantations and may represent the 
same pathophysiology. 199, 200 Togni et al demonstrated sirolimus DES treated 
segments do not change their lumen size due to a loss of vasomotion.  Interestingly 
however, adjacent segments paradoxically constrict on exercise. 193 
DCB (Paclitaxel coated balloon) and late lumen enlargement. 
Kleber et al described late lumen enlargement after paclitaxel coated balloon-only 
percutaneous coronary intervention in a study of 58 coronary artery lesions with a mean 
reference vessel diameter of 2.58 ± 0.47 mm. 171  Quantitative coronary angiography 
analysis at 4.1 ± 2.1 months revealed 69% of lesions demonstrating late lumen gain. 
Interestingly, the mean luminal diameter increased not only of the drug coated balloon 
(DCB) treated segment but also occurred in the 2 adjacent 5mms segments.  
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Figure 11 Minimal lumen diameter of the lesion site during pre, post and follow up angiography (Kleber  et al) 
 
The authors suggest late lumen enlargement with paclitaxel coated balloon may be 
explained by paclitaxel driven inhibition of smooth muscle cell proliferation by 
modulation of microtubule formation and upregulation of pro-apoptotic factors and also 
possibly due to thinning and enlargement of tunica media. 201-203  We therefore presume 
the effect is due to a combination of inhibition of cell proliferation and cell death.  
Ann et al found a significant increase of mean vessel and lumen area of 28 de novo 
lesions treated with paclitaxel coated balloon-only angioplasty at 9 months follow up 
angiography (12.0 ± 3.5mm2 to 13.2 ± 3.9mm2, p <0.001; and 5.4 ± 1.2mm2 to 6.5 ± 
1.8mm2, p <0.001).204 IVUS virtual histology during the follow up assessment showed 
no change in the mean plaque area (6.6 ± 2.6mm2 to 6.6 ± 2.4mm2, p = 0.269) but 
reduction of percentage atheroma volume (53.4 ± 7.9% to 49.5 ± 6.4%, p = 0.002).  
Plaque composition did not change significantly. Serial changes of percentage 
atheroma volume and minimal lumen area are shown in figure 8 whilst figure 9 shows 
the changes of pre, post and follow up mean vessel, lumen and plaque areas.  
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Figure 12 Serial changes in percent atheroma volume and minimal lumen area. (Ann SH et al) 
 
Figure 13. Serial changes of mean vessel, lumen and plaque area (Ann SH et al)  
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Similar to Kleber, the authors attributed these findings to arrest of micro-tubule function 
resulting in prolonged anti-proliferative and anti-migration effects and prolonged 
retention of paclitaxel. 201, 202, 205 
Her et al assessed  the size of 28 side branches where the main vessel has been 
treated with a paclitaxel coted balloon-only angioplasty  and found increased ostial size 
of the side branch at 9 months follow up using optical coherence tomography (OCT).206 
Inclusion criteria were lesion stenosis of >70%, vessel diameter of 2.5-3.5mm, lesion 
length of ≤24mm and a side branch (SB) of ≥1.5 mm. Angiographic and OCT 
assessments were carried out pre, immediate post angioplasty and at 9 months from 
the index procedure.  The minimum lumen area of SB ostia were pre PCI 0.92±0.68 
mm2, immediate post PCI 1.03±0.77 (p 0.726) and at follow up 1.42±1.18 (p0.013). In 
addition, the main vessel minimal luminal diameter and mean luminal area were both 
significantly increased by both angiographic and OCT follow up at 9 months. This late 
enlargement of side branch ostia could be attributed to overall lumen enlargement 
and/or effects of paclitaxel alone. Figure 10 shows serial changes of main vessel and 
side branch ostial mean lumen area. 
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Figure 14. Serial changes of mean lumen area of main vessel and side branch ostia (Her AY et al) 
 
Levin et al studied intra mural drug distribution and transport properties for paclitaxel 
and rapamycin in bovine internal carotid segments.207 It was shown that paclitaxel which 
binds microtubules remained primarily in the sub intimal tissue, mainly the tunica 
adventitia. Figure 11 shows the tissue binding capacity of dextran, paclitaxel and 
rapamycin in 0.040-mm-thick bovine internal carotid tissue segments.  
This could explain the positive vessel re-modelling (increased vessel diameter/area) 
shown above resulting in late lumen enlargement in an effect similar to described by 
Glagov et al. 208 They reported  an enlargement of the vessel area of coronary arteries 
thus maintaining the lumen area during plaque progression, up to the point of 40% 
stenosis of internal elastic lamina area. Figure 12 (a and b) illustrates this phenomenon. 
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Figure 15 Transmural equilibrium distribution of labeled dextran (♦), paclitaxel (□), and rapamycin (⋄) in 0.040-
mm-thick bovine internal carotid tissue segments. (Levin AD et al) TBC – tissue binding capacity 
 
Figure 16 (a and b). Adaptive remodeling of coronary artery (Glagov  et al) 
 
As described above, paclitaxel is a potent cytotoxic drug which arrests microtubule 
function resulting in prolonged anti proliferative and migration effects and upregulation 
of pro-apoptotic factors.201, 202, 205 Additionally paclitaxel has been shown to cause a 
reduction in smooth muscle cell and collagen content in the intima as well as the media 
after local delivery. 203 Late lumen enlargement may also be partly explained by positive 
vessel remodeling (increased vessel diameter/area) as described by Glagov et al. 208  
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In summary the effects of paclitaxel, the presence of coronary dissections and the lack 
of either a metallic or polymeric cage implant may all contribute to late lumen 
enlargement seen after paclitaxel coated balloon-only angioplasty.  
DCB angioplasty         At follow up 
Resolved spasm and acute recoil 
Coronary dissections (healing and fibrosis 
with retraction and endothelialisation of  
separated intimal flaps)  
Absence of an implant (non-caged artery allowing 
function of vasomotor reflexes) 
Effects of paclitaxel on tunica intima, media and adventitia 
 
Figure 17 Possible causes for late lumen gain after DCB-only angioplasty 
 
The implications for PCI are enormous.  The initial results of balloon-only angioplasty no 
longer need to be “stent-like” in order to achieve an adequate long term result.  The 
application of the German consensus guidelines accepting a residual post balloon 
stenosis of <30% will allow many patients to have successful procedures without the 
long term hazard of a permanent metallic implant, with the added benefit of a return to 
normal endothelial and vasomotor function.  
1.4.3 Potential disadvantages 
Acute recoil and NHLBI dissections of type c and above would be two not so uncommon 
drawbacks of DCB only PCI in de novo vessels. Unlike in the POBA only days, the 
availability of DES as a bail-out option helps mitigate this issue effectively. Also use of 
cutting/scoring balloons will be helpful in overcoming acute recoil. The percentage of 
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bail out stenting tends to vary from study to study. The cross over rate from POBA arm 
to stent arm was 5-6% in the Stress and Benestent trials. The SCAAR registry showed 
8% bail-out stenting whilst REVELATION study showed bail out stenting/additional 
stents in 18% of the 60 patients in the DCB arm. 
 It is also perceived that deliverability of DCB is less compared to conventional stents 
and also the time limit of 2 minutes to deliver the DCB to a lesion and fully expand can 
make it challenging in difficult/complex lesions. 
Acute vessel closure/instability requiring patients to be brought back to the catheter lab 
will be the most feared draw back out of all. This study will give valuable information on 
the incidence of acute vessel closure of an all comer population in the real world setting. 
DCB arm of the BASKET-SMALL randomized study had no acute vessel closures. 
Similarly Sequent Please world-wide registry which included 453 de novo lesions had 
no acute vessel closures in the DCB only arm. SCAAR registry data does not provide 
this information.124, 137, 138 
Enhanced quality of imaging over the years will undoubtedly help identifying vessel 
threatening dissections that can lead to acute vessel closures. Additionally one to one 
proctoring in the initial stages of DCB-only PCI will be beneficial to understand how 
these dissections behave and progress in the acute setting and what could be safely left 
without a bail-out stent. 
Impact of Paclitaxel on mortality 
Konstantinos K. et al published a systematic review and a meta-analysis of 28 
randomised controlled trials including 4663 patients who received a paclitaxel coated 
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device (stent or balloon) or a non-paclitaxel treatment for femoro-popliteal arterial 
disease. At two years all-cause death (12 RCTs with 2316 cases) was significantly 
increased in the case of paclitaxel versus control (7.2% versus 3.8% crude risk of death; 
risk ratio, 1.68; 95% CI, 1.15–2.47; number-needed-to-harm, 29 patients [95% CI, 19–
59]). This trend in increased all-cause death persisted up to 5 years (3 RCTs with 863 
cases) in the paclitaxel arm (14.7% versus 8.1% crude risk of death; risk ratio, 1.93; 
95% CI, 1.27–2.93; number-needed-to harm, 14 patients [95% CI, 9–32]).209 Not having 
patient level data for the analysis is a major limitation of this study.  
Schneider PA published a patient level meta-analysis including 1837 patients treated 
with paclitaxel coated balloon and 137 balloon-only angioplasty treated patients and this 
did not show a significant difference in mortality after 5 years.210 Secemsky EA et al 
showed no increase in mortality after drug coated devices treatment compared to 
balloon only or bare metal stent treatment of femoro-popliteal disease in a study 
including 16560 patients. 5989 patients had received a drug coated device therapy. 
Median follow up was 389 days. Drug-coated devices arm showed a lower incidence of  
all-cause death compared with treatment with non–drug-coated devices through 600 
days post procedure (32.5%vs 34.3%, log-rank P = .007).211  
Albrecht et al published a pooled analysis of four randomized controlled multicentre 
trials (433 patients) to compare two year mortality of paclitaxel coated balloons (PCB) 
with uncoated balloons for femoro-popliteal disease. Importantly this included individual 
patient level data. At two years, mortality was numerically low in the PCB group but not 
statistically significant (7% vs. 8.7% (p 0.55).212 
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Whilst the debate is ongoing there certainly is no study/evidence to suggest increased 
mortality in use of paclitaxel in coronary PCI.  
A recent publication by Scheller et al which included 4590 patients in 26 randomised 
controlled trials (RCT) comparing paclitaxel coated balloons (PCB) vs. non-DCB 
devices in coronary artery disease showed no difference of death at two years (RR: 
0.84; 95% CI: 0.51 to 1.37; p = 0.478). At 3 year follow up (9 RCTs, 1775 patients) 
mortality was significantly lower (RR: 0.73; 95% CI: 0.53 to 1.00; p = 0.047) in the 
paclitaxel coated balloon group.213 Cardiac death showed a similar reduction in the 
paclitaxel coated balloon treated group (RR: 0.53; 95% CI: 0.33 to 0.85; p = 0.009). 
This certainly is an encouraging finding for the use of PCB in coronary artery disease 
but more studies with longer term follow up are required to ascertain these findings 
further. 
1.5 Hypothesis 
DCBNORWICH Registry: Main hypothesis is DCB angioplasty is a safe and effective 
method of percutaneous coronary intervention.  A target vessel revascularisation (TVR) 
rate of 4.9 to 11.1% or less at 12 months for de novo lesions and approximately 20% or 
less for the ISR group were considered to be within expected ranges based on real 
world data of DES studies. Assuming 830 patients in the de novo lesions group and a 
TVR rate of 4.9% and a censoring rate of 0.5% for all groups, the study would be able to 
estimate the survival rate with a standard error of 0.8 percentage points (estimated 
using Greenwood’s formula). The registry data is most importantly also seen as 
hypothesis generating. 
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DCBNORWICH propensity score matched comparison of DCB vs. 2nd generation 
DES: 
Major adverse cardiac outcomes (MACE) of DCB angioplasty is non-inferior to DES by 
a non-inferiority margin of 4.5%. The DCB outcomes will be considered non-inferior to 
DES, if the 95% CI of the estimated OR from the logistic regression model excludes 
1.56. 
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 Chapter 2: Methods 2
2.1 DCBNORWICH Registry 
2.1.1 Study Design 
This was a single centre, retrospective, all-comer, observational registry to assess the 
outcomes of patients who received Drug Coated Balloon Angioplasty treatment from 
01/01/2009 to 31/12/2015 at Norfolk and Norwich University Hospital (NNUH). We have 
included patients with both acute and stable coronary artery disease using DCB, in all 
sizes of coronary arteries and all vessels including left main stem.  
2.1.2 Patient Identification 
Up until June 2011, all PCI data has been entered to a data base named PATS and 
thereafter INTELLECT, which is in use to date in the Norfolk and Norwich University 
Hospital NHS Foundation Trust. PCI operators enter data that are mandatory for 
submission to British Cardiac Interventional Society (BCIS) data base as well as other 
data required by the trust data base for each PCI procedure.  
Patients who have undergone DCB angioplasty were identified from these two data 
bases by the manager in charge of the data base, thereby allowing extraction of their 
demographic details, coronary risk factors and procedural details.  
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2.1.3 Patient Eligibility Criteria 
Inclusion Criteria 
All patients who have undergone DCB angioplasty at the Norfolk and Norwich University 
Hospital from 01/01/2009 to 31/12/2015 were eligible for the study. 
Exclusion Criteria 
No patients were excluded. 
2.1.4 Approvals 
NNUH Research and Development 
Firstly the project proposal was forwarded to the NNUH Research and Development 
department and it was registered as a research study. It was agreed that NNUH would 
be the project sponsor. 
Caldicott Guardian 
Following this an application was forwarded to trust’s Caldicott Guardian together with 
the project proposal to obtain a letter of support.  
National Research Ethics Committee Approval 
Thirdly an application for ethics approval was forwarded to a national ethics committee 
via the centralized application system (Integrated Research Application System – IRAS) 
of the Health Research Authority (HRA) of the United Kingdom. 
Health Research Authority Approval 
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Following the favourable response from the ethics committee, HRA approval was 
sought. HRA recommended seeking Confidentiality Advisory Group recommendations 
prior to giving its approval, as HRA considered National Institute for Cardiac Outcomes 
Research (NICOR) a third party for the study’s purpose. The role of NICOR in this study 
is described in subsequent paragraphs. 
Confidentiality Advisory Group (CAG) 
Confidentiality Advisory Group is an independent body that provides expert advice to 
the HRA on use of confidential personal information of patients for the use of research 
activities. It also provides advice to the Department of Health on use of patient 
confidential information for non-research work. The HRA web site quotes ‘The key 
purpose of CAG is to protect and promote the interests of patients and the public, while 
at the same time facilitating appropriate use of confidential patient information for 
purposes beyond direct patient care’. 
As per recommendations made by the HRA, an application form (IRAS based 
application) together with required supporting documents was forwarded to CAG to 
seek legal support in order to share patient identifiable details (NHS number, date of 
birth and gender) with NICOR. Supporting documentation including a confidentiality 
advisory team advice form and a public notice that was to be uploaded in the hospital 
web site was forwarded. 
NICOR 
The National Institute for Cardiovascular Outcomes Research is the national body that 
collects data of cardiovascular procedures carried out in the United Kingdom. It also 
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analyses outcomes of these procedures and publishes them annually. This is a vital 
source of data that helps hospitals and healthcare bodies to monitor and draw plans to 
improve outcomes of the cardiovascular patients. NICOR consists of clinicians, IT 
experts, analysts, academics and managers who run the national audit programmes as 
well as registries. There are six national clinical audits run by the NICOR. They are 
1. Adult cardiac surgery 
2. Adult percutaneous interventions 
3. Cardiac rhythm management 
4. Congenital heart disease 
5. Heart failure 
6. MINAP (Myocardial Ischaemia National Audit Project)  
 
An application together with the supporting documents was forwarded requesting 
outcome data. Approvals of the three audit leads (Adult percutaneous interventions, 
Adult cardiac surgery and MINAP) were obtained. 
HQIP (Healthcare Quality Improvement Partnership) 
An application was forwarded to HQIP data access request group (DARG) meeting 
requesting permission for NICOR to release outcome data.  
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The HQIP is an independent organisation established in 2008 to improve quality of 
healthcare and specifically to enhance the use of national clinical audits in achieving 
this. Academy of Medical Royal Colleges, the Royal College of Nursing and National 
Voices lead the HQIP. 
Researchers requesting data from NICOR are required to forward an application to Data 
Access Request Group (DARG) of the HQIP. An application together with the 
supporting documents from the trust, HRA and CAG was forwarded to HQIP as an 
amendment to the previously forwarded application. 
Time frames for each of the approval stages and the length of the completed application 
forms are listed below in table 5. 
NICOR had the legal authority to provide researchers with mortality data at the time of 
planning this study. However this mandate had been taken away from the NICOR by 
the time we obtained ethics committee and HRA approvals. Upon inquiry from the 
cardiac department at NNUH, we found out that the department is in possession of up 
to date mortality data obtained through the spine portal of the NHS Digital. We therefore 
submitted an amendment to the ethics committee and HRA seeking permission to use 
this data, permission for which was granted.  
The time taken for the approval process and to receive data from the NICOR was about 
31 months. This was a major hurdle in completing this study. The data extraction was 
costly at £ 15,558.  
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Table 5 Stages of approval process and time taken for completion 
Approving body Time duration Length of 
application 
Research and Development 
(NNUH)- initial registration 
1 week Email 
Caldicatt guardian 3 months 5 pages 
NREC 2 weeks 24 pages 
HRA 4.5 months (including time taken for 
CAG) 
Email 
NNUH Information 
governance (IG) and NHS 
Digital for IG tool kit 
assessment 
4 weeks  
CAG 3.5 months 34 pages 
NREC amendment 2 weeks 2 pages 
HQIP 4 weeks 29 pages 
NICOR From application to receipt of data: 
22 months 
Cost £ 15,558.00 (data on MI and 
revascularisation only) 
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2.1.5 Consent 
This was a retrospective study obtaining data from the existing hospital data base, 
medical records and NICOR. We did not plan to carry out any activity which would have 
led to any patient or relative contact.  
We did not plan to obtain consent from the patients included in the study for the 
following reasons: 
Firstly, we believed attempting to gain consent would add bias to the study. For 
example, for deceased patients there was no method of obtaining consent and mortality 
is the most important outcome. Lack of mortality figures would have added bias to 
MACE rates and had a significant impact on the study. Equally if patients elected not to 
give consent, the value of this study as an all-comer study would have lessened. The 
reasons for patient refusal are complex, but might have followeda pattern adding 
confounding factors that would be impossible to accommodate within our analysis. If a 
decision was made to include patients who were deceased, but patients who were alive 
were given a chance to opt out, this would  certainly have had an impact on event rates.  
Secondly due to the large number of patients involved (more than 1000 expected), 
retrospectively consenting them would have increased the cost and labour requirement 
significantly. 
Thirdly, as this is was retrospective study, consenting would have had no impact on the 
clinical procedures already performed or the appropriate care provided. 
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Most importantly, utmost care was given to protect patient confidentiality.  All identifiable 
data were only handled by members of the research team who also are members of the 
Cardiology department (Cardiology doctors). All data were anonymised after initial 
identification from the data base (very early in the study) and had no identifiable data on 
the excel sheet where data is entered, which were the source data. Hence no 
identifiable data were used for statistical analysis or publication. 
A patient group discussion was carried out to test the methodology of the study, to 
obtain suggestions and to find out any concerns from a patient perspective. No 
concerns were raised and the response was a very positive one.  
In addition a public notice was displayed in the Norfolk and Norwich University Hospital 
web site regarding the study and the proposed methodology explaining the data sharing 
with the NICOR. This included contact details of the principal investigator if a patient 
wished to opt out from the study and none such request was received. 
As the HRA recognised National Institute of Cardiac Outcomes Research (NICOR) as a 
third party, we were recommended to seek legal permission from the Confidentiality 
Advisory Group (CAG) of the HRA to share patient identifiable data with the NICOR. 
Subsequently an application was forwarded to the CAG seeking legal permission to 
share the NHS number, date of birth and gender with NICOR in-order to track outcomes 
through the three national cardiac audits namely Myocardial Infarction National Audit 
Programme (MINAP), British Cardiovascular Interventional Society (BCIS) PCI audit 
and Society of Cardio-thoracic Surgery (SCTS) audit. The application was approved by 
the CAG. 
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2.1.6 Study Observations 
The study observations were categorised under demographic details, indication for the 
procedure, procedural details and clinical outcomes (table 6) 
Table 6 Study observations of the DCB Norwich registry study 
Demographic 
details 
Indication and 
antiplatelet therapy 
Procedural details Clinical 
Outcomes 
N N N N 
Age Stable coronary 
artery disease 
Cardiogenic shock MACE (death, MI, 
TLR) 
Gender STEMI – Primary 
PCI 
Out of hospital cardiac arrest Death 
Previous MI Other acute 
coronary 
syndrome 
pH and Lactate if so MI 
Previous PCI Dual antiplatelet 
combination 
Access Target vessel 
revascularisation 
(TVR) 
Previous CABG Duration of dual 
antiplatelets 
Vessel treated Target lesion 
revascularisation 
(TLR) 
Hypertension  Number of vessels treated Acute vessel 
closure 
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Dyslipidaemia  Denovo/ISR/ST Treated lesion 
thrombosis/ Stent 
thrombosis 
Diabetes 
Mellitus 
 Coronary dissection and type  
Chronic Kidney 
disease (stage) 
 Any peri/immediate post PCI 
complication 
 
Family history  Additional stent/s if used  
Smoking 
history 
 If stents used was it as bail-
out 
 
  Bifurcation lesion  
  Bifurcation type  
  Calcific lesion  
  Tortuous vessel  
  Small vessel/diffuse disease  
  Thrombus present  
  Pre dilatation balloon  
  Additional devices used  
  Intra coronary imaging  
  DCB diameter  
  TIMI flow pre procedure  
  TIMI flow post  
  Length of treated segment  
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  Procedure duration  
  Contrast volume  
  Radiation dose  
 
Follow up data/Outcomes. 
At the protocol stage, our primary outcome was considered to be MACE, defined as the 
composite of death, myocardial infarction and target vessel revascularisation. This was 
because we were confident the revascularisation data from the NICOR would be correct 
to a vessel level but to determine whether a revascularisation was a target lesion 
revascularisation (TLR), angiographic images would have been required. After receipt of 
data from the NICOR it was clear that apart for one event, data was available for us to 
determine whether a revascularisation was a TLR or not.  
Therefore, primary outcome (MACE) was defined as a composite of all cause death, MI 
and TLR. Secondary outcomes were acute vessel closure events and TLR. All 
components of the primary outcome were described individually too. Clinical outcomes 
were obtained from NICOR which is the national data base holding data of any 
revascularisation and MI. Death data were obtained from the spine portal of the NHS 
Digital. 
At the time of writing the protocol and forwarding for ethics approval, the NICOR could 
share mortality data with research group. But a subsequent change in the data sharing 
agreement led to NICOR not being able to do so. However department of Cardiology at 
NNUH had up-to-date mortality data available through the Spine portal of the NHS 
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Digital. We applied for hospital’s Caldecott guardian’s approval to use these data and 
also made a major amendment to our protocol enabling us to do so. This amendment 
was forwarded for ethics committee and HRA approval which was obtained 
subsequently. 
Acute vessel closures were reported from information derived from local data base. We 
reported TLR by reviewing angiograms of the revascularisations performed. 
Outcomes were reported for pre specified groups, mainly DCB for de novo disease and 
DCB for ISR. Of the first group three sub groups namely, DCB-only for de- novo CAD, 
DCB-only for PPCI, and DCB-only angioplasty with balloon diameter of 3mm or more 
were reported. A small group of patients who had bypass grafts treated and chronic 
total occlusions were reported separately. 
2.1.7 Definitions 
2.1.7.1 Primary Outcome 
The primary outcome, MACE, was a composite (time to first event) of all-cause 
mortality, myocardial infarction and target lesion revascularisation up to 12 months after 
the procedure.  Individual outcomes of the primary outcome were also presented. 
All-cause Mortality. 
Defined as death due to any cause. 
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MI 
An MI was defined as per MINAP definition (a hospital diagnosis reported as a troponin 
positive MI as recorded in the MINAP data base). Whilst it is likely, it was difficult to 
ascertain whether the reported events met the universal definition i.e. a rise/fall of 
troponin and one value above 99th percentile or upper reference limit, with one other 
feature from the list below.214 
1. Symptoms of acute myocardial ischaemia 
2. New ischaemic ECG changes 
3. Development of pathological Q waves 
4. Imaging evidence 
5. Identification of coronary thrombus by angiography or by autopsy 
When the reported event was local it was cross checked with hospital data. This 
reporting method applied to both DCB and DES arms in the propensity score 
matched study. 
 
 Target lesion revascularisation (TLR)  
A TLR was defined as any repeat percutaneous intervention of the target lesion or 
bypass surgery of the target vessel performed for restenosis or other complication of the 
target lesion. The target lesion was defined as the treated segment from 5 mm proximal 
and 5 mm distal to the treated lesion (by visual assessment). 
2.1.7.2 Secondary outcomes. 
Target Vessel Revascularisation (TVR) 
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A TVR was defined as any repeat percutaneous intervention or surgical bypass of any 
segment of the target vessel. The latter was defined as the entire major coronary vessel 
proximal and distal to the target lesion, including upstream and downstream branches 
and the target lesion itself. 
Acute Vessel Closure 
Acute vessel closure was defined as an event where a patient had to be taken back to 
cardiac catheterisation lab and require repeat angioplasty (during the same hospital 
stay) for a complete or partial occlusion of the artery due to a dissection. 
Stent/Treated Lesion Thrombosis 
Stent or treated lesion thrombosis was categorized as acute (<1 day), subacute (1 to 30 
days), and late (>30 days) and defined in parallel to the ARC guidelines on Stent 
Thrombosis. It is as follows: definite: acute coronary syndrome and angiographic or 
pathological confirmation of thrombus in the previously treated lesion and 5mm proximal 
or distal to it, probable: unexplained death ≤30 days or target vessel MI without 
angiographic information; and possible: unexplained death >30 days after treatment. 
Longer term up to date follow up data wereobtained from NICOR and were incorporated 
into the database prior to final analysis.  
All interventional centres in the UK enter patient and procedural details into a local 
database which in turn downloads to the national British Cardiovascular Interventional 
Society (BCIS) database. NICOR obtain these data from BCIS as well as data from the 
Myocardial Ischaemia National Audit Project (MINAP) and Society of Cardiothoracic 
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Surgery (SCTS) database and publish annual national audit reports. NICOR complete 
data acquiring by June each year for the preceding year and process data before it 
publishes the report in the autumn.  
We obtained data from NICOR in 2019 (data valid until March 2017) allowing us to 
record a minimum of 12 months follow up for all patients. NICOR was the trusted third 
party linking the outcomes. The percutaneous revascularisation data obtained from the 
NICOR were vessel specific allowing us to determine target vessel revascularisations. 
We obtained graft details from the Royal Papworth Hospital to determine TVR for the 
patients who have had CABG. Reviewing angiographic data allowed us to determine 
whether a revascularisation was a target lesion revascularisation.  
MI data were obtained from MINAP dataset version 9.1. For revascularisation events, 
data from Adult percutaneous intervention dataset version 5.6.1 and Adult cardiac 
surgery data set version 4.1.2 will be obtained. Appendix 3 describes the specific 
variables we requested from each of these data sets. Mortality data were obtained from 
the spine portal of the NHS Digital. 
We plan to obtain follow up data out to ten years for this cohort of patients from NICOR, 
which will give us the opportunity to assess long term impact of DCB treatment.  
2.1.8 Sample size 
We considered a TVR rate of 4.9 to 11.1% or less at 12 months for de novo lesions and 
approximately 20% or less for the ISR group to be within expected ranges based on real 
world data of DES studies.112, 215, 216 
108 
 
Assuming 830 patients in the de novo lesions group and a TVR rate of 4.9% and a 
censoring rate of 0.5% for all groups, the study would be able to estimate the survival 
rate with a standard error of 0.8 percentage points (estimated using Greenwood’s 
formula).  If the TVR rate was as high as 11.1%, the corresponding standard error 
would be 1.2 percentage points.  Assuming 235 ISR patients and a TVR rate of 20% in 
this group, the standard error for the survival estimate for this group would be 2.9 
percentage points.  
2.1.9 Statistical analysis plan 
A CONSORT style diagram was produced to show patients flow through the registry 
(figure 19).  Anonymised data were analysed by an independent statistician. Continuous 
variables were presented as mean and SD whilst discrete variables werepresented as 
counts and percentages. Time-to-event data were shown as Kaplan-Meier curves and 
were compared using log rank tests. Cox proportional hazards were used for the 
multivariate regression analysis in order to assess the risk factors pre-disposing to 
MACE after treatment. 
Table 7  Variables used in the multivariate regression analysis to find out association between the composite 
of all cause death, MI and target lesion revascularisation. 
Age (10y increase) 
 Female 
 Device diameter>=3mm 
 Bifurcation lesion 
 Current smoker 
 Diabetes 
 Previous MI 
 NSTEMI/UA 
 STEMI(PPCI) 
 Previous PCI 
 Hypertension 
 Vessel treated 
 Thrombus present 
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MI – myocardial infarction, NSTEMI- Non ST elevation MI, UA- unstable angina, STEMI – St elevation MI, PPCI- primary 
percutaneous coronary intervention, PCI- percutaneous coronary intervention 
Descriptive statistics were presented on baseline characteristics, procedural and lesion 
details and clinical outcomes.  The main groups considered were  
- De novo lesions (native coronary artery receiving first time PCI) 
- In stent restenosis (lesion has been previously treated with a stent which has a 
stenosis) 
- Primary PCI cohort (patients with ST elevation MI treated with DCB) 
- Bifurcation lesions (stenosis involves two or more major arteries) 
- Device diameter of 3mm or more (large vessel) group 
Other smaller groups like chronic total occlusions (CTO) and left main stem were 
considered for descriptive purposes.  For each of the three main groups descriptive 
tables were presented for baseline characteristics, procedural details and outcomes: 
- Age <70 and ≥ 70 years 
- Female and male 
- Diabetes/ no diabetes 
- ST elevation MI/ Non ST elevation MI (including unstable angina)/ stable angina 
(not for the PPCI group) 
 
A comparison between the bifurcation lesions and non- bifurcation lesions and also 
between the device diameter of less than 3mm (small vessels) vs. device diameter 
equal or more than 3mm (large vessels) were carried out. 
110 
 
2.1.10 Data quality assurance 
It is mandatory that all PCI operators in the UK enter a BCIS specified data set following 
each procedure. These data bases of individual centres are accessed by BCIS before 
formulating the country wide audit annually. NICOR is the main body which holds data 
sets generated by BCIS, Society of Cardiothoracic surgeons (SCTS) and MINAP. Data 
from these sources are eventually used to understand UK wide PCI practice hence 
recognized to be of good quality. Each year missing data percentages are published in 
the annual audit report. The most recent BCIS audit presented in 2019 reports a UK 
wide completion rate of 92.9% with regards to PCI procedures. 157 Revascularisation 
data were available for all patients and mortality data were available for 99.71% (3 
patients did not have NHS numbers).  
In this study we not only obtained data from the NICOR but also from the patients’ 
medical records which enabled us to provide a complete and an accurate data set.  
2.2 DCBNORWICH propensity score matched study 
2.2.1 Study Design 
The study was a retrospective observational comparative study. In addition to the drug 
coated balloon treated cohort, patients who received second generation Drug eluting 
stents for de novo disease from June 2011 (inception of the Intellect database) to 
31/12/2015 were identified by the data base manager at Norfolk and Norwich University 
Hospital. The methodology used to record their demographic details, risk factors, 
procedure details and clinical outcomes was as same as for the DCB Norwich registry 
study. This is described in section 2.1.  
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Null hypothesis: Outcomes of DCB-only angioplasty in de novo coronary artery disease 
are inferior to the outcomes of treatment with drug eluting stents (DES) by a margin (M) 
or more.  
Alternative hypothesis: Outcomes of DCB-only angioplasty in de novo coronary artery 
disease are not inferior to the outcomes of treatment with drug eluting stents (DES) by 
more than the pre-specified margin (M). 
The choice of the margin M has been discussed in the sample size calculation section. 
2.2.2 Patient Identification 
Up until June 2011, all PCI data have been entered to a data base named PATS. 
Thereafter to a database called INTELLECT, which is in use to date in the Norfolk and 
Norwich University Hospital NHS Foundation Trust. PCI operators enter data that are 
mandatory for submission to British Cardiac Interventional Society (BCIS) data base as 
well as other data required by the trust data base for each PCI procedure.  
Patients who have undergone DCB angioplasty were identified from these two data 
bases by the manager in charge of the data base, thereby allowing extraction of their 
demographic details, coronary risk factors and procedural details. 
Patients who underwent DES angioplasty were identified from the INTELLECT data 
base i.e. from June 2011 onwards by the data manager. The difference in start date in 
the two arms was partly due to adopting the new data base in June 2011 and also wide 
spread use of second generation drug eluting stents during the time. Even though our 
start time goes back to 2009 for the DCB arm (enabling to include every patient treated 
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with a DCB) the vast majority of DCB use in de novo vessels is recorded from 2011 
onwards. For example only 6 patients had DCB PCI in de novo vessels during 2009 and 
2010. Figure below depicts the use of DCB vs. stents in our department from 2009 to 
2019. 
Figure 18 Use of DCB vs. stents in the department from 2009 to 2019 
 
X axis; year. Y axis; number of procedures 
2.2.3 Patient Eligibility Criteria 
Inclusion Criteria 
1. All patients who have undergone DCB angioplasty at the Norfolk and Norwich 
University Hospital from 01/01/2009 to 31/12/2015 were eligible for the study.  
2. All patients who received a second generation drug eluting (Promus, Xience, 
Endeavour, Synergy and Onyx) stent from 01/06/2011 to 31/12/2015 at the Norfolk and 
Norwich University Hospital. 
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Exclusion Criteria 
1. The patients who received a first generation drug eluting stent treatment were 
excluded as second generation stents have shown better outcomes than the first and 
also as it is the current standard practice. 
2. Patients who received a DES in one procedure and a DCB in a second procedure 
appeared in both arms of the study. As follow up was until the first clinical event or 12 
months, the patients who had a DES in the first procedure and had a clinical event prior 
to the DCB procedure were excluded from the DCB arm and remained in the DES arm. 
Others remained in the DCB arm (for example a patient who had a DES and a DCB in 
two successive procedures and if a MI occurred due to stent thrombosis after the DCB 
procedure and prior to 12 months, this would have been still counted under DCB arm) 
2.2.4 Approvals 
As described in section 2.1.4 under DCB Norwich registry study, approvals were sought 
from the NNUH Research and Development, caldicott guardian, confidentiality advisory 
group (CAG), NICOR and HQIP (Healthcare Quality Improvement Partnership), as an 
amendment to include the patients treated with drug eluting stents during the mentioned 
period.   
2.2.5 Consent 
This is a retrospective study obtaining data from the existing hospital data base, medical 
records and NICOR. We did not plan to carry out any activity which will lead to any 
patient or relative contact.  
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We did not plan to obtain consent from the patients included in the study for the same 
reasons described in the DCBNORWICH Registry methodology under the section 2.1.5.  
In addition, the public notice which was displayed in the Norfolk and Norwich University 
Hospital web site regarding the DCBNORWICH study was amended to include the drug 
eluting stent treated patients. This included contact details of the principal investigator if 
a patient wished to opt out from the study and none such request was received. 
2.2.6 Study Observations 
The study observations are the same as in DCBNORWICH registry as described in 
2.1.6. 
2.2.7 Definitions 
The primary outcome was MACE, a binary indicator of either death, MI or TLR. The 
secondary outcomes were death, MI, TVR, TLR individually and also acute vessel 
closure and treated lesion/stent thrombosis. The definitions were as same as for the 
registry study as described in 2.1.7. 
2.2.8 Sample Size 
The sample size is described below under the statistical analysis plan. 
2.2.9 Statistical Analysis Plan 
Additional statistical analysis involved forming matched groups of DCB and DES 
patients using propensity scores (Rosenbaum and Rubin 1983) and then using logistic 
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regression analysis to compare patients’ outcomes between the DCB and DES 
groups.217 
Outcome variables 
We considered MACE as the primary outcome. We also analysed death, MI and TVR 
individually as secondary outcomes. The researcher conducting the propensity 
matching analysis was blinded to the outcome data to minimise any selection bias.  
Dealing with correlated observations within the matched sample 
The statistical balance in terms of covariate distributions in a propensity score matched 
sample does not come without a price. It has been argued that propensity score 
matched sample does not contain independent observations.218 Subjects within the 
same matched set have similar values of the propensity scores, therefore, are more 
likely to have similar outcomes than are randomly selected subjects. The lack of 
independence in the propensity score matched sample should be accounted for when 
estimating the standard error of the estimated treatment effect (group difference) which 
affects statistical inference (p-value and confidence intervals). We took account of 
possible correlation structure of the outcomes within the matched sets by including a 
random effect for the marching ID within the logistic regression analysis.  The logistic 
regression analysis including random effects is termed mixed effects logistic regression 
analysis.   
Effect measure for assessing group difference 
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We used mixed effects logistic regression analysis on the matched sample considering 
MACE (a binary indicator of any major adverse cardiac event) as the primary outcome 
and the binary group indicator (DCB=1, DES=0) as the exposure variable. The 
coefficient of the group indicator from the mixed effects logistic regression model 
represented the difference of the outcome (in terms of log-odds of MACE events) 
between the two groups. Conveniently, the regression coefficients from the logistic 
regression could be expressed as Odds Ratios (OR) which were easily interpretable. 
We  considered the estimated OR from the logistic regression model as an effect 
measure for comparing the outcome measure (MACE) between DCB and DES groups. 
No difference in outcome (proportion of MACE events) between the two group would be 
indicated by OR=1. Estimated OR <1 would indicate that patients undergoing DCB only 
angioplasty are less likely to experience MACE than those undergoing DES procedure. 
On the other hand, estimated OR >1 would indicate that patients in the DCB group are 
more likely to experience MACE than the patients in the DES group. The mixed effects 
logistic regression analysis would also provide 95% confidence interval for the 
estimated OR taking account of the intra-class correlation of the outcome measures 
within matched sets which were used for testing statistical significance of the null 
hypothesis. As stated earlier, with 9.3% MACE rate in the DES group, 4.5% non-
inferiority margin for DCB vs. DES comparison is equivalent to an OR=1.56. If the 95% 
CI of the estimated OR from the logistic regression model exclude 1.56, the null 
hypothesis would be rejected in favour of the DCB group implying that DCB outcomes 
are not inferior to DES by more than 4.5% (the margin of non-inferiority).    
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The analysis and interpretations for the secondary outcomes (death, MI, TLR and TVR) 
were carried out in the same manner. 
Propensity score matching   
Propensity score matching involves creating comparable (matched) groups of subjects 
who share a similar value of the propensity score. Propensity score matching allows 
observational studies to mimic some of the desirable characteristics of randomised 
controlled trials (RCTs) which are considered as gold standard approach for estimating 
the effects of treatments or interventions. Propensity score is a balancing score: 
observed distributions of the baseline covariates will be similar between the matched 
groups, so that subsequent comparisons made between the matched groups are not 
confounded by the differences in covariate distributions. 
Selection of covariates for the propensity score model:  A logistic regression model with 
the binary group indicator (DCB=1, DES=0) as the dependent variable was used to 
calculate propensity scores. The predictor variables for the propensity score model were 
considered from the following list of baseline covariates (which are available for patients 
in both the hospital database and NICOR database): 
• Demographics: age and sex.  
• Behavioural factor: smoking status. 
• Co-morbidity/medical history: Previous history of MI/PCI/CABG, diabetes 
mellitus, hypertension, history of renal disease, cerebrovascular disease, peripheral 
vascular disease, cardiogenic shock, out of hospital cardiac arrest, indication: 
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STEMI/NSTEMI/UA/stable angina, length of the longest treated segment, diameter of 
the balloon/stent used, vessel treated, number of vessels treated, and CTO or not.  
We examined the proportion of missing data and only covariates with acceptable 
amount (less than 5%) of missing data were considered in the propensity score 
calculation. If the majority of the covariates were found to have unacceptable level 
(more than 5%) of missing data, the plan was to use multiple imputation techniques to 
deal with missing data, in which case maximum likelihood method under missing at 
random (MAR) assumption with standard covariate adjustments in a logistic regression 
model (rather than propensity score method) was to be used for the main analysis. But 
this was not necessary. 
Matching algorithm 
We used nearest neighbour matching within caliper (NNC) algorithm to match each 
patient in the DCB group with one or more (up to 3) patients from the DES group 
(NICOR database). The nearest neighbour matching without caliper runs the risk of 
picking up bad matches in the sense that patients in the DCB group may get matched to 
DES patients with very different propensity scores. For this reason, a tolerance level, 
defined as caliper, was imposed on the maximum propensity score distance. Bad 
matches could be avoided, since anything that exceeds the caliper was not considered 
hence the matching quality is expected to be better. Although one-to-one (1:1) matching 
is the most common practice, we used one-to-many (1:M) with M=3 to take advantage 
of higher statistical power. The choice between 1:1 and 1:M matching depends on the 
trade-off between bias and variability (precision): higher M improves precision, but also 
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increases bias. It has been recommended in the literature that researcher should 
consider either M=1 (1:1 matching) or M=2 (1:2 matching in most settings when using 
propensity score matching.219 Although we proposed to consider 1-to-many matching 
with M=3, actual number of matched patients in the DES group for each DCB patient 
varied due to imposing a caliper within the nearest neighbour matching. We restricted 
the maximum number not to exceed 3. Therefore, on average, the effective matching 
ratio was similar to what has been recommended in the literature (e.g., 1:2). Allowing a 
variable number of matched subjects within 1-to-M settings was found to be more 
effective in reducing bias compared to matching with a fixed number. 219 
Statistical software 
We used Stata (StataCorp. 2015. Stata Statistical Software: Release 14. College 
Station, TX: StataCorp LP.) for the propensity score matching and the mixed logistic 
regression analysis. We used the psmatch2 module in Stata for propensity score 
matching. The mixed effects logistic regression analysis on the matched sample was 
performed using the xtmelogit command.  Any lacks in the capabilities of the Stata 
module psmatch2 (such matching without replacement for 1-to-many matching) was 
supplemented by the R software (R Core Team, 2016. R: A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 
https://www.R-project.org/). In R, the Matching, MatchIt and Optmatch packages 
provide implementations of various propensity score matching methods.  
 Sample size calculation 
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We estimated the required sample size for the proposed propensity score matched 
analysis based on the average MACE rate (9.3%) found in three DES studies, and 
assuming a non-inferiority margin, M=4.5% (absolute risk difference between DCB and 
DES).  
Effect size: 
• MACE rates in DES=0.093 (9.3%) – average from three studies 215, 216, 220   
• Non-inferiority margin (M) = 0.045 (4.5%) – the absolute difference in MACE 
rates between DCB and DES. 
• MACE rate difference of 4.5% is equivalent to Odds Ratio (OR) for the upper 
boundary of the 95% confidence interval = 1.56 (DCB vs. DES)  
Chosen statistical power and level of significance: 
• Power = 80% 
• Level of significance (one-sided) = 0.025 
Intra-class correlation (ICC) and variance inflation factor (VIF): 
• Assumed ICC of MACE events within matched set: 0.05 (5%) 
• VIF= 1+(m-1)*ICC=1.1 (assuming m=3, 1 DCB patient matched to 2 DES 
patients on average) 
Estimated sample size (N): 
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• Minimum total sample size (N) required (assuming 1:2 allocation ratio) = 1619. 
The sample size was calculated to achieve 80% power at one-sided 2.5% level of 
significance. All else remaining the same, the required sample size was 2169 to detect 
the effect size at 90% power. The sample size calculation has taken into account the 
possibility that patients’ outcomes within matched sets are likely to be correlated 
(assumed ICC=5%) due to propensity score matching. 
Expected available sample size: There were approximately 750 eligible patients in the 
DCB treated group (hospital database).  Using propensity score matching and assuming 
each DCB treated patient matched to two DES patients on average, we expected to 
recruit 1500 DES treated patents from the DES cohort. This would have led to a total 
simple size of 2250 patients from both databases, which is higher than that is required 
(N=1619) and therefore sufficient to conduct the proposed statistical analyses with 
adequate statistical power. If the size of matched sample reached 2250, the 4.5% non-
inferiority margin could have been detected with 90% power.     
2.2.10 Data Quality Assurance 
The mechanisms put in place both locally and countrywide to ascertain the data is 
collected and maintained at highest standards is described in section 2.1.10 in the DCB 
Norwich registry study. 
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 Chapter 3 Results 3
3.1 DCBNORWICH Registry 
A total of 1394 lesions in 1122 patients have been treated with drug coated balloons 
from 01/01/2009 till 31/12/2015 at Norfolk and Norwich University Hospital. The results 
will be described separately in three sub chapters for de novo group, in-stent restenosis 
(ISR) group and for the other sub groups. 
Figure 19 Schematic representation of various subgroups of the DCB Norwich registry study 
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3.1.1 De Novo group 
Results of patients who had a native coronary artery treated with PCI for the first time 
are included in this group. 
3.1.1.1 Patient Characteristics 
From 01/01/2009 to 31/12/2015, a total of 1026 de novo lesions in 812 patients have 
been treated with DCB angioplasty. Approximately 40% was for stable angina, 25% for 
ST elevation MI and 35% for non ST elevation MI/unstable angina.  Mean age was 65.8 
and vast majority were male patients (75.6%).  Table 8 outlines the patient 
characteristics further. 
Table 8 Patient characteristics of de novo group 
 
 Attribute   Freq. n 812  Percent 
Age  mean (SD) 
 
65.8     ( 12.2) 
Min 24.0, Max  93.0 
 
Female/Male 198 24.4% 
Previous MI  199 24.5% 
Previous PCI  221 27.2% 
Previous CABG  33 4.1% 
Hypertension  412 50.7% 
Dyslipidaemia  297 36.6% 
Diabetes  137 16.9% 
Family history  189 23.3% 
Never smoked  308 37.9% 
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Ex-smoker  292 36.0% 
Current smoker  181 22.3% 
Smoking not known 31 3.8% 
Stable  324 39.9% 
NSTEMI/UA  271 33.4% 
STEMI(PPCI)  217 26.7% 
Cardiogenic shock 10 1.2 
Out of hospital cardiac arrest 18 2.2 
 
MI- myocardial infarction, NSTEMI- non ST elevation MI, STEMI- ST elevation MI, PCI- percutaneous coronary intervention, PPCI- 
primary percutaneous coronary intervention 
3.1.1.2 Lesion/Procedural Characteristics 
Table 9 Lesion/Procedural characteristics of the de novo group 
Attribute   Freq. (n 1026)  Percent 
Access (per patient data) 
Radial 
Femoral 
Right Ulnar 
  
731 
58 
1 
  
90.0 
7.1 
0.1 
Number of vessels treated – 
1 
576 70.8% 
Number of vessels treated - 
2 or more 
237 29.2% 
Lesion Level    
LAD  529 51.6% 
RCA  245 23.9% 
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CX  238 23.2% 
LMS  14 1.4% 
CTO  30 2.9% 
Heavy calcification  222 21.6% 
Diffuse disease / small 
vessel  
407 39.7% 
Severe tortuosity  174 17.0% 
Thrombus present  207 20.2% 
Stable  467 45.5% 
NSTEMI/UA  329 32.1% 
STEMI(PPCI)  230 22.4% 
DCB type 
Sequent please 
Falcon 
Sequent please + Falcon 
Dior 
  
875 
136 
14 
1 
  
85.3 
13.3 
1.4 
0.1 
Mean (SD) treated lesion 
length  
     24.5 (12.5)       
Mean (SD) device diameter        2.9 (0.6)        
Coronary dissections 
Type A 
Type B 
Type C or above 
148 
41 
85 
22 
14.6 
4.0 
8.2 
2.3 
Bail – out stents after DCB 
During the index procedure 
During the same hospital 
stay for acute vessel 
 42 
 
4 
 4.1 
 
0.4 
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closure/instability 
Stents used elective 19 1.8 
Drug coated balloon therapy 
and stent(s)  
61 5.9% 
DCB-only PCI 965 94.1 
 
 
As shown in table 8, 217 (26.7%) patients presented with ST elevation MI, whilst 271 
patients (33.4%) presented with NSTEMI or unstable angina. This constitutes 60.1% of 
the de novo patient population. 323 patients (39.9%) had stable angina. 
In most patients (90%) access was through the radial artery. One patient had ulnar 
arterial access and the rest femoral or femoral and radial combination. 576 (70.9%) of 
the patients had a single vessel treated and 29.1% had two or more vessels treated. 14 
(1.4%) were left main stem (LMS) lesions whilst 529 (51.6%) were left anterior 
descending (LAD) artery lesions. The circumflex artery (Cx) was treated in 238 (23.2%) 
instances whilst the right coronary artery was treated in 245 (23.9%) patients.   Out of 
the 1026 de no lesions treated 350 (34.1%) were in a bifurcation. 30 (2.9%) were 
chronic total occlusions.  
The most commonly used DCB type was Sequent please (in 881; 85.9% of lesions) and 
the Inpact falcon was used in 143 (13.9%) lesions. Dior balloon was used in one lesion. 
The mean (SD) DCB diameter was 2.9 (0.6) mm and in 603 (58.8%) lesions, a DCB 
with a diameter of 3mm or more was used. The mean (SD) treated length was 24.5. 
(12.5) mm. 
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 Coronary dissections are classified in to Type A to F as per NHLBI classifications 
(figure 3, Chapter 1.4.2). There were 148 (14.6%) coronary dissections noted.  Out of 
which 41(4%) were type A coronary dissections, 85 (8.2) type B and 22 (2.3%) type C 
or above.  
In 42 (4.1%) instances, bail out stents were used during the index procedure after DCB 
angioplasty. 4 (0.4%) further patients had to be taken back for angioplasty with bail out 
stenting during the first 24 hours after the index procedure due to ongoing chest pain or 
acute vessel closure. In 19  (1.8%) lesions stents were used electively in addition to the 
DCB. DCB-only PCI were carried out in 965 (94.1%) lesions. 
3.1.1.3 Clinical outcomes 
Table 10 Clinical outcomes of the de novo group, DCB Norwich registry study 
Outcome   Freq.   Percent 
Per patient (n 809)   
All cause death – 30 days 10 1.2% 
Death 12 months 29 3.6% 
TVR 12 months 40 4.9% 
MI 12 months 25 3.1% 
MACE (TVR) 12 months 85 10.5% 
MACE (TLR) 12 months 66 8.2% 
Death at 3 years 61 7.5% 
Per lesion (n 1026)   
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TLR 12 months  22 2.1% 
Acute vessel 
closure/instability (per 
lesion) 
4 0.4 
Definite treated segment 
thrombosis 
0 0.0 
 
 
Table 11 Cox regression analysis of the de novo cohort for one year death,  
Cox regression de novo cohort: one-year death  
  Hazard 
Ratio 
 z  P>|z|  [95% Conf  Interval]  Sig 
 Age (10y increase) 2.078 3.82 0.000 1.428 3.022 *** 
 Female 1.000 -0.00 0.999 0.481 2.079  
 Diameter>=3mm 0.514 -1.80 0.072 0.249 1.062 * 
 Bifurcation lesion 0.707 -0.83 0.406 0.313 1.600  
 Current smoker 1.137 0.24 0.808 0.405 3.191  
 Diabetes 1.757 1.34 0.181 0.770 4.009  
 Previous MI 1.374 0.76 0.450 0.602 3.134  
 NSTEMI/UA 1.893 1.36 0.172 0.757 4.736  
 STEMI(PPCI) 2.643 1.65 0.100 0.830 8.414  
 Previous PCI 0.832 -0.36 0.719 0.306 2.263  
 Hypertension 2.249 1.94 0.052 0.992 5.100 * 
 RCA 0.492 -1.43 0.152 0.186 1.300  
 CX 0.853 -0.37 0.709 0.370 1.965  
 LMS 0.000 0.00 1.000 0.000 .  
 Thrombus present 1.591 0.87 0.385 0.558 4.535  
 
*** p<0.01, ** p<0.05, * p<0.1 
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Figure 20 Forest plot of cox proportional hazard multivariate modelling on one year death, de novo cohort 
 
x axis- hazard ration, y axis- co variate 
Figure 21 Kaplan-Meier curve for three year death, de novo cohort 
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Figure 22 Kaplan-Meier curve for one year target vessel revascularisation (TVR), de novo cohort 
 
Figure 23 Kaplan-Meier curve for one year target lesion revascularisation, de novo cohort 
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As the table 10 shows, the 30 day mortality was 1.2% (10 patients). There were 29 
(3.6%) deaths within the first year. 11 were cardiac deaths and exact cause of death 
was not known for 8. 10 others were non-cardiac. We obtained death data from the 
spine portal of the NHS Digital but it was not possible to obtain cause of death. The 
information we have on death is from our local records. The details of the 10 cardiac 
deaths are as follows. One died same day after PCI due to heart failure (known severe 
left ventricular impairment), same admission day 3 (hypoxic brain injury, presenting with 
out of hospital cardiac arrest), out of hospital cardiac arrest on day 5 (combination of 
DES and DCB), MI on day 6 (self-discharged and presented to another hospital on day 
6, likely to be non-compliant), cardiac arrest due to a complication following an elective 
staged PCI day 19, MI on day 24 (angiography not performed as unfit for procedure with 
poor known left ventricular failure), MI on day 52, STEMI related to another vessel day 
61, death due to heart failure and pneumonia at day 62, cardiac arrest during a staged 
procedure day 129 and MI day 193 (no intervention due to oesophageal Ca). 14 out of 
the 29 were STEMI presentations as primary PCIs (PPCI). Another 8 were after PCI for 
acute coronary syndrome. 4 patients have been in cardiogenic shock. 4 patients died 
due to metastatic cancers (two due to metastatic lung cancer and another due to 
metastatic renal cancer and a fourth patient had an oesophageal cancer). One patient 
died due to an intracerebral haemorrhage (day 131 on triple therapy) and another one 
due to a gastro intestinal haemorrhage day 1. 1 patient died of severe pulmonary 
hypertension due to obesity and another due to interstitial lung disease (was on home 
oxygen). 3 patients died due to prolonged hospital stays complicated with pneumonia 
and heart failure. The numbers of days to death for the 8 patients whose cause of death 
132 
 
is not known are 2, 2, 10, 84, 164, 182, 196 and 348). Table 11 and figure 20 depict the 
multivariate cox regression analysis on one year death which shows that age (10 year 
increment) and hypertension were the most predictive variables. Figure 21 shows 
Kaplan-Meier survival curve for 3 year death, figure 16 for one year TVR and figure 17 
for one year TLR.  
25 (3.1%) patients had a myocardial infarction (MI) within the first 12 months from the 
index PCI. Spontaneous myocardial infarction presenting after the index event as well 
as a peri-procedural infarction that resulted in a troponin rise after an elective procedure 
(1 patient) was also included. There were 3 deaths following MIs (Day 6, 24 and 61). 
The patient who died on day 6 is a self-discharged patient following the index PCI 
therefore carries high chance of non-compliance. The patient who died on day 24 after 
a MI was an 81 year old known to have severe triple vessel disease and on his 
recurrent presentation was deemed to be unfit for any intervention due to severe left 
ventricular impairment and heart failure. The patient who had a MI and died on day 61 
presented with an anterior STEMI on the second time and had PCI to LAD whereas the 
index PCI was to his RCA. Out of the 25 MIs, 6 lead to target vessel revascularisations 
and 4 of those were target lesion revascularisations. Therefore target vessel MI (MI 
leading to a repeat revascularisation of the same vessel) is 0.7%.  Two of the 25 were 
ST elevation MIs (day 61 and 359 post index PCI) and both were due to occlusion of 
another vessel.  
There were 40 (4.9%) patients who underwent subsequent target vessel 
revascularisations within the first 12 months. 8 patients had bypass graft surgeries and 
the rest were repeat PCIs. No emergency bypass graft surgeries were required. 1 
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patient underwent CABG at Basildon therefore graft details are not known, assumed 
TVR as there was distal stenosis. Out of the 40 patients who had target vessel 
revascularisation, 22 lesions (2.2% per lesion) were target lesion revascularisations. 
Included are 4 (0.4%) patients who had to be taken back to the catheter laboratory on 
the same day for suspected acute vessel closure and had repeat PCI to the same 
lesion. No events definite target lesion thrombosis reported. Table 13 and figure 25 
show the multivariate cox regression for one year TLR. STEMI was the most predictive 
factor for TLR up to one year.  
MACE (all cause death, MI, TLR) was 8.2% (66 patients) during the first 12 months. The 
multivariate cox regression analysis showed that hypertension and STEMI were 
associated with worst MACE outcomes (table 12 and figure 24). The composite of 
death, MI and TVR was 10.5% (85 patients). 
Table 12 Cox regression de novo cohort: one-year MACE (death, MI, TLR) 
  Hazard 
Ratio 
Robust 
St.Err. 
 z  P>|z|  [95% Conf  Interval]  Sig 
 Age (10y increase) 1.122 0.117 1.11 0.268 0.915 1.377  
 Female 0.848 0.220 -0.64 0.525 0.509 1.411  
 Diameter>=3mm 0.770 0.182 -1.10 0.269 0.484 1.224  
 Bifurcation lesion 1.099 0.265 0.39 0.695 0.685 1.764  
 Current smoker 0.496 0.187 -1.86 0.062 0.237 1.037 * 
 Diabetes 1.077 0.301 0.27 0.791 0.622 1.864  
 Previous MI 1.372 0.388 1.12 0.264 0.787 2.389  
 NSTEMI/UA 1.235 0.351 0.74 0.457 0.708 2.156  
 STEMI(PPCI) 1.943 0.732 1.76 0.078 0.929 4.065 * 
 Previous PCI 0.856 0.264 -0.51 0.614 0.468 1.565  
 Hypertension 2.399 0.614 3.42 0.001 1.452 3.963 *** 
 RCA 0.661 0.201 -1.36 0.172 0.364 1.198  
 CX 0.641 0.185 -1.54 0.124 0.363 1.130  
 LMS 0.612 0.628 -0.48 0.632 0.082 4.576  
 Thrombus present 1.163 0.435 0.41 0.685 0.559 2.420  
 
*** p<0.01, ** p<0.05, * p<0.1  
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Figure 24 Forest plot of cox proportional hazard multivariate modelling on one year MACE (TLR), de novo 
cohort 
 
MACE: Major adverse cardiac events, TLR: Target lesion revascularization 
Table 13 Cox regression de novo cohort: one-year TLR 
  Hazard 
Ratio 
 z  P>|z|  [95% Conf  Interval]  Sig 
 Age (10y increase) 1.111 0.47 0.636 0.719 1.717  
 Female 0.440 -1.17 0.243 0.111 1.748  
 Diameter>=3mm 1.476 0.76 0.447 0.542 4.019  
 Bifurcation lesion 1.573 1.00 0.319 0.645 3.835  
 Current smoker 0.318 -1.63 0.104 0.080 1.265  
 Diabetes 0.562 -0.76 0.450 0.126 2.511  
 Previous MI 1.622 0.85 0.396 0.531 4.953  
 NSTEMI/UA 2.225 1.36 0.175 0.700 7.073  
 STEMI(PPCI) 4.966 2.48 0.013 1.399 17.631 ** 
 Previous PCI 0.897 -0.18 0.855 0.281 2.868  
 Hypertension 0.822 -0.38 0.707 0.295 2.287  
 RCA 0.406 -1.40 0.160 0.116 1.428  
 CX 0.127 -1.96 0.050 0.016 0.999 * 
 LMS 0.000 -64.96 0.000 0.000 0.000 *** 
 Thrombus present 0.401 -1.79 0.073 0.147 1.091 * 
*** p<0.01, ** p<0.05, * p<0.1 
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Figure 25 Forest plot of cox proportional hazard multivariate modelling on one year target lesion revascularization (TLR), 
de novo cohort 
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3.1.2 De novo Bifurcations 
Percutaneous coronary intervention (PCI) in a lesion involving a side branch of 2mm or 
more (visual assessment) was considered a bifurcation lesion and is included in this 
analysis. This cohort is comprised of only de novo bifurcation lesions and not the in-
stent restenosis lesions.  
There were 327 lesions in 309 patients. For this analysis if both coronary 
branches/arms were treated in a bifurcation lesion, it was considered as a single lesion 
rather than two separate lesions. Mean age was 66, predominantly male and almost 
half were due to some form of an acute coronary syndrome (48.3%) (Table 14).  
Table 14 Demographics for de novo bifurcation cohort 
Attribute Frequency (n 309) % 
Number of patients 309   
Number of lesions 327  
Male/Female 237 76.7% 
Mean Age (SD) 66 (12.2)  
STEMI/NSTEMI/UA 158 48.3% 
Stable 169 51.7% 
Out of hospital cardiac arrest 6 1.9% 
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Lesion Characteristics 
Predominantly LAD/D1 bifurcations have been treated. 37.1% of lesions were true 
bifurcation lesion i.e. Medina 1,1,1 or 0,1,1 lesions. 21 lesions have both branches/arms 
treated. Of note there were 10 lesions involving the left main stem. 
Table 15 Lesion characteristics of de novo bifurcation lesions 
Attribute Frequency (n 327) % 
Left main stem (LMS) 10 3.1% 
LAD/D  208 63.6% 
Circumflex (Cx) 87 26.6% 
RCA 22 6.7% 
Bifurcation type 
Medina 1.1.1 
Medina 0.1.1 
Other Medina types 
  
95 
26 
206 
  
29.1% 
8.0% 
62.9% 
Side branch occlusions 
(Peri procedural, flow regained in all) 
4 1.2% 
Medina classification is explained in section 1.3.3 
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Procedural characteristics 
Most procedures were done using radial access. Mean DCB diameter was 3mm and 
59% had a DCB diameter of 3mm or more. 15% had some form of a coronary 
dissection and 2 (0.6%) had bail out stenting during the procedure and another 5.2% 
had additional stent/s placed. Accordingly 94.2% had DCB only PCI. Vast majority were 
paclitaxel eluting Sequent please DCBs. 
Table 16 Procedural characteristics for de novo bifurcation lesions 
Attribute Frequency (n 327) % 
Radial access 292 89.3% 
Mean (SD) DCB diameter 2.9 (0.5) mm  
DCB diameter of 3mm or more 193 59.0% 
Mean (SD) length  24.2 (11.3) mm  
IVUS/OCT 23  7.0% 
Guideliner 29 8.9% 
Cutting/scoring balloon 22 6.7% 
Rotational atherectomy 3 1.0% 
Coronary dissections 
Type A and B 
Type C and above 
 
46 
3 
 
14.1% 
0.9% 
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Additional stents during the index 
procedure 
17 5.2% 
DCB-only PCI 310 94.8% 
Bail-out stents during the index admission 2 0.6% 
DCB Type 
Sequent please 
Falcon 
Dior 
 
283 
43 
1 
 
86.5% 
13.1% 
0.3% 
 
Clinical Outcomes 
Table 17 Clinical outcomes for de novo bifurcation cohort 
Clinical outcomes  for all patients – 12 months  Number (%) 
Per Patient ( n 309)  
All cause death 8 (2.6%) 
MI 12 (3.8%) 
TVR 14 (4.5%) 
death, MI, TVR 31 (10.0%) 
MACE (death, MI, TLR) 27 (8.7%) 
Per Lesion (n 327)  
TLR 10 (3.1%) 
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12 months all cause death was 2.6% (8 patients). 4 were primary PCIs and 1 patient 
was ventilated pre PCI. Another was in cardiogenic shock requiring IABP. 12 (3.8%) 
patients returned with a myocardial infarction after the index procedure but only two of 
them required target vessel revascularisations. Out of the 12 one was a STEMI but this 
was due to occlusion of a different vessel.  
There were 14 (4.5%) target vessel revascularisations (TVR). 2 were after acute 
myocardial infarctions.  Out of the 14 TVRs 10 (3.1%) were target lesion 
revascularisations (TLR). There were neither acute vessel closures nor definite treated 
lesion thrombosis during the first 12 months. 
Out of the 47 lesions with coronary dissections, none had target lesion revascularisation 
within the first 12 months. Two returned with MI’s, one due to severe disease in a non- 
target vessel requiring further PCI and a second at 253 days post PCI (presented to 
another local DGH) but has not had further angiography or revascularisation. 1 patient 
died due on day 173 due to metastatic renal cell carcinoma. 
Comparison of bifurcation and non-bifurcation lesions. 
We carried out a comparison between the bifurcation lesions and the non-bifurcation 
lesions as bifurcations are generally considered to be a high risk group. As above, all 
lesions which involved a side branch of 2mm or more on visual assessment were 
included in the bifurcation arm and other lesions in the non-bifurcation arm. If a patient 
has had both a bifurcation and a non-bifurcation treated he/she was attributed to the 
bifurcation arm for the comparison’s sake.  
141 
 
Patient characteristics are as described in the table below. Apart for the indication 
(higher percentage of ACS/MI patients in the non-bifurcation group) other variables 
were well matched.  
Table 18 Comparison of de novo bifurcation and non-bifurcation cohorts: demographics 
 
Attribute Non-bifurcation (n=503) Bifurcation (n=309) P-value† 
  Freq.  Percent  Freq.  Percent 
Female  126 25.0% 72 23.3% 0.573 
Previous MI  115 22.9% 76 24.6% 0.572 
Previous PCI  121 24.1% 88 28.5% 0.162 
Previous CABG  19 3.8% 14 4.5% 0.598 
Hypertension  256 50.9% 155 50.2% 0.839 
Dyslipidaemia  180 35.8% 115 37.2% 0.680 
Diabetes  86 17.1% 51 16.5% 0.827 
Fhx of CAD  111 22.1% 76 24.6% 0.406 
Current smoker  119 23.7% 63 20.4% 0.278 
Indication     <0.001 
 Stable  177 35.2% 156 50.5%  
 NSTEMI/UA  163 32.4% 105 34.0%  
 STEMI(PPCI)  163 32.4% 48 15.5%  
Cardiogenic shock  9 1.8% 1 0.3% 0.066 
      
Attribute Mean SD Mean SD  
Age (y) 65.9 12.2 65.5 12.2 0.633 
 
* Patient taken as “bifurcation” if any bifurcation lesion, only bifurcation lesions taken if patient has both types 
† Based on χ2 tests for categorical variables and t-tests for continuous 
 
Lesion characteristics 
Table below describes the lesion characteristics. Apart from vessel treated and 
presence of thrombus, the two groups appeared well matched.  
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Table 19 De novo bifurcation and non-bifurcation comparison: lesion characteristics 
Attribute Non-bifurcation (n=584) Bifurcation (n=327) P-value† 
  Freq.  Percent  Freq.  Percent 
Vessel treated     <0.001 
 LAD  267 45.7% 208 63.6%  
 RCA  189 32.4% 22 6.7%  
 CX  127 21.7% 87 26.6%  
 LMS 1 0.2% 10 3.1%  
Device diameter ≥3mm  355 60.8% 193 59.0% 0.601 
Diffuse disease / small vessel  223 38.2% 135 41.3% 0.358 
Heavy calcification  109 18.7% 83 25.4% 0.017 
Thrombus present  149 25.5% 49 15.0% <0.001 
Severe tortuosity  87 14.9% 67 20.5% 0.031 
Drug coated balloon therapy and 
stent(s)  
39 6.7% 17 5.2% 0.373 
Bail out stent  27 4.6% 11 3.4% 0.362 
CTO  16 2.7% 10 3.1% 0.782 
      
Attribute Mean SD Mean SD  
Longest stented / treated section 24.6 12.6 24.2 11.3 0.5937 
Device diameter (n=632/371) 2.96 0.61 2.87 0.54 0.0159 
  
† Based on χ2 tests for categorical variables and t-tests for continuous 
 
Clinical Outcomes 
Clinical outcomes are described in table 20 and 21. There was no significant difference 
in individual outcomes as well as MACE. Apart for death, other outcomes were 
numerically better for non-bifurcation lesions. Figures 20, 21, 22, 23 and 24 show the 
KM survival curves for three year death, one year MI, MACE, TVR and TLR for the 
bifurcation and non-bifurcation group. The survival curves are almost overlapping each 
other indicating a non- significant difference. 
 
 
 
143 
 
Table 20 De novo bifurcation vs. non bifurcations: patient level clinical outcomes 
 
 
Table 21 Lesion-level outcomes: bifurcation vs non-bifurcation  
 
Outcome Non-bifurcation (n=584) Bifurcation (n=327)  
 Freq.  Percent  Freq.  Percent  
TLR by one year  10 1.7% 9 2.8% 0.289 
  
 
Figure 26 Kaplan-Meier curve for three year death, bifurcation vs. non bifurcation lesion comparison 
 
 
 
 
 
 
Outcome  Non-bifurcation (n=503) Bifurcation (n=309) Log rank p 
 Freq.  Percent  Freq.  Percent  
TVR by one year  22 4.4% 14 4.5% 0.909 
MI by one year  12 2.4% 12 3.9% 0.22 
MACE (death, MI, TLR) by 
one year  
38 7.6% 27 8.7% 0.535 
Dead by one year  21 4.2% 8 2.6%       0.242 o.242 
Dead by three years  38 7.6% 23 7.4%       0.939 
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Figure 27 Kaplan-Meier curve for one year myocardial infarction (MI), bifurcation vs. non bifurcations 
 
Figure 28 Kaplan-Meier curve for one year target vessel revascularisation (TVR), bifurcation vs. non 
bifurcations  
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Figure 29 Kaplan-Meier curve for one year major adverse cardiac events (MACE with target lesion 
revascularisation/TLR), bifurcation vs. non bifurcations 
 
 
Figure 30 Kaplan-Meier curve for one year target lesion revascularisation (TLR), bifurcation vs. non 
bifurcations 
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3.1.3 De novo large vessel cohort 
All lesions treated with a DCB diameter of 3mm or more were considered as large 
vessel lesions for this analysis. This cohort includes 603 lesions in 520 patients. We 
carried out a comparison between vessels treated with a device diameter of <3mm and 
=>3mm to find out whether there is any difference in outcomes. Table 22 describes the 
patient characteristics of the two groups whilst lesion characteristics are described in 
the table 23.  
Table 22 De novo large vessels vs. small vessels, patient characteristics 
Attribute Device diameter <3mm 
(n=292) 
    Device diameter ≥3mm 
(n=520) 
P-value† 
 
 Freq.  Percent  Freq.  Percent 
Female  101 34.6% 97 18.7% <0.001 
Previous MI  77 26.4% 110 21.2% 0.090 
Previous PCI  93 31.8% 112 21.5% 0.001 
Previous CABG  14 4.8% 18 3.5% 0.349 
Hypertension  164 56.2% 248 47.7% 0.020 
Dyslipidaemia  119 40.8% 176 33.8% 0.050 
Diabetes  57 19.5% 79 15.2% 0.113 
Family history 72 24.7% 116 22.3% 0.446 
Current smoker  53 18.2% 130 25.0% 0.025 
Indication     <0.001 
 Stable  144 49.3% 183 35.2%  
 NSTEMI/UA  84 28.8% 184 35.4%  
 STEMI(PPCI)  64 21.9% 153 29.4%  
      
Cardiogenic shock  2 0.7% 8 1.5% 0.290 
      
Attribute Mean SD Mean SD  
Age (y) 66.6 11.5 65.3 12.5 0.155 
 
* Patient taken as “device diameter≥3mm” if any lesion had device diameter ≥3mm 
† Based on χ2 tests for categorical variables and t-tests for continuous 
 
Table 23 De novo large vessels vs. small vessels, lesion characteristics 
Attribute Device diameter <3mm 
(n=333) 
    Device diameter ≥3mm 
(n=603) 
P-value† 
 Freq.  Percent  Freq.  Percent 
Vessel treated     <0.001 
 LAD  184 55.3% 287 47.6%  
 RCA  43 12.9% 191 31.7%  
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 CX  105 31.5% 112 18.6%  
 Graft  1 0.3% 13 2.2%  
 LMS  0 0.0% 0 0.0%  
Bifurcation lesion  112 33.6% 193 32.0% 0.611 
Diffuse disease / small vessel  205 61.6% 151 25.0% <0.001 
Heavy calcification  61 18.3% 142 23.5% 0.063 
Thrombus present  41 12.3% 164 27.2% <0.001 
Severe tortuosity  67 20.1% 92 15.3% 0.058 
Drug coated balloon therapy and 
stent(s)  
21 6.3% 38 6.3% 0.998 
Bail out stent  8 2.4% 32 5.3% 0.035 
Chronic total occlusion 12 3.6% 15 2.5% 0.329 
Out of hospital cardiac arrest  7 2.1% 11 1.8% 0.767 
      
Attribute Mean SD Mean SD  
Longest stented / treated section 24.6 13.2 24.6 12.2 0.983 
Device diameter (n=364/665) 2.35 0.25 3.30 0.41 <0.001 
  
† Based on χ2 tests for categorical variables and t-tests for continuous 
 
In the comparison between the two groups, the large vessel group had a higher 
percentage of patients who presented with acute myocardial infarction or acute 
coronary syndrome. Also a higher percentage of lesions in the large vessel group had 
thrombus in them 
Clinical outcomes 
There was no significant difference in one year death, three years death, one year TVR 
and one year TLR, although numerically death rates were higher in the smaller vessel 
group (table 25 and 26). Figures 31, 32, 33, 34 and 35 show the KM survival curves for 
three year death, one year MI, TVR, TLR and MACE.  
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Table 24 De novo large vessels vs. small vessels, patient-level clinical outcomes  
 
 Outcome  Device diameter <3mm (n=292)     Device diameter ≥3mm (n=520) Log rank p 
 Freq.  Percent  Freq.  Percent  
TVR by one year  13 4.5% 26 5.0% 0.77 
MI by one year  9 3.1% 16 3.1% 0.981 
MACE (death, MI, TLR) 
by one year  
23 7.9% 42 8.1% 0.885 
Death by one year  15 5.1% 14 2.7% 0.069 
Death by three years  27 9.2% 34 6.5% 0.147 
  
 
Table 25 De novo large vessels vs. small vessels, lesion-level outcomes  
 
 Outcome Device diameter <3mm (n=333)     Device diameter ≥3mm (n=603) Log rand p 
 Freq.  Percent  Freq.  Percent  
TLR by one year  4 1.2% 15 2.5% 0.183 
  
 
Figure 31 Kaplan-Meier curve for three year death, de novo small vs. large vessel disease 
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Figure 32 Kaplan-Meier curve for one year myocardial infarction, de novo small vessel vs. large vessel 
disease 
 
 
 
Figure 33 Kaplan-Meier curve for one year target vessel revascularisation (TVR), de novo small vessel vs. 
large vessel disease 
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Figure 34 Kaplan-Meier curve for one year target lesion revascularisation (TLR), de novo small vessel vs. 
large vessel disease 
 
 
Figure 35 Kaplan-Meier curve for one year MACE with TLR, de novo small vessel vs. large vessel disease 
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3.1.4 Primary PCI cohort 
DCB-only treated primary PCI cohort is another important group in this registry. There 
were 284 lesions in 268 patients treated. Vast majority (81%) were de novo lesions and 
large vessels with a device diameter of 3mm or more (73.2%). 3.7% were in cardiogenic 
shock 6.3% were out of hospital cardiac arrests. Patient characteristics are described in 
table 26. 
 
Table 26 Patient demographics; primary percutaneous coronary intervention (PPCI) cohort  
 
Attribute (n 268)  Freq.  Percent 
Female  71 26.5% 
Previous MI  60 22.4% 
Previous PCI  64 23.9% 
Previous CABG  5 1.9% 
Hypertension  123 45.9% 
Dyslipidaemia  78 29.1% 
Diabetes  29 10.8% 
Family history of CAD  45 16.8% 
Current smoker  90 33.6% 
Cardiogenic shock  10 3.7% 
Out of hospital cardiac arrest  17 6.3% 
Ventilated prior to PCI 8 3% 
Attribute  Min Max  Mean SD 
Age (y) 36 95 65.3 13.6 
 
 
Lesion and Procedural characteristics 
There were 205 (72.2%) lesions with thrombus and in 87.5% of them thrombus 
aspiration was carried out. This constitutes 63.4% of total lesions. In 135 (50.4%) 
lesions glycoprotein IIb/IIIa inhibitors was used. All patients are treated with a loading 
dose of aspirin 300mg and Clopidogrel 600mg by the paramedical team unless there 
was an absolute contraindication and  67 (23.6%) lesions were treated with aspirin and 
clopidogrel whilst 192 (67.6%) lesions were treated with a combination of aspirin and 
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Ticagrelor post PCI. 90.1% patients had DCB-only PCI. 
 
Table 27 Lesion-level attributes (n=284); PPCI cohort 
 
Attribute (n 284)  Freq.  Percent 
Vessel treated   
 LAD  127 44.7% 
 RCA  102 35.9% 
 CX  51 18.0% 
 LMS  2 0.7% 
De novo disease 230 81.0% 
ISR/stent thrombosis 54  
Device diameter >=3mm  208 73.2% 
Diffuse disease / small vessel  80 28.2% 
Bifurcation  64 22.5% 
Heavy calcification  45 15.8% 
Thrombus present  205 72.2% 
Thrombus aspiration 180 63.4% 
TIMI 0 flow pre PCI 175 61.6% 
TIMI III flow post PCI 267 94.0% 
Glycoprotein IIb/IIIa inhibitors 135 50.4% 
Severe tortuosity  33 11.6% 
Coronary dissections A,B 11  
Coronary dissection type C and above 8  
Drug coated balloon therapy and stent(s)  28 9.9% 
Bail out stent  14 4.9% 
DCB-only PCI 256 90.1% 
 
Attribute  Min Max  Mean SD 
Longest stented / treated section 10 100 25.9 13.9 
Device diameter (n=289) 2 4 3.18 0.59 
 
 
Clinical Outcomes 
30 day all cause death was 6 (2.2%). One year death was 16 (6.0%). MI by one year 
was 8 (3.0%). TVR by one year was 20 (7.5%). Target lesion revascularization (TLR) 
was 10 (3.5%). MACE (TVR) was 40 (14.9%) whilst MACE with TLR was 31 (11.6%) 
All-cause mortality at 3 years was 32 (11.9%). There were two acute vessel closures 
0.7% which were bailed-out with stents with no further complications at 12 months. No 
events of definite lesion thrombosis. Table 28 describes the clinical outcomes and 
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figures 36-38 show the CM curves for three year death, one year MACE and one year 
TLR. 
Table 28 Clinical outcomes; PPCI cohort  
 Outcomes (n 268)  Freq.  Percent 
Per patient (n 268)   
Death 30 days 6 2.2% 
Death 12 months 16 6.0% 
MI 12 months 8 3.0% 
TVR 12 months 20 7.5% 
MACE (death, MI, TLR) 12 
months  
31 11.6% 
Dead by three years  32 11.9% 
   
Per lesion (n 284)   
TLR by one year (per lesion) 10 3.5% 
 
 
 
 Figure 36 Kaplan-Meier curve for three year death; PPCI cohort 
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Figure 37 Kaplan-Meier curve for one year MACE (death, MI, TLR); PPCI cohort  
 
 
 
Figure 38 Kaplan-Meier curve for one year target lesion revascularisation (TLR); PPCI cohort  
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3.1.5 Left Main Stem Cohort 
20 patients who received DCB-only PCI (consecutive patients) during the study period 
are described in this section. Mean (SD) age was 68.8(10.6) and 13 were unprotected 
LMS patients. 14 were de novo lesions. Patient level characteristics are described in 
table 29. 
Table 29 Left main stem cohort; patient-level attributes (n=20) 
 
Attribute (n20)  Freq.  Percent 
Female  4 20.0% 
Previous MI  9 45.0% 
Previous PCI  10 50.0% 
Previous CABG  7 35.0% 
Hypertension  14 70.0% 
Dyslipidaemia  16 80.0% 
Diabetes  5 25.0% 
Family history of CAD  4 20.0% 
Current smoker  2 10.0% 
Attribute  Min Max  Mean SD 
Age (y) 46 87 68.8 10.6 
 
Lesion and procedural characteristics are described in table 30.  
 
Table 30 Left main stem cohort; Lesion-level attributes (n=20) 
 
Attribute (n 20)  Freq.  Percent 
Unprotected LMS 13 65% 
De novo lesions 14 70% 
STEMI 
NSTEMI 
Stable 
2 
7 
11 
10% 
35% 
55% 
Bifurcation  15 75.0% 
Heavy calcification  7 35.0% 
Thrombus present  1 5.0% 
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Drug coated balloon therapy and 
stent(s)  
1 5.0% 
DCB only PCI  191 95.0% 
 
Attribute  Min Max  Mean SD 
Longest stented / treated 
section 
10 
60 22.8 10.8 
Device diameter (n=20) 2.5 4 3.63 0.51 
 
 
Outcomes 
 
Apart from a MI due to a distal LAD occlusion at 21 days post index PCI, there were no 
other adverse outcomes. There was one death up to three years follow up. An 87 year 
old patient died due to pneumonia 497 days after PCI. No cerebro vascular accidents 
up to one year. Figure 39 shows the KM curve for three year death. 
 
Table 31 Left main stem cohort; patient - level outcomes  
 
 Outcomes 12 months  Freq.  Percent 
Death 0 0.0% 
MI  1 5.0% 
TVR  0 0.0% 
TLR  0 0.0% 
MACE (TLR) by one year  1 5.0% 
MACCE* 1 5.0% 
Dead by three years  1 5.0% 
 
** MACCE: Major adverse cardiac and cerebral events (death, MI, TLR, Stroke) 
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Figure 39 Kaplan- Meier curve for three years death; left main stem cohort 
 
 
Figure 40 (a) shows critical distal LMS disease with Thrombolysis In Myocardial Infarction (TIMI) II flow. 
Figure 34(b) shows follow up angiographic appearance after 4 months from DCB-only angioplasty to LMS.  
            
 Figure 40 (a)    
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 Figure 40 (b)                  
    
3.1.6 Chronic total occlusions (CTO) 
Results of 38 consecutive chronic total occlusions in 36 patients treated with DCB 
angioplasty during the study period (01/01/2009 to 31/12/2015) is described in this 
section.  
Method of treatment and all aspects of the procedure were at the discretion of the 
operator. There is a dedicated CTO list and two experienced operators perform the 
procedure. Dual access was gained as felt appropriate by the operator/s and guide 
catheters, wires, crossing technique and other adjunctive devices used were at their 
discretion. DCB was applied only as a mode of drug delivery after successful 
recanalization and lesion preparation. A DCB with a 1:1 balloon-to-artery ratio was 
inflated for 30 to 60 seconds. Patients were monitored overnight prior to discharge. The 
German consensus guidelines on DCB angioplasty was followed generally i.e. greater 
159 
 
than 30% residual stenosis or dissections of more than type B of National Heart, Lung, 
and Blood Institute (NHLBI) classification were considered for bail-out stenting however 
this was not adhered to strictly, given higher occurrence of dissections in this cohort. 
Bail-out stenting was an individual patient based decision considering factors such as 
grade of dissection, TIMI flow grade and haemodynamic status. Patient level 
characteristics are described in table 32. 
Table 32 Chronic total occlusions; patient -level attributes (n=36) 
 
Attribute (n 36)  Freq.  Percent 
Female  6 16.7% 
Previous MI  12 33.3% 
Previous PCI  21 58.3% 
Previous CABG  5 13.9% 
Hypertension  19 52.8% 
Dyslipidaemia  25 69.4% 
Diabetes  10 27.8% 
Fhx of CAD  14 38.9% 
Current smoker  3 8.3% 
   
Attribute  Min Max  Mean SD 
Age (y) 42 82 63.8 9.7 
 
 
 
Lesion and procedural characteristics are described in table 33. Of note 79% were de 
novo lesions and in 37% of lesions, the JCTO score was 2 or more. Antegrade wire 
escalation technique was used in all lesions. In 90% of cases DCB only PCI was 
feasible. 
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Table 33 Chronic total occlusions; lesion and procedural characteristics (n=38) 
 
Attribute (n38)  Freq.  Percent 
Vessel treated   
 LAD  18 47.4% 
 RCA  16 42.1% 
 CX  4 10.5% 
   
JCTO =>2 14 36.8% 
Antegrade wire escalation 38  
Coronary dissections 
Type a  
type b  
type c  
17 
3 
10 
4 
44.7% 
DCB only PCI 34 89.5% 
Device diameter >=3mm  20 52.6% 
De novo 30 78.9% 
ISR 8  
Access 
Dual 
Single 
 
20 
18 
 
52.3% 
47.7% 
Technique 
Anterograde wire escalation 
 
38 
 
100% 
Guidewires 
Fielder XTA 
BMW 
Sion blue 
Pilot 50 
Pilot 200 
Gaia 
Corsair  
Guideliner 
 
29 
11 
9 
3 
6 
3 
22 
4 
 
76.3% 
28.9% 
23.7% 
7.9% 
15.8% 
7.9% 
57.9% 
10.5% 
Additional devices used 
Scoring balloon 
 
5 
 
13.2% 
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Cutting balloon 
Rotational atherectomy 
1 
1 
2.6% 
2.6% 
Number of DCBs per lesion 1.6  
SeQuent please 
Falcon 
33 
5 
86.8% 
13.2% 
Bifurcation  10 26.3% 
Heavy calcification  7 18.4% 
Severe tortuosity  2 5.3% 
Drug coated balloon therapy and 
stent(s)  
4 10.5% 
Bail out stent  2 5.3% 
 
Attribute  Min Max  Mean SD 
Longest stented / treated 
section (mm) 
15 
120 41.6 27.1 
Device diameter (mm) 2 4 2.81 0.59 
 
 
Clinical Outcomes 
There were no cardiac deaths in the first 12 months and one death up to three years 
(one patient suffered a non- cardiac death at 456 days from the index procedure due to 
traumatic chest and head injuries). One patient (2.8%) suffered a non ST elevation MI 
(non- target vessel related). There were 2 TLRs (5.3%) at 112 and 161 days after the 
index procedure respectively. One of them was a repeat intervention to an in-stent 
restenosis adjacent to the previously treated CTO and the second TLR was for 
restenosis of the index lesion. There was one (2.3%) non target lesion related TVR and 
this was a staged procedure for a CTO of posterior descending artery (PDA) after an 
initial successful opening of a proximal RCA CTO. There were no acute vessel closure 
or treated lesion thrombosis. 15 (39.5%) lesions have been assessed by further follow 
up angiography and no re occlusions seen. Out of the16 patients who had coronary 
dissections, apart for one patient who presented with a non- target vessel related MI, no 
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other adverse outcomes were noted. Figures 41-43 show the KM survival curves for 
three year death, MACE and TLR. 
Table 34 Chronic total occlusions; clinical outcomes 
 
 Outcome   Freq.  Percent 
Per Patient (n 36)   
Death by one year  0 0.0% 
MI  1 2.8% 
TVR  3 8.3% 
MACE (TVR) by one year  3 8.3% 
MACE (TLR) by one year  3 8.3% 
Death by three years  1 2.8% 
   
Per lesion (n 38)   
TLR by one year  2 5.3% 
 
 
Figure 41 Chronic total occlusions; Kaplan-Meier curve for three year death 
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Figure 42 Chronic total occlusions; Kaplan-Meier curve for one year MACE (all cause death, MI, TLR) 
 
 
Figure 43 Chronic total occlusions; Kaplan-Meier curve for one year target lesion revascularisation 
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Figure 44 Pre (a), immediate post treatment (b) and follow up (c) images of a proximal left anterior 
descending artery chronic total occlusion. 
Figure 44 (a) - pre treatment 
 
 
Figure 44 (b) – immediate post treatment 
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Figure 44 (c) – appearance at 24 months 
 
 
Figure 45 Pre-treatment (a) and follow up (b) images of a right coronary artery chronic total occlusion. 
Figure 45 (a) – pre treatment 
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Figure 45 (b) – appearance at 17 months 
 
3.1.7 In-stent Restenosis group 
There were 353 in stent restenosis (ISR) lesions in 324 patients treated with DCB 
angioplasty during the study period. 31 lesions had bare metal stent (BMS) restenosis 
and 77 were drug eluting stent (DES) re stenosis. 1 lesion was a restenosis of a bio 
resorbable scaffold. Stent type of other lesions was not known. Patient demographics 
are described in table 36 whilst lesion and procedural characteristics are described in 
table 37. In 20.7% of lesions a cutting or scoring balloon was used as part of lesion 
preparation which is a higher percentage compared to de novo lesions.  
Table 35 In-stent restenosis cohort; patient-level attributes (n=324) 
 
Attribute (n324)  Freq.  Percent 
Female  77 23.8% 
Previous MI  203 62.7% 
Previous CABG  52 16.0% 
Hypertension  202 62.3% 
Dyslipidaemia  157 48.5% 
Diabetes  98 30.2% 
Family history of CAD  64 19.8% 
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Current smoker  51 15.7% 
Cardiogenic shock  2 0.6% 
Out of hospital cardiac arrest  3 0.8% 
   
Attribute  Min Max  Mean SD 
Age (y) 33 95 66.8 11.1 
 
 
 
Table 36 In-stent restenosis; lesion and procedural characteristics (n=353) 
 
Attribute (n 353)  Freq.  Percent 
Vessel treated   
 LAD  150 42.5% 
 RCA  101 28.6% 
 CX  70 19.8% 
 LMS  6 1.7% 
 Graft  26 7.4% 
BMS restenosis 31 8.8% 
DES restenosis 77 21.8% 
BVS restenosis 1 0.3% 
Stent unknown 244 69.1% 
Device diameter >=3mm  296 83.9% 
Diffuse disease / small vessel  113 32.0% 
Bifurcation  80 22.7% 
Heavy calcification  44 12.5% 
Thrombus present  55 15.6% 
Severe tortuosity  34 9.6% 
Drug coated balloon therapy and 
stent(s)  
65 18.4% 
Bail out stent  20 5.7% 
Chronic total occlusion 8 2.3% 
Cutting/scoring balloons 73 20.7% 
 
Attribute  Min Max  Mean SD 
Longest stented / treated 
section 
10 
110 28.6 17.3 
Device diameter (n=403) 2 4 3.24 0.52 
 
 
 
Clinical outcomes 
 
As described in table 38, at 12 months all cause death is 3.4%, MI 8%, TVR 9.6%, 
MACE (TVR) 15.7%, MACE (TLR) 13.0%. TLR rate was 4.8%. Out of the MIs reported 
5 patients had ST elevation MI and two of them led to target vessel revascularizations. 
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Out of the other 21 patients who represented with a MI, 14 had a target vessel 
revascularization and 9 had a target lesion revascularisation. Out of the 17 target lesion 
revascularization one was a definite lesion thrombosis which occurred after 2 hours 
from the index PCI which was bailed out with a bare metal stent. Figures 46-48 show 
the KM survival curves for three year death, one year MACE and one year TLR. 
 
 
Table 37 In-stent restenosis; clinical outcomes  
 
 Outcome at 12 months  Freq.  Percent 
Patient level outcomes (n 324)   
All cause death  11 3.4% 
TVR  31 9.6% 
MI  26 8.0% 
MACE (death, MI, TLR)  42 13.0% 
All cause death at 3 years  34 10.5% 
   
Lesion level outcomes (n 353)   
TLR 17 4.8% 
 
Figure 46 In-stent restenosis; Kaplan-Meier curve for three year death 
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Figure 47 In-stent restenosis; Kaplan-Meier curve for three year MACE (all cause death, MI, TLR) 
 
Figure 48 In-stent restenosis; Kaplan-Meier curve one year target lesion revascularisation 
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3.1.8 DCB in bypass graft stenosis 
40 lesions in 37 patients who received DCB angioplasty to coronary artery bypass grafts 
are included in this cohort. Patient and lesion characteristics are as described in the 
tables 38 and 39. Of note 65% of lesions were in stent restenosis within bypass grafts. 
Table 38 Bypass grafts; patient-level attributes (n=37) 
 
Attribute (n37)  Freq.  Percent 
Female  9 24.3% 
Previous MI  24 64.9% 
Previous PCI  29 78.4% 
Previous CABG  37 100.0% 
Hypertension  27 73.0% 
Dyslipidaemia  31 83.8% 
Diabetes  14 37.8% 
Family history of CAD  5 13.5% 
Current smoker  1 2.7% 
Cardiogenic shock  0 0.0% 
   
Attribute  Min Max  Mean SD 
Age (y) 47 87 72.8 7.9 
 
Table 39 Bypass grafts; lesion and procedural characteristics (n=40) 
 
Attribute  (n 40)  Freq.  Percent 
Graft de novo 14 35.0% 
Graft in stent restenosis  26 65.0% 
Device diameter >=3mm  34 85.0% 
Diffuse disease / small vessel  14 35.0% 
Bifurcation  5 12.5% 
Heavy calcification  3 7.5% 
Thrombus present  6 15.0% 
Distal emboli protection device 
(Spider) 
11 27.5% 
Severe tortuosity  5 12.5% 
Drug coated balloon therapy and 
stent(s)  
6 15.0% 
Bail out stent  0 0.0% 
 
Attribute  Min Max  Mean SD 
Longest stented / treated 
section 
14 
66 26.1 13.9 
Device diameter (n=40) 2 4 3.31 0.53 
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Clinical Outcomes 
Clinical outcomes are much worse than the previously described sub sets. Both MACE  
and TVR are high at 21.6% at 12 months. Clinical outcomes are summarized in table 
40. Figures 49-51 show KM survival curves for three year death, MACE and TLR. 
Table 40 Bypass grafts; clinical outcomes 
 Outcome   Freq.  Percent 
Patient level (n37)   
Death by one year  1 2.7% 
TVR by one year  8 21.6% 
MI by one year  4 10.8% 
MACE (TLR) by one year  8 21.6% 
Death by three years  4 10.8% 
   
Lesion level (n40)   
TLR by one year 8 20.0% 
 
 
Figure 49 Bypass grafts; Kaplan-Meier curve for three year death 
 
 
 
Figure 50 Bypass grafts; Kaplan-Meier curve for one year MACE (all cause death, MI, TLR) 
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Figure 51 Bypass grafts; Kaplan-Meier curve for one year target lesion revascularisation 
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3.2 Propensity score matched study; comparison of clinical outcomes between 
DCB angioplasty vs. 2nd generation DES 
A total of 3938 patients (4939 de novo lesions) treated with stents and 812 patients 
(1026 de novo lesions) treated with drug coated balloon (DCB) angioplasty were 
identified from the hospital data base. 38 patients who had a DCB as well as a stent in 
the same lesion ( +/- 5mm proximal or distal to index lesion) were excluded from the 
DCB arm. Also another 43 patients who had received a prior drug eluting stent (DES) 
and had a clinical event prior to DCB angioplasty were excluded from the DCB arm. 
1044 patients who received bare metal stents (BMS) or 1st generation DES were 
excluded from the DES arm as per protocol. Finally 2894 patients (3473) lesions treated 
with 2nd generation DES and 731 patients (922 lesions) treated with DCB were selected 
for propensity score matching. Pre propensity matching patient and lesion 
characteristics are described in tables 41 and 42. Consort style diagram in figure 52 
describes the patient flow. 
Propensity score matching. 
The method of propensity score matching is described in the analysis plan in detail. A 
nearest neighbour matching within caliper algorithm was used. 1:3 lesion level matching 
was used to alleviate the differences noticed in the pre propensity matching cohort. 
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Figure 52 Consort style diagram describing patient enrolment, propensity score matching and follow up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stents3938 patients (4939 lesions) 
DCB 812 patients (1026 lesions) 
  DCB and Stents used in the same lesions 38 patients  
  Prior DES with clinical outcome prior to DCB PCI (excluded 
from DCB arm) 43 patients 
  BMS and 1
st
 generation stents excluded from DES arm 
1044 patients 
 
903 lesions (718 patients) 
DCB arm 
904 lesions (719 patients) 
1421 lesions (1268 patients) 
DES arm 
1424 lesions (1271 patients) 
    Propensity score matching 
        Follow-Up 
Selected for propensity score matching 
DES 2894 patients (3473 lesions), DCB 731 patients (922 
lesions) 
 
 
 
Enrolment 
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Table 41 Patient characteristics; pre-propensity score matching. 
 DCB 731 % DES 2894 % P value 
Male gender 558 76.3 2,213         76.5 Pr = 0.939 
Diabetes 121 16.6 349         12.1 Pr = 0.001 
Hypertension 371 50.8 1,256         43.4 Pr = 0.000 
Previous MI 159 21.8 479        16.6 Pr = 0.001 
Previous PCI 154 21.1 454      15.7 Pr = 0.001 
Previous 
CABG 
33 4.5 104     3.6 Pr = 0.243 
Primary PCI 186 25.5 999         34.5 Pr = 0.000 
ACS/AMI 
Stable 
424 
307 
58.0 
42.0 
1,906     
 988          
65.9 
34.1 
Pr = 0.000 
Cardiogenic 
shock 
9 1.2 44       1.5 Pr = 0.561 
OOHCA 16 2.2 45        1.6 Pr = 0.234 
MI-myocardial infarction, PCI-percutaneous coronary intervention, CABG- coronary artery bypass graft, ACS- acute coronary 
syndrome, AMI- acute myocardial infarction 
There was no difference in the number of patients who had out of hospital cardiac 
arrest, cardiogenic shock, previous bypass grafts and gender between the two groups. 
Primary PCI, acute coronary syndrome, length of the treated segment and presence of 
thrombus were higher in the drug eluting stent arm. All of the other risk factors such as 
diabetes, hypertension, previous MI, previous PCI, small device diameter, bifurcation 
lesions, diffuse disease, calcific lesions and severe tortuosity   were higher in the DCB 
arm indicating that the DCB cohort is a more complex lesion group. 
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Table 42 Lesion characteristics; Pre- propensity score matching 
 DCB 922 
lesions 
% DES 3473 
lesions 
% P value 
LMS 
LAD 
Cx 
RCA 
14 
467 
227 
214 
1.5 
50.7 
24.7 
23.2 
92 
1,600       
694  
1,087       
2.6 
46.1 
20.0 
31.3 
Pr = 0.000 
Device 
diameter 
mean(SD) 
2.9 (.59)  3.4 (.61)  Pr(T > t) = 
0.0000 
Length of 
treated 
segment 
23.56 (10.9)      29.65(16.4)         Pr(T > t) = 
0.0000 
Bifurcation 
lesion 
314 34.1 743     21.4 Pr = 0.000 
Heavy 
calcification 
195 21.1 607   17.5 Pr = 0.010 
Diffuse 
disease/SVD 
358 38.8 876    25.2 Pr = 0.000 
Severe 
tortuosity 
158 17.1 495         14.3 Pr = 0.029 
Thrombus 191 20.7 1,020       29.4 Pr = 0.000 
 
Gender, previous CABG, cardiogenic shock and out of hospital cardiac arrest were not 
used in the propensity score model as these covariates did not differ between the 
groups before matching. Demographics and lesion characteristics post propensity 
matching are listed in table 43. 
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Table 43 Post propensity score matching demographics and lesion characteristics 
Covariate DCB  n904 lesions 
(719 patients) 
DES  n1424 lesions 
(1271 patients) 
p 
Age 65.8 64.9 Pr(T > t) = 0.9586 
Previous MI 209 (23.1) 301       (21.1) Pr = 0.260 
Previous PCI 210 (23.2) 289       ( 20.3) Pr = 0.093 
Hypertension 463 (51.2) 682        (47.9) Pr = 0.118 
Diabetes 152 (16.8) 219        (15.4) Pr = 0.357 
Indication 
Stable 
ACS/MI 
 
399 (44.1) 
505 (55.9) 
 
586     (41.2) 
838      (58.8) 
Pr = 0.155 
Primary PCI 209 (23.1) 363      (25.5) Pr = 0.195 
Vessel treated 
LMS 
LAD 
Circumflex 
RCA 
 
14 (1.5) 
452 (50) 
226 (25) 
212 (23.5)      
 
31  (2.20 
716 (50.3) 
311 (21.8) 
366  ( 25.7)        
Pr = 0.198 
Length of the 
treated segment 
23.7 (11.0)       25.6 (11.8)       Pr(T > t) = 0.0001 
Device diameter 3.0 (0.6)       3.2 (0.5)        Pr(T > t) = 0.0000 
Bifurcation lesion 297 (32.9) 376    (26.4) Pr = 0.001 
Heavy calcification 187 (20.7) 278    (19.5) Pr = 0.494 
Diffuse 
disease/small vessel 
disease 
340 (37.6) 445    (31.3) Pr = 0.002 
Severe tortuosity 149 (16.5) 225     (15.8) Pr = 0.662 
Thrombus present 191(21.1)  339      (23.8) Pr = 0.133 
 
Length of the treated segment, device diameter, diffuse disease and bifurcation lesion 
covariates were different in the two arms even after propensity score matching. 
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Clinical outcomes 
Pre propensity score matching. 
Pre propensity matching clinical outcomes at 12 months are described in table 44. 
There was no significant difference between the individual outcomes as well as MACE.  
Table 44 Clinical outcomes; pre-propensity matching, unadjusted. 
 DCB  (922 
lesions, 731 
patients) 
DES (3473 
lesions, 2894 
pts) 
P value OR 95% CI 
12 months death 26 (3.6%) 71 (2.5%) 0.10 1.47 0.93 – 2.32 
12 months MI 20 (2.7%) 85 (2.9%) 0.77 0.93 0.57-1.52 
12 months TVR 34 (4.7%) 104 (3.6%) 0.18 1.31 0.88-1.95 
12 months TLR 
(per lesion) 
21 (2.3%) 88 (2.5%) 0.66 0.90 0.55-1.45 
12 months MACE 
(death, MI, TLR) 
60 (8.2%) 200 (6.9%) 0.23 1.20 0.89-1.63 
 
Clinical outcomes after propensity score matching are described in table 45. The 
covariates: length of treated segment, device diameter, bifurcation lesion and diffuse 
disease were adjusted for in the logistic regression analysis as they were not well 
balanced by propensity matching. There was no difference between MACE or individual 
outcomes between the two groups. MACE for the DCB arm met the pre-specified non-
inferiority criteria (non-inferiority margin of 4.5%, upper bound of the 95% confidence 
interval of the odds ratio was 1.47, which is below the pre specified 1.56 margin). Death 
was numerically higher in the DCB are at one year and at 3 years but not statistically 
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significant. Occurrence of myocardial infarction and target lesion revascularisation was 
numerically better in the DCB arm. TVR was higher in the DCB arm. No definite lesion 
thrombosis was noted in the DCB cohort whilst this was 0.6% with DES. Acute vessel 
closure/need for repeat intervention on the same day was 0.4% for the DCB group and 
0.3% for the DES group. 
Table 45 Clinical outcomes; post propensity score matching, risk adjusted 
 DCB 718 
patients /903 
lesions1 
DES 1268 
patients /1421 
lesions2 
OR P value 95% 
confidence 
interval 
Per patient 
outcomes 
     
Death 12 months 26 (3.6%) 37 (2.9%) 1.10 0.723 0.65-1.86 
Death 3 yrs 57 (7.9%) 80 (6.3%) 1.20 0.336 0.83-1.72 
Death/MI 43 (6.0%) 71 (5.6%) 0.99 0.955 0.66-1.48 
MI 19 (2.6%) 41(3.2%) 0.74 0.744 0.42-1.31 
TVR 34 (4.7%) 48 (3.8%) 1.12 0.627 0.71-1.78 
Death, MI, TVR 72 (10.0%) 102 (8.0%) 1.16 0.384 0.83-1.60 
MACE (death, mi, 
TLR) 
59 (8.2%) 
 
93 (7.3%) 1.04 0.834 0.73-1.47 
Per lesion      
TLR 21 (2.3%) 35(2.5%) 0.86  0.726      0.37-2.02 
Definite 
lesion/stent 
thrombosis 
0 (0%) 8 (0.6%) 0.09 0.10 0.01-1.60 
Acute vessel 
closure/re 
intervention on the 
same day 
4 (0.4%) 4 (0.3%) 1.58 0.52 0.39-6.32 
1 One loss to follow up. 2 3 loss to follow up. 
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3.3 Summary of Results 
The DCBNORWICH registry included 1394 lesions in 1122 patients that have been 
treated with drug coated balloons from 1st of January 2009 till 31/12/2015 at Norfolk 
and Norwich University Hospital. The results were described under de novo group, de 
novo bifurcations, large vessel group, primary PCI group, left main stem, chronic total 
occlusions, instent restenosis and bypass graft groups. 
1. De novo cohort: 12 months all cause death rate for the de novo group was 
3.6%. The rate of myocardial infarction was 3.1%. Target vessel 
revascularisation (TVR) was 4.9%. Target lesion revascularisation was 2.1%. 
MACE was 8.1%.There were 4 (0.4%) acute vessel closures/instability requiring 
a repeat procedure within 24 hours after DCB. No definite treated segment 
thrombosis was noted. 
2. De novo bifurcation cohort: There were 327 lesions in 309 patients. 12 months 
all cause death rate was 2.6%. The rate of myocardial infarction was 3.8%. 
Target vessel revascularisation (TVR) was 4.5% and the target lesion 
revascularisation was 3.1%. MACE was 8.7%. The comparison between 
bifurcation lesion and non-bifurcation lesions showed no statistically significant 
difference between the outcomes. 
3. Large vessels/device diameter 3mm or more cohort: The group had 603 
lesions in 520 patients. 12 months all cause death was 2.7%. The rate of 
myocardial infarction was 3.1% and target vessel revascularisation (TVR) was 
5%. Target lesion revascularisation was 2.5%.  MACE was 8.1%. The 
comparison between less than 3mm and 3mm or more group showed no 
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significant difference in individual outcomes or MACE. Death by one and three 
years was numerically worse with small vessels whilst TLR was numerically 
better in the small vessel group.  
4. PPCI cohort: 284 lesions in 268 patients were included in this cohort. 30 day 
mortality was 2.2% whilst 12 months mortality was 6%. The rate of myocardial 
infarction was 3%. Target vessel revascularisation (TVR) was7.5% and target 
lesion revascularisation was 3.5%. MACE was 11.6%. 
5. The left main stem (LMS) cohort: There were 20 patients who received DCB 
PCI to their LMS during the study period. There was no cardiac death up to three 
years. One non-target vessel related MI was reported and no repeat 
revascularisations within the first year. MACCE (death, MI, TLR, Cerebro 
vascular event) 0.5%. No cerebro-vascular accidents occurred.  
6. Chronic total occlusions (CTO): There were 38 lesions in 36 patients. No 
deaths reported in the first 12 months and one patient (2.8%) had a non-target 
vessel MI. There were 3 (5.3%) target lesion revascularisations (TLR) and overall 
MACE rate was 8.3%. 
7. ISR cohort: 353 lesions in 324 patients were included in this cohort. All cause 
death was 3.4% at 12 months and TVR was 9.6%. MI rate was 8% whilst TLR 
rate was 4.8%. MACE was 13.0% at 12 months. 
8. Bypass graft cohort:  37 patients (40 lesions) received DCB angioplasty during 
the study period. All cause death at one year was 2.7% and TVR was 21.6%. MI 
at one year was 10.8% and MACE was 21.6%. At 12 months TLR rate was 20%. 
182 
 
9. Propensity score matched comparison between DCB and 2nd generation 
stents: There were 904 lesions (719 patients) in the DCB arm and 1424 lesions 
(1271 patients) in the DES arm after propensity score matching. 12 months 
outcomes were all cause death 26 (3.6%) vs. 37 (2.9%), MI 19 (2.6%) vs. 
41(3.2%), TLR 21 (2.3%) vs. 35 (2.5%), TVR 34 (4.7%) vs.48 (3.8%) and MACE  
59 (8.2%) vs. 93 (7.3%) for the DCB and DES groups respectively. Differences 
were not statistically significant. The MACE outcome for DCB met the non-
inferiority criteria. The definite treated lesion thrombosis/stent thrombosis was 0% 
vs. 0.6% for 12 months. 
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 Discussion 4
The discussion will cover aspects of both the DCBNORWICH Registry including its sub 
groups and the propensity score matched comparison of the DCB vs. Drug eluting stent 
study.  
4.1 Discussion on DCB NORWICH Registry 
4.1.1 Key Findings 
1. DCB angioplasty is feasible and safe, and provides clinical outcomes in the 
expected range in a broad spectrum of coronary lesions and indications including de 
novo lesions, STEMI, bifurcations, CTO, post CABG and most importantly larger 
(>3.0mm) coronary arteries 
2. Main factors associated with target lesion revascularisation in multivariate 
analysis in the de novo population are STEMI and NSTEMI/ACS.  
3. Findings show that DCB in STEMI provides comparable outcomes to established 
stent registries  
4. Extends the experience of DCB angioplasty to more complex patients e.g. CTO 
and post CABG 
5.  There was no definite treated lesion thrombosis in the de novo cohort up to one 
year. 
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4.1.2 De Novo Group  
During the study period a total of 1026 lesions in 812 patients have been treated with 
DCB angioplasty.    This constitutes the largest cohorts of DCB treated bifurcations, 
large vessels (3mm or more device size) and primary PCI reported thus far. It should be 
noted that as in most centers, DCB angioplasty was first carried out in patients with in-
stent restenosis. The next stage of natural progression was to treat small calibre 
vessels and diffusely diseased segments which otherwise would have required very 
long segments of stents. Encouraging results from other studies such as the Sequent 
please world-wide registry and observing satisfactory results of the previously treated 
lesions especially in the context of staged procedures would have played a role in 
adopting this technology for wider indications123, 124, 132.  
De Novo Group Patient demographics. 
This was an all comer study which included all patients treated with drug coated 
balloons during the given period. Therefore this cohort reflects contemporary UK 
practice.  Table 46 outlines the demographic details of the patients in the de novo 
registry against the UK BCIS audit data published in 2019157. Apart from comprising 
lesser number of diabetics in the DCBNORWICH registry, other characteristics were 
comparable in the two groups. This would further support that the DCB treated cohort is 
not a selected sample of simple cases but a cohort reflective of contemporary practice.  
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Table 46 Patient demographics of DCB Norwich registry vs. UK BCIS audit report 
Patient Characteristics DCBNORWICH registry – 
de novo group 
 UK BCIS report    
2019 
Number of patients  812   102258 
Age – Mean (SD)  65.8   65.4 
Gender Male % 75.6   74.3 
Previous MI % 24.5    27 
Previous PCI % 27.2    26.9 
Previous CABG % 4.1    7.5 
Diabetes Mellitus% 16.9    23.5 
Current smoker% 22.7   22.7 
 
DCB de novo group indications, lesion complexity and procedural details 
Vast majority (60.1%) of DCB angioplasty were done for acute coronary syndromes. ST 
elevation MI comprised of 26.7% and NSTEMI/Unstable angina percentage was 33. In 
the UK wide BCIS data 27.2% were for STEMI, 38.6% were for NSTEMI/UA and 30.4% 
were for stable disease. Table 47 outlines these percentages. 
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Table 47 Indication for PCI; DCB Norwich registry vs. UK BCIS audit report 
Indication DCB de novo group  UK BCIS data 
STEMI % 26.7 27.2 
NSTEMI/UA % 32.5 38.6 
Stable % 40.8 30.4 (34.1 including 
staged procedures) 
 
Most procedures were carried out through the radial artery which comprised of 89.9% of 
procedures conforming to the current UK practice. 70.9% of patients had a single vessel 
treated and the balance had two or more vessels treated at the same sitting. This in 
comparison to 77.7% in the UK BCIS data indicate more multi-vessel treatment in the 
DCB group. 
As in most studies left anterior descending artery (LAD) is the most commonly treated 
artery at 51.6%.The left main stem was treated in 1.4% of DCB de novo patients whilst 
the UK BCIS data showed LMS PCI of 4%. 
Chronic total occlusions (CTO) constituted 2.9% of the total de novo group and were 
8.8% of the total stable disease cohort. UK BCIS data showed 11.6% CTOs out of the 
stable disease cohort. 
Other variables such as heavily calcifications (21.6%), lesions in a bifurcation (34.1%)   
severe tortuosity (17%), diffuse disease/small vessel disease (39.7%), presence of 
thrombus (20.2%) and lesion length of more than 2cm (41.3%)  would indicate that this 
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a mix of type A, B and C lesions not a selected cohort of simple lesions. Mean (SD) 
treated lesion length was 24.5 (12.5) and mean (SD) device diameter was 2.9 (0.6) mm. 
DCB of a 3mm or more diameter was used in 603 (58.8%) lesions indicating large 
vessels. 
Procedural aspects were left to operator’s discretion entirely. German consensus 
guidelines on DCB angioplasty were largely followed but not all type C coronary 
dissections have been bailed-out with stents especially in the case of CTO lesions50.  
Results 
Out of the 1026 de novo lesions 965 (94.5%) lesions were successfully treated with 
DCB-only angioplasty. In total 148 (14.6%) coronary dissections were noted and 22 
(2.3%) of these were type C and above. 42 (4.1%) lesions required bail-out stents 
during the index procedure, for type C or above dissections or due to severe recoil. In 
another 19 (1.8%) lesions stents have been used electively. Sequent Please world-wide 
registry reported a smaller rate of coronary dissections of 3.1% in the de novo arm but 
this consisted of only small vessel coronaries.124  In our registry 100% of lesions were 
pre dilated and good lesion preparation was considered a must. DCB was used only to 
deliver the drug. It is common practice to start pre dilatation with non-compliant balloons 
rather than semi compliant ones expecting a better angioplasty result. Cutting or scoring 
balloons have been used in 77 (7.5%) lesions as part of pre dilatation. In the case of a 
coronary dissection of type C or above after DCB use, bail-out stenting with a second 
generation DES is recommended rather than a BMS. The results of a small study 
comparing BMS vs. DES bail out after DCB angioplasty was published in collaboration 
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with a team of researchers from Tan Tock Seng Hospital, Singapore and it is included in 
the appendix. Dual antiplatelets were recommended for 1 month for a stable lesion and 
1 year for a lesion with ACS/MI.  
Clinical Outcomes 
The target lesion revascularisation rate for 12 months was 2.1%. This is in keeping with 
other DCB studies such as 1% at 9 months in Sequent please world-wide registry, 3.6% 
at 9 months in a prospective registry by Zeymer et al and 2.6% at 9 months in the 
registry by Rosenberg et al.123, 124, 133 There were 4 (0.4) acute vessel closure/instability 
that required bail-out stenting during the same admission and all those 4 patients are 
alive at 3.5 (for two), 4 and 5 year follow up  respectively from the procedures and have 
not had further MIs or revascularisations. Even though we did not perform quantitative 
coronary analysis, naked eye assessment suggests under sizing during pre-dilatation is 
a potential reason for TLR. It should be noted that this registry includes every lesion 
treated with a DCB which includes early learning curves of the DCB operators. 
Target vessel revascularisation was 4.9% (40) at 12 months. TVR was 3.4% in the 
BASKET-SMALL trial at 12 months.138 One patient had repeat PCI in another hospital 
but we did not have access to angiograms to determine whether this was a TLR or not. 
25 patients (3.1%) had a MI within the first 12 months from the index PCI. Out of the 25 
MIs, only 6 led to target vessel revascularisations and 4 of those were target lesion 
revascularisations. Therefore MI leading to a repeat revascularisation of the same 
vessel is 0.7%.  Two of the 25 were ST elevation MIs (day 61 and 359 post index PCI) 
and both were due to occlusion of another vessel. 0% treated lesion thrombosis in the 
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first 12 months was a positive result for DCB-only PCI and could be due to full re 
endothelialisation of the lesion in the absence of a permanent metallic stent.  
We did not have access to death certificates to determine the cause of death of all 
deaths. All cause death was 3.6% (29). There were 10 definite cardiac deaths, 8 cause 
unknown (no information) and 11 non-cardiac. Assessing relationship of DCB-only PCI 
to death becomes difficult in this cohort due the heterogeneity of the group. For example 
27.2% of patients have had previous PCIs and some with POBA, bare metal stents, first 
and second generation stents.  
Out of the 42 lesions which had a bail-out stent after DCB PCI there were no TLRs in 
the first 12 months. There was one death and one MI reported in this group which 
supports the safety of bail-out stenting with a new generation drug eluting stent. Out of 
the 147 lesions with coronary dissections (other than the ones already included in the 
acute vessel closures) there was only one TLR. There were 3 deaths, 2 due to 
metastatic carcinomas and the other had no information available on cause of death.  
Two patients have had subsequent MIs and one had target vessel revascularisation at 
day 79. Treated lesion remained patent and had no further PCI. These results would 
further strengthen the old data from POBA days that all coronary dissections do not 
need bail-out stenting196, 197 
MACE was 66 (8.1%) and these rates are in keeping with other real world studies and 
also it should be noted that patients who were in cardiogenic shock and out of hospital 
cardiac arrests, intubated and ventilated are also included in our registry. Zanchin et al 
in their Bern registry of patients comparing biodegradable polymer vs. durable polymer 
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stents reported a device oriented end point (cardiac death, target vessel MI and TLR) of 
7.8 and 7.1% in each arm which is somewhat similar to MACE outcome in the 
DCBNORWICH registry. 221  
The multivariate regression analysis as described in tables 11,12, 13 and figures 24 and 
25 showed that 10 year increment in age is associated one year death, hypertension 
with MACE and primary PCI with target lesion revascularisation. Whilst effectiveness of 
the drug delivery to the vessel wall in a primary PCI setting could be questioned, the 
fact that presence of thrombus was negatively affecting the TLR makes the said 
argument not so valid. It is understood that PPCI is a high risk setting and clinical 
outcomes are worse compared to stable CAD.It is likely this effect that we are observing 
rather than a specific failure of DCB in PPCI setting. As described in the PPCI section 
separately the one year mortality of the PPCI cohort of the DCBNORWICH registry is 
lower than the 30 day mortality described for PPCIs in the UK wide BCIS registry. In the 
Sequent Please world-wide registry, the most predictive factor for TLR was diabetes 
mellitus but in our registry there was no significant association124. 
In summary these results show that DCB-only angioplasty in de novo lesions is not only 
technically feasible but safe and effective at 12 months. 
The encouraging results observed in this study after DCB angioplasty may be 
attributable to anti proliferative drug delivery reducing restenosis whilst avoiding other 
stent related issues such as chronic inflammation, neo atheroma, stent fracture, stent 
gap, stent overlap, non- uniform stent struts, non-homogenous drug delivery, uncovered 
stent struts, under expansion and late malapposition. 
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4.1.3 De Novo Bifurcations 
Apart from the studies by Shultz et al (39 patients) and Her et al (16 large vessels), 
there are no studies identified with DCB-only PCI in bifurcation lesions173, 206. Most 
studies published are with either a DES or a BMS in the main vessel and DCB used in 
side branch. DCB Norwich appears to be the largest number of bifurcation lesions 
reported under DCB-only PCI category.52, 132, 172, 173, 222, 223 
There were 350 separate lesions involving a bifurcation in this cohort. For the purpose 
of describing them under the heading bifurcation, a lesion where both arms were treated 
was considered as a single lesion. Hence the total number of bifurcation lesions was 
considered as 327 (309 patients). A lesion was defined as a bifurcation if the side 
branch was 2mm or more by visual assessment.  
Bifurcation lesions are the Achilles heel in Interventional Cardiology and higher event 
rates have been reported.170 Technical complexities such as plaque/carina shift 
compromising the ostium of the side branch, difficulties in re-crossing through a stent, 
complexities with two stent strategies and amount of metal/polymer layers overlapped 
are some of the issues that PCI operators have to face when carrying out a bifurcation 
PCI using stent/s. DCB-only PCI would be very attractive as it simplifies the procedure 
with no re-crossing, no metal overlap or gap and not requiring numerous kissing balloon 
dilatations.  
It should be noted that 94.8% of the bifurcation lesions were treated with DCB-only PCI. 
37.1% were true bifurcations (medina 1.1.1, or 0.1.1). 21 lesions had both the main 
branch and the side branch treated with sequential DCBs. There were 4 side branch 
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occlusions during the procedure but operator was able to re-establish the flow of all 4 
before the end of the procedure.  
Outcomes. 
At 12 months all cause death was 8 (2.6%), MI 12 (3.8%), TVR 14 (4.5%), MACE was 
27 (8.7%). TLR was 10 (3.1%). 2 (0.6) lesions had bail out stenting during the index 
admission. No definite treated lesion thrombosis. These outcomes are largely 
comparable with other reported bifurcation studies treated with stents. Schulz in her 
study with 39 bifurcation lesions treated with DCBs reported a MACE rate of 7.7% at 4 
months. Follow up angiography at 4 months showed restenosis of 3/39 lesions requiring 
treatment. TLR rate in our registry is better than some of the bifurcation studies using 
stents. For example, the BBC study reported TLR rate of 5.6% in the single stent arm 
and 6.8% in the two stent (complex) arm at 9 months167. DKCRUSH V study showed 
TLR of 7.9% vs. 3.8% at 12 months in the provisional arm and two stent arm 
respectively224 . Absence of definite treated lesion thrombosis is another important 
factor favouring DCB-only PCI. Her et al showed that when the main branch is treated 
with a paclitaxel coated balloon the minimal luminal diameter of the ostium of the side 
branch(SB) increases at 9 months in their OCT pre, post treatment and 9 months follow 
up study involving 16 main vessels and 26 side branches. Minimal luminal diameter of 
the side branch was 0.97±0.44 mm at pre-procedure, 1.02±0.33 mm at post-procedure 
and 1.04±0.38 mm at 9-months, the late luminal loss of SB ostium was -0.02±0.22 
mm.206  
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In the comparison we carried out between bifurcation and non-bifurcation lesions there 
was no statistically significant difference in individual outcomes. Apart from death other 
outcomes were numerically in favour of the non-bifurcation group though not statistically 
significant. These results may indicate that DCB-only PCI could influence outcomes of 
bifurcation lesions to reach levels similar to non-bifurcation lesions in the first 12 months 
of follow up. 
In summary DCB-only PCI in bifurcation lesions is not only feasible but also has other 
advantages such as simplification of the procedure, less or no permanent overlapping 
metal layers, less or no plaque/carina shift and also presence of late lumen gain in the 
side branch ostium. Our current practice is sequential DCB delivery unless there is a 
significant size mismatch between the proximal and distal vessel. The simultaneous 
delivery of two DCBs take time resulting in loss of drug and also has the potential to 
cause a dissection in the proximal vessel. If there is significant plaque/carina shift post 
DCB, there is always the option of carrying out a final kissing balloon dilatation. 
 As shown above the initial 12 months results are very positive and encouraging. This is 
the largest DCB-only de novo bifurcation study reported thus far hence these results will 
be important as a benchmark for future studies.  
4.1.4 De Novo large vessel cohort 
Evidence for DCB-only PCI in de novo large vessels is small but growing. Lu et al 
published a registry of  94 lesions in 92 patients who received DCBs with diameter of 
3mm or more225. Bail-out DES was used in only 6.4% cases. There were two acute 
vessel closures due to haematoma formation (detected by IVUS and OCT). At 9 months 
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angiographic follow up late lumen loss was -0.02 +/- 0.49 mm. The TLR rate and overall 
MACE rates were 4.3% and 4.3%. Quantitative coronary angiography data (QCA) 
showed that 61.5% (n = 48) of patients showed luminal enlargement indicating late 
lumen enlargement does occur in large vessel coronaries too after DCB treatment.  
Yu et al reported a comparison of large vessel disease (LVD) vs. small vessel disease 
(SVD) treated with DCB strategy in 222 and 373 lesions respectively226. Large vessel 
group had no MACE events at 10 months clinical follow up. A significant late lumen gain 
was shown in QCA analysis in follow up angiography LVD group (2.26 ± 0.66 vs. 2.09 ± 
0.40 mm, P = 0.067) as well as the small vessel group. 
Rosenberg et al published a propensity score matched comparison of LVD vs. SVD 
treated with DCB-only PCI comprising of 117 patients in each arm showed a MACE rate 
of 6.1% and 5.7% respectively at 9 months227. 
DCBNORWICH registry is comprised of 603 large vessel coronary lesions in 520 
patients treated with DCBs. Patient demographics were similar to our previously 
described overall de novo cohort. Clinical outcomes at 12 months for the LVD group 
were similar to other studies with MACE rate of 8.3%, TVR 27 (5.2%), MI 16 (3.1%), all 
cause death of 14 (2.7%).  We carried out a comparison between the LVD and SVD 
treated with DCB-only PCI. The large vessel group had more patients presenting with 
MI and more lesions with thrombus. The results showed no significant difference 
between the clinical outcomes at 12 months. Numerically lower TLR rate was reported 
in the SVD cohort. Higher number of acute MIs and lesions with thrombus in the large 
vessel cohort could be attributed for this finding. The mortality was numerically higher in 
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the SVD group which may be due to the inherently poor outcomes associated with this 
group. 
This will be an important set of findings in benchmarking outcomes for DCB angioplasty 
in large vessel coronary disease as the existing evidence is very limited. 
4.1.5 Primary PCI Cohort 
Primary PCIs (PPCI) are high risk procedures associated with higher rates of major 
adverse cardiac outcomes. The PPCI cohort described in the DCBNORWICH registry 
includes patients with cardiogenic shock (3.7%), out of hospital cardiac arrests(6.3%) 
and also patients who were intubated and ventilated prior to PCI(3%). This is the largest 
DCB-only PPCI patient cohort reported thus far. Previously described (section 1.3.4) 
DCB PPCI studies by Vos et al, Ho et al, Nijhoff et al, and Revelation studies have a 
smaller number of patients comparatively.158 159 160 These showed that DCB-only PCI is 
feasible in PPCI setting and the randomised Revelation study showed the FFR at 9 
months was non inferior in DCB treated lesions compared to DES in the PPCI setting in 
a total of 120 patients.  
As described in the introduction section we recommend thrombus aspiration prior to the 
deployment of the DCB to enhance drug delivery especially in a lesion with heavy 
thrombus burden. This will explain the large proportion (63.4%) of thrombus aspiration 
reported in this cohort. This number amounts to 87.5% of lesions with thrombus. In the 
PPCI sub study of the BIOSCIENCE trial which compared biodegradable polymer DES 
(BP-DES) to durable polymer DES (DP-DES), 34 and 39% had thrombus aspiration in 
each arm228. BIOSCIENCE had 58 and 52% TIMI 0/1 flow lesions in each arm whilst our 
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registry has 70% of lesions with TIMI 0/1 flow.  Final TIMI III flow was gained in 97% in 
BIOSCIENCE study whilst it was 94% in the DCBNORWICH registry. The use of 
glycoprotein 11b/111a inhibitors was also noted to be high at 50.4% in our study. More 
than 1 vessel was treated in 14.8% of the cases. 
The BCIS registry published in 2019 showed a 30 day mortality of 7.8% across the 
United Kingdom in 25, 612 patients.157 All STEMI patients with no cardiogenic shock 
had a 30 day mortality of 4.4%. Patients who were in cardiogenic shock had a mortality 
of 43.1% at 30 days. As described in the results section in the DCBNORWICH registry, 
30 day all cause death was low at 6 (2.2%) and one year death was 16 (6.0%). Of note, 
our registry includes all intubated patients whereas the BCIS registry does not. Possible 
causes of low mortality could be absence of metal implant enabling the vessel healing 
and complete re endothelialisation.  Our use of glycoprotein IIb/IIIa inhibitors (GPI) was 
higher than the UK-wide use recorded in the BCIS data (50.4% vs. 37.4%) and may 
have had in impact on the low mortality rate. Orzalkiewicz M. et al recently showed that 
routine use of GPI was associated with lower all-cause mortality in comparison to 
selective use, in a study of 110,327 patients undergoing PPCI in the UK.163  
TIMI III flow was achieved in 94% of the cases in our study cohort. Whilst UK BCIS data 
did not provide this information, the National Cardiovascular Data Registry (NCDR) of 
the United States which included 291,280 acute MI (62% STEMI) patients reported TIMI 
III flow in 94% patients post angioplasty.229 In the US registry, 44% of patients had TIMI 
0 flow pre intervention whereas in our registry it was higher at 62% indicating that our 
post procedure TIMI III flow rate was comparatively better. 
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Target lesion failure (cardiac death, target vessel MI and clinically indicated TLR) of the 
BIOSCIENCE study was 8.8% and 3.4% in the DP-DES and BP-DES arms 
respectively. Whilst the MACE (all cause death, MI, TLR) defined in DCBNORWICH 
registry is not as specific as target lesion failure, it was recorded at 11.6%. TLR rate 
was 3.5% and MI was 3%. It should be noted that 19% of our cohort had PCI to either 
instent restenosis or stent thrombosis which are considered risk factors for further 
repeat revascularisations. No definite lesion thrombosis was recorded. There were two 
acute vessel closures and both were successfully bailed out with stents.  
Target lesion revascularisation rate of 3.5% and MI rate of 3% at 12 months are 
encouraging results in this high risk group of patients. 90.1% patients had DCB-only PCI 
indicating that ubiquitous use of stents is not a necessity even in this high risk group.  
In summary, this largest reported DCB PPCI cohort shows that DCB-only PCI is feasible 
and safe in this high risk category. The chance of under sizing and causing late mal-
apposition as in the case with a stent is not an issue with DCB-only PCI. This factor is 
more pertinent to this group as coronary vessels constrict during an acute MI. 
4.1.6 Left Main Stem PCI with DCB 
Significant LMS disease (greater than 50% stenosis), is present in approximately 6% of 
all patients undergoing coronary angiography with 80% having complex bifurcation 
lesions or multi-vessel disease.230-234  PCI to the LMS is a high-risk procedure due to 
the large area of myocardium at risk plus the complex nature of the anatomy, with 
higher major adverse cardiac event (MACE) rates largely driven by repeat 
revascularisations.235, 236 
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The Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) trial comparing 
PCI and CABG for LMS lesions showed, major adverse cardiac or cerebrovascular 
events at 12 months were significantly higher in the PCI group (17.8%, vs. 12.4% for 
CABG; P=0.002) largely due to repeat revascularisations. The rates of MI and death 
were similar in the two groups.237 The 5 year outcome analysis of the SYNTAX trial 
have shown no difference in MACCE between the two groups whilst PCI group had 
similar individual outcomes (death, MI, stroke and repeat  revascularisations) in  low to 
intermediate SYNTAX score (SS) group (SS of less than 32).238 The Nordic-Baltic-
British Left Main Revascularisation Study (NOBLE) and Evaluation of Xience versus 
Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularisation 
(EXCEL) study showed no difference in mortality and stroke (individually) between 
CABG and PCI for LMS disease.239, 240 Both showed higher non procedural MI rates in 
the PCI group whilst EXCEL showed a higher rate of peri- procedural MIs in the CABG 
group. The percentage of any revascularisation was higher in the PCI arm in both 
studies. There was no significant difference in ischaemia driven TLR between PCI and 
CABG but it was numerically less in the CABG arm. The NOBLE trial reported a 
MACCE rate of 7% in the PCI arm at one year. 
Our cohort, whilst a small number of patients, had a 1 year MACE rate of 4.2% 
suggesting that DCB-only angioplasty to LMS lesions is effective and safe in the short to 
medium-term. We found no evidence of acute complications, such as acute vessel 
closure, flow limiting dissections, acute recoil or vessel thrombosis as has previously 
been associated with plain old balloon angioplasty (POBA). Access to better quality 
angiography imaging, use of dual antiplatelet therapy, intravascular imaging techniques 
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and improved angioplasty devices could provide a plausible explanation for this 
difference. 
A significant number of lesions in this patient group involved distal LMS (82.6%). 
Analysis of the DELTA registry by Naganuma et al has demonstrated a higher incidence 
of target lesion revascularisation in distal LMS lesions following PCI with stents.236 
Distal LMS lesions are known to pose a significant anatomical challenge in relation to 
optimal stent treatment. The efficacy of DCBs particularly in these lesions, as we have 
demonstrated, may provide an attractive alternative treatment strategy. We suggest that 
part of the appeal of DCB-only PCI for the distal LMS is that of a simplified procedure 
avoiding plaque and carina shift and the resultant multiple layers of stents. 
4.1.7 DCB-only PCI in CTO (chronic total occlusions) 
The implications of use of DES and potential benefits of DCB in this cohort have been 
discussed in section 1.3.6 in detail. Koln et al reported a re-occlusion rate of 5.9% and 
restenosis rate of 11.8% at 8 months follow up in 39 de novo lesions treated with DCB 
PCI.192 Ours is the second registry of DCB PCI in CTO lesions. EUROCTO trial reported 
ischaemia driven target revascularisation of 2% and MACCE rate of 5.2% at 12 months 
in the PCI arm (274 patients with 91% of DES use).241  The TLR rate of 5.3% and an 
overall MACE rate of 8.3% reported in our registry are encouraging. Also    the absence 
of any re occlusions in the 15 lesions which have had follow up angiography should be 
highlighted.  
Not having long stented segments or so called full metal jackets and being able to avoid 
mal apposition due to late lumen gain are two advantages of DCB-only PCI in this 
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setting. This report also highlights the safety of type B as well as some type C 
dissections left without any bail-out stenting. As reported all these lesions were treated 
with the antegrade wire escalation technique suggesting no sub intimal delivery of 
DCBs. In the case of dissection re-entry approach, perhaps spot stenting the dissection 
and treating the rest of the lesion/disease with DCBs will be an option. 
4.1.8 In stent restenosis (ISR) group. 
Drug coated balloon angioplasty was first utilized in treating in stent restenosis as 
deploying a second or third metal layer inside a previous stent was deemed 
unfavourable. There have been many registries and randomised controlled trials to 
assess efficacy of DCBs in treating ISR. Evidence of DCB in ISR has been widely 
discussed in section 1.3.2.  
We were unable to identify the type of original stent in 69% of patients. From the 
recorded ones DES-ISR proportion was higher than the BMS-ISR. We carry out 1:1 
balloon pre dilatation and aggressive lesion preparation when treating ISR lesions. 
Although less than 30% stenosis is considered an acceptable result before deploying a 
DCB, in ISR cases we aim to achieve near 100%. Non- compliant balloons are used 
most commonly at high pressures and in 21% of lesions cutting or scoring balloons 
have been used for lesion preparation.  
In our registry TLR at one year was 17 (4.8%) and MACE was 42 (13.0%). In RIBS IV 
(EES vs. DCB in 309 DES-ISR patients) study, 1 year TLR rate was 4.5% and 13% for 
EES and DCB arms respectively. MACE was 16% and 7%. Number of MIs reported in 
our registry is 26 (8%), higher than what is reported in other studies. DAEDALUS study 
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reported MI rate of 4.7% at 3 years and RIBS IV reported 3% at one year.242 One 
reason could be the inclusion of bypass graft ISR lesions, 5 of which had recurrent MIs 
within the first year. Apart for one definite target lesion thrombosis which occurred 2 
hours after the procedure, no other late thromboses were reported.  
However the overall MACE rate in our study is within the observed range in other 
studies despite having a higher rate of MIs. 
4.1.9 Coronary bypass grafts 
This sub set of lesions are a high risk group in terms of success of the procedure as 
well as long term outcomes. 65% were ISR lesions which would elevate the risk in 
terms of long term clinical outcomes, even further. Redfors et al reported a target vessel 
failure of 20.4%, death 4.5%, myocardial infarction 7.9% and ischemia-driven target 
vessel revascularization of 13.0% at one year in vein graft PCI arm comprised of 405 
patients to 8177 non bypass graft PCIs.243 In our cohort TLR rate was 20% and MACE  
was 21.3%. These higher rates perhaps could be explained by the high number of ISRs 
present. In summary, these findings further supports the fact that clinical outcomes of 
percutaneous coronary intervention to bypass grafts is linked with high rates of adverse 
outcomes despite the device used in PCI.  
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4.2 Discussion on propensity score matched study; comparison of DCB vs. DES 
Key Findings 
1. There were no significant differences in clinical outcomes between DCB 
angioplasty in de novo lesions and a matched cohort receiving second 
generation DES at one year. 
2. Rates of target lesion revascularisation and myocardial infarction were 
numerically lower with DCB compared to a matched cohort receiving second 
generation DES over 12 months. 
3. Definite lesion/stent thrombosis was higher in the DES arm (0.6%) compared 
to DCB (0%). 
4. The risk adjusted composite of death, MI and TLR of DCB is non-inferior to 
second generation DES (the upper bound of the 95% confidence interval of 
the odds ratio was 1.47, below the pre specified 1.56).   
5. Propensity matching was feasible for clinical parameters but not for some 
lesion based parameters (length of the treated segment, device diameter, 
bifurcation lesion and diffuse disease) 
  
There are no data available in the literature to our knowledge for a comparison between 
2nd generation DES and DCB in all size coronaries. The previously available such 
comparisons namely the BASKET-SMALL trial and the SCAAR registry data are 
confined to largely small vessel coronaries.137, 138 Our comparison includes all vessel 
sizes representing day to day practice. The BASKET-SMALL randomised trial showed 
non inferiority for MACE (cardiac death, MI, TVR) in DCB-only angioplasty compared to 
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DES in coronaries of 2-3mm diameter in 382 and 376 patients respectively. The SCAAR 
registry showed no difference in target lesion restenosis (7.0% vs. 6.2%) but 
significantly less target lesion thrombosis (0.2% vs. 1.1%, adjusted HR 0.18; 95% CI 
0.04–0.82 ) with DCB angioplasty compared to 2nd generation DES, in a propensity 
matched cohort of 1197 lesions in each arm at a median follow up of 901 days. This 
however did not give information on target lesion revascularisation, target vessel 
revascularisation and myocardial infarctions, which our study does. Also this included 
only 5.8% lesions treated with a DCB with a diameter of  3mm or more indicating largely 
a small vessel cohort in contrast to ours which had 61% of the lesions treated with a 
DCB diameter of 3mm or more. 
As mentioned in section 3.2 under the results, the complexity of lesions pre propensity 
matching was higher in the DCB arm compared to the DES arm. After propensity score 
matching most variables were comparable for the two cohorts apart for length of the 
treated segment, device diameter, bifurcation status and presence of diffuse disease. 
There appeared to be systematic differences between the two groups for these 
parameters.  The length of the treated segment was shorter in the DCB arm which 
would be favourable for clinical outcomes. However, the presence of a higher number of 
bifurcation lesions, diffuse disease and smaller device diameter in the DCB arm are risk 
factors for adverse clinical outcomes. These factors were further adjusted in the 
analysis post propensity scoring. 
The MACE (all cause death, MI, TLR) rates of 8.2% vs. 7.3% for DCB and DES arms 
respectively in our study are consistent with the MACE (cardiac death, MI,TVR) rates in 
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the randomised BASKET-SMALL-2 trial (7.5% vs 7.3% respectively). The individual 
outcomes are discussed below. 
Death 
1 year (3.6% vs 2.9%) and 3 year death is numerically high in the DCB group but not 
statistically significant. The cardiac death rate in the BASKET-SMALL 2 trial at one year 
was slightly better than our DCB arm at 3.1% but all cause death was not stated. We 
did not have access to cause of death which was a major limitation on asserting actual 
aetiology. In the post propensity matched cohort, DCB arm had a shorter length of 
treated segment which will have been favourable but also had more bifurcations, more 
diffuse and small vessel disease which are unfavourable in terms of outcomes. As 
described in section 3.1.1 device diameter of 3mm or more was inversely associated 
with death in the DCB registry. Though not statistically significant, mortality for small 
vessel coronary disease was constantly higher in comparison to large vessels as 
depicted in figure 31. The final outcomes were further risk adjusted for these unmatched 
variables to minimise the impact.  
The heterogeneity of these two cohorts in terms of treatment methods may have 
confounded the patient level outcomes such as death and makes it difficult to interpret. 
For example the DCB arm consists of patients who have received drug eluting 
stents/bare metal stents in the past for different lesions in same or different vessels. If 
for example a death has occurred due to a late or very late stent thrombosis in a similar 
patient, it still would have fallen under the DCB arm. 
Myocardial infarctions 
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The rate of myocardial infarction is numerically less in the DCB arm (2.6% vs 3.2%) but 
not statistically significant. The MI rate in the DCB arm of the BASKET-SMALL 2 trial 
was lower at 1.6%. The comparatively lax definition of MI in our study may have led to 
this. One of the expected advantages with DCBs is a reduction of MIs due to absence of 
permanent metal/polymer (and associated stent related factors such as fracture, 
overlap, bifurcation stents, under expansion and mal apposition), reduced inflammation 
and complete endothelialisation. Not having enough event specific details to clarify 
whether these are target vessel specific MIs, makes it difficult to assess what 
percentage is lesion/vessel specific. However it should be noted that there was 0% 
definite treated segment thrombosis in the DCB arm whilst it was 0.6% in the DES arm. 
The pathophysiology of persistent inflammation, neo intimal hyperplasia and neo 
atherosclerosis associated with stents is discussed in detail in the section 1.3.1. Whilst 
the difference of MI is not statistically significant at 12 months it could be expected to 
swing in favour of DCB in the long term due to above reasons and absence of definite 
lesion thrombosis in the DCB arm is a very positive signal in this regard. 
Target lesion Revascularisations (TLR) 
Target lesion revascularisation could be considered the outcome that is directly related 
to the treatment modality in this study given the confounding factors for other outcomes 
such as death, MI or target vessel revascularisation.  TLR rate is numerically better with 
DCBs at 2.3% vs. 2.5% at 12 months, but not statistically significant, despite having a 
higher number of bifurcation lesions and diffusely diseased lesions. Interventionists may 
have a low threshold for intervention in a previously DCB treated lesion than a lesion 
with a stent as the former is technically similar to a de novo lesion given the absence of 
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metal. The 2.3% TLR rate in the DCB arm includes the 4 (0.4%) lesions that were 
intervened on during the same admission due to haemodynamic instability/persisting ST 
changes. As described in section 4.2.2, primary PCI was the most associative variable 
to TLR in the DCB registry study. But presence of thrombus was inversely associated 
with TLR which will dispute the theory of reduced drug delivery to the vessel wall after 
DCB PCI in the setting of a STEMI. Under sizing during pre-dilatation and selecting 
DCB, geographical miss and spending more than 2 minutes to deliver and fully expand 
the DCB at the lesion site could all be leading to repeat revascularisations.  
Target vessel revascularisation (TVR) 
TVR was numerically better with DES compared to DCB in this study at 3.8% vs. 4.7% 
but not statistically significant. There seemed to be a tendency to treat the affected area 
only during DCB PCI compared to normal to normal segment stenting in DES PCI which 
could be argued as a reason for higher percentage of TVR seen. However In the 
BASKET SMALL-2 trial, TVR was higher in the DES arm (4.5% vs. 3.4%) which would 
go against this. Also two of the TVR in the DCB arm in our study were staged 
procedures. Previously mentioned heterogeneity of the cohorts, i.e. having stents in the 
same vessel in the past makes TVR analysis complex in our study. For example one 
TVR was for an ISR of a separate lesion of the same vessel.  
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4.3 Limitations 
This is a single centre observational study. Selection bias and confounding errors are 
inherent limitations of such studies. Baseline characteristics and data on PCI 
procedures were collected in a prospectively established bespoke departmental 
database (Intellect) which is used to collect departmental data for quality assurance and 
audit purposes as well as transfer to national datasets.  The departmental database is 
subject to routine quality assurance of the data for completeness and consistency. 
Outcome data (MI and repeat revascularisations) were derived from the NICOR 
databases which are quality assured for completeness and consistency and forms the 
main source of National PCI, MI and cardiac surgery data. Mortality was derived from 
the NHS digital which is recognised to be a reliable data source. Specific validation of 
outcome events by cross checking with our own hospital based data and also with 
surgical data from Royal Papworth Hospital (our cardiac surgical referral center) was 
carried out for this analysis. The cause of death was not available for all the deaths 
making it difficult to delineate the aetiology. We were not able to scrutinize (no access to 
ECGs for example) the myocardial infarctions that were reported outside NNUH. MINAP 
definition of a MI had to be adopted as we obtained clinical outcomes from it and this 
could be considered lax comparing to stringent criteria usually adopted in research 
studies. However it could be argued that this was an issue for both arms of the study. 
As per latest BCIS audit results, 92.9% of the UK wide PCI procedures has been 
recorded with NICOR. This leaves some room for a small number of repeat 
revascularisations to be missed in the NICOR data. However the chance of such event 
will be the same for both DCB and DES arms. NNUH being the only PCI center for most 
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of the Norfolk County helps to secure follow up for these patients at our center.  This 
reduces the chance of not recording an event. 
It is appreciated that the rate of use of DCB was largely driven by a single operator in 
the initial period and was increasing steadily throughout the period of study as shown in 
Figure 18.  These factors will affect the validity and interpretation of the propensity 
matched analysis as the DCB group characteristics will potentially be changing over 
time and therefore the results may not be generalisable for future patients.  To address 
this further comparative studies of DES and DCB are in progress 
DCB angioplasty has a learning curve and operators were at different stages of this 
curve during the study ranging from zero experience to being well experienced whereas 
they were all very experienced in angioplasty with stents.   
It is recognised that the analyses carried out have been retrospective in nature with all 
the limitations associated with this type of study design including selection bias, missing 
data, and potential for misclassification of outcome events.  Patients selected for DCB 
procedures will likely have been “healthier” in the earlier phase of the study although 
several patient comorbidities occurred more frequently in the DCB group compared to 
DES pre-propensity matching including diabetes, prior MI and hypertension (Table 41). 
The DES group had a higher percentage of patients presenting with STEMI and acute 
coronary syndrome (high risk) pre- propensity score matching. The lesion complexity 
was higher in the DCB arm. Propensity matched analysis helps to reduce variation 
between groups but cannot eliminate bias and any results need to be interpreted with 
caution. The need for carefully conducted prospective observational studies and 
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randomised controlled trials, as well as health economic analysis (costs and cost 
efficacy specially given that cost of a DCB is higher than that of a DES at present) to 
evaluate the safety and efficacy of DCB angioplasty are needed to provide greater 
confidence in this approach. 
We used a non-inferiority test as part of the assessment of DCB angioplasty compared 
to DES in the propensity scored analysis.  This approach is limited by identifying the 
clinically acceptable boundaries to determine non-inferiority.  We used thresholds that 
have been used in previous studies and as advised by the United States Food and Drug 
Administration (FDA).244Numerical differences in outcomes between DCB and DES 
were generally small at 1-2%, providing further confidence that our findings provide 
encouraging results for DCB angioplasty compared to standard DES. 
One of the major limitations was the time taken to obtain clinical outcomes from the 
NICOR. NICOR was undergoing major changes within, including change of hands in 
terms of management by the University College of London to Barts and the London 
NHS Trust. From the first application to obtaining clinical outcomes data took 22 months 
(July 2019). This is much longer than European counterparts take. For example the 
investigators of the Swedish SCAAR registry of DCB, which included patients treated in 
2016, were able to finish their study and publish the results by September 2017. When 
data was finally provided by the NICOR in July 2019, it was able to provide clinical 
outcomes (MI and revascularisation data) valid up to beginning of 2017 only. This 
limited our follow up duration for all patients to 12 months whereas mortality data was 
valid for 3 years. The cost involved in obtaining clinical outcome data amounting to 
£15,000 is far higher than what is charged in the USA for example. The Healthcare Cost 
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and Utilization Project (HCUP) web site of the USA quoted data from Nationwide 
Readmission Database (NRD) for a student, costed $200 for the year 2015, and $150 
for each year from 2010 till 2015. The time taken for approvals and the number of 
bodies involved was another limitation. The bodies/persons included caldicott guardian 
of the hospital, Research and development of NNUH, Information governance of NNUH 
and NHS Digital, National Research Ethics Committee, Confidentiality advisory group 
(CAG), Health Research Authority and finally Healthcare Quality Improvement 
Partnership, before requesting data from the NICOR. The process is described in 
section 2.1.4. A simplified process will be immensely helpful to the researchers 
especially where the primary sponsor is a NHS Trust/body, to publish data in a timely 
manner. 
4.4 Conclusion 
This analysis has shown that DCB only angioplasty in de novo coronary angioplasty is 
technically feasible and produces clinical outcomes that are not statistically different to 
outcomes with second generation drug eluting stents at 12 months. Its safety and 
efficacy has been shown in many sub groups such as large vessels, primary PCIs, 
chronic total occlusions and bifurcation lesions in the registry study. The composite of 
all cause death, MI and target lesion revascularisation of drug coated balloon arm is 
non-inferior to that of second generation drug eluting stents. 
Randomised clinical trials comparing drug coated balloons to conventional drug eluting 
stents in the above mentioned different cohorts as well as real world all comer 
comparisons are warranted to further investigate these findings. 
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DCB coronary angioplasty has the potential to change the current practice of ubiquitous 
stenting to using stents when only vessel threatening dissections or severe acute recoil 
is present. It is certainly a useful tool in the armamentarium of an Interventional 
Cardiologist. Studies with long term follow up will reveal whether the expected beneficial 
results of not having permanent metal/polymer are leading to fewer clinical events.   
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6.2 Appendix 2 Public notice 
03/08/2018 
Public Notice – Outcomes of Drug Coated Balloon Angioplasty, A UK Real Life 
Experience from 2009 to 2015 (DCBNORWICH).  
 
DCBNORWICH study is a proposed registry to assess outcomes of patients who have 
received angioplasty treatment with a novel device called a drug coated balloon during 
the aforementioned period. Norfolk and Norwich University Hospital (NNUH) is the 
leading hospital in the UK performing these procedures and has been recognized as a 
center of expertise for this type of treatment. 
The study involves retrieving clinical outcomes from the National Institute of Cardiac 
Outcomes Research (NICOR) which collects patient data of all angioplasty procedures, 
coronary artery bypass graft surgeries and heart attacks from all NHS hospitals. In order 
to track the outcomes, patient identifiable data such as the NHS number, DOB and 
gender will be shared with the NICOR. It is proposed to report outcomes for the next 10 
years making this a study with a very long term follow up period. Patient identifiable 
data will be accessed only by hospital doctors/direct care team members and the 
NICOR. In a very small number of patients, identifiable information will be shared with a 
member of the direct care team of another hospital if they have received angioplasty 
outside Norfolk and Norwich Hospital on a later date. No identifiable data will be 
published nor divulged to any other party. 
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All relevant approvals such as Caldicott guardian of the hospital, National Research 
Ethics Committee and Health Research Authority (HRA) approval have been obtained 
prior to commencement of the study. HRA advised to apply for recommendations from 
Confidentiality Advisory Group (CAG) which has been adhered to. The CAG provides a 
recommendation to the Health Research Authority (HRA) as appointed decision-maker 
for research applications. The HRA takes the final decision to support an application 
under Regulation 5 of the Health Service (Control of Patient Information) Regulations 
2002 to process patient identifiable information without consent. 
This will be one of the largest registries published on this domain once completed and 
will be invaluable in further advancements of the field. 
A patient group meeting has been held to obtain patient views and a patient is in the 
study steering committee to oversee adherence to guidelines as well as to make sure 
patient interests are met. 
If you are a patient who has received drug coated balloon angioplasty treatment at the 
NNUH during the above mentioned period and if you have any objection to your data 
being used in the above manner please do get in touch with us using any of the below 
mentioned contact portals. 
Amendment: A proposal is in place to include all the patients who received drug 
eluting stent angioplasty during the above period to enable a meaningful 
comparison between the two treatment modalities. This proposal will also be 
subjected to approval by all of the above mentioned bodies. If you have received 
drug eluting stent treatment during the above period at NNUH and if you have any 
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objection to your data being used as described above please do get in touch 
using the same contact portals. 
Dr Upul Wickramarachchi, Clinical Research Fellow, NNUH – Chief Investigator 
(upul.wickramarachchi@nnuh.nhs.uk) 
Dr Simon Eccleshall, Consultant Cardiologist, NNUH – Primary Supervisor of the project 
(simon.eccleshall@nnuh.nhs.uk) 
Research and Development, Norfolk and Norwich University Hospital NHS Foundation 
Trust, Colney Lane, NR4 7UY. Telephone 01603 289808 or email 
rdoffice@nnuh.nhs.uk 
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6.3 Appendix 3: Data Requests from NICOR 
6.3.1 Data request format for BCIS 
6.3.2 Data request format for Adult Cardiac Surgery data set 
6.3.3 Data request format for MINAP 
Please see the attached Excel data sheets for above. 
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